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INTRODUCTION 
Siddha system of medicine is one of the oldest systems of medicine in South India 
especially in Tamilnadu. It is a traditional system of medicine which is gradually evolved.  
Eighteen Siddhars had contributed much to the development of this medical system. 
According to the ancient Siddha texts human body is made up of five 
elements(Panja Bootham-earth,water,fire,air and space) and controlled by three humors 
called Vatham,Pitham,andKapham. 
In normal healthy individual these three vital humours exists in the ratio of 
1:1/2:1/4 respectively, when the three humours disturbed disease will occur. 
Vatham is formed by air and space elements. It controls the nervous system. 
Pitham is formed by fire element. It controls the metabolic functions of the body. 
Kapham is formed by water and earth elements and concerns with all types of secretions 
inthe body. 
The three humours are considered as the three pillar of health and support the 
structure and functions of the body 
According to Siddha system various psychological and physiological function of 
body depends on seven physical constituents(Udalthathukkal):  Saram (food juice), 
Cheneer (Blood), Oon (muscle) Kozhuppu (Fatty tissue), elumbu (bone),  Majai (bone 
marrow), Sukkilam or suronitham ( semen or ovum). 
Siddhar‟s classified the disease into 4448. The disease Kalladaippu is one among 
them.It is caused due to the derangement of Pitham humour. 
According to Tamil Vaithyasathagam, the seats of pitham humour are as 
follows:pingalai ,urinary bladder, Stomach, umbilicus, epigastric region, sweat, saliva, 
essence of food, eyes, and  skin.  
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Jhdhd gpj;jk; gpq;fiyiag;gw;wp 
  rha;thd gpuhzthAtjidr;Nrh;e;J 
  Cdhd ePh;igapy Zfp%yj; 
  Jjpj;njOe;jtf;fpdpia AwTnra;J 
  khNd NfspUjaj;jp ypUg;Gkhfp 
  Nfhdhd rpue;jdpNy apwf;fkhfpf; 
  nfhz;L epd;w gpj;jepiy $wpNdhNk 
     - jkpo; itj;jparjfk;. 
 
As per Yugi Vaithya Chintamani Kalladippu is classified into 4 types.Azhal 
Kalladaippu one among them.The signs and symptoms of azhalkalladaippu 
Yugivathiyachinthamani text, oliguria, urethral pain which mimics the  pain caused 
by the insertion of iron rod in the urethra, sweating all over the 
body,anuria,agonizing pain, blood stained calculus stagnated in urethra can be 
correlated with renal calculus in modern science. 
In India approximately 5-7 million persons are suffering from stone disease in 
India and at least 1/1000 of Indian population needs hospitalization due to kidney stone 
disease. India the „stone belt” occupies parts of Maharastra, Gujarat, Punjab, Haryana, 
Delhi and Rajasthan. In these regions the disease is so prevalent, that most of the 
members of a family will suffer from kidney stones sometimes in their lives.   
 Kidney stones are most commonly found in people between the ages of 20-40.
 Urinary stones can be classified according to the following aspects of stone size 
shape, and location composition.  
 In the text PatharthagunaVilakkamThaathujeevavaguppu, SAARA PARPAM 
(Internal drug) a Siddha formulation has been indicated for Kalladaippu. The method of 
preparation seems to be simple and cost effective. The main drugNavacharam, Vediuppu 
are well known for theirdiuretic actions as per Siddha literature.  
 The above said drug formulation has undergone safety 
studies[Ref.1.Dr.P.Arunmozhi,RegNo- 3210102 hepatoproductive activity of SAARA 
PARPAM in Ccl4 induced RatsIOSR journal of Pharmacy and Biological science volume 
5,Issue (6 March – april 2013) 2.Dissertation done in 2013] and clinical documentation 
was not done yet.So I have selected the siddha formulation “SAARA PARPAM” 
(Internal) for further clinical evaluation in Azhal Kaladaippu. 
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 Dietary risk factors for stone disease were shown different by age and sex. In 
particular inyounger women dietarycalcium, phytate, fluid intake was associated with a 
reduced risk of stone formation, whereas animal   protein and sucrose increased the risk 
of stone incidence. In older adults there was no association betweendietary calcium and 
stone formation.  Whereas magnesium, potassiumand fluid intake decreased and total Vit 
C intake increased the risk of symptomatic nephrolithiasis.  Animal protein was 
associated with risk only in men with a body mass index 25 kg / m². 
 Type   2 diabetes and several other coronary heart disease risk factors including 
hypertension and obesity are associated with nephrolithiasis.  
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AIM 
 
Clinical evaluation of siddha drug “Saara parpam” (internal) in the treatment 
of“Azhal kalladaippu noi” (Renal calculi)  
 
OBJECTIVES:  
1. Primary objective:  
To study the siddha formulation Saara parpam in the treatment of Azhal   
Kalladaippu (Renal Calculi) for the Clearance/reduction in the size of renal 
calculus. 
2. Secondary objective:  
To study azhal kalladaippu, on the basis of Envagai thervu, 
mukkutram, kalam, naadi, neerkuri, neikuri, etc,, in order to evaluvate the 
pathology.  
To study the siddha cofactors related to the diseases such as age, sex, 
food habits, occupation etc. 
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A. SIDDHA ASPECT 
AZHAL KALLADAIPPU 
Siddhars classified the diseases into 4448 and described each one separately and 
elaborately. They classified the disease on the basis of Vatham, Pitham, and Kabham 
humors. 
The disease kalladaippu is placed under NeerinaiArukkalnoi (Oligurial diseases). 
This has been mentioned by Therayar in his: “Therankarisal” as follows, 
 
ePupUtpidFzj;ijePawptpj;Jnrhy;thk; 
ePupidngUf;fnyhd;WePhpidaUf;fnyhd;W 
ePupopTlNdnfhy;Yk; ePh;f;fl;Ltpidfnshd;W 
        -Njud; fhpry; 
As per Yugi Vaithiya Chinthaamanai, Kalladaippu is classified into 4 types. 
AzhalKalladaippu is one among the four types of Kalladaippu. 
 
Njhd;wpd Njhh; ehypdplehkq; Nfsha; 
RWf;fhd thjj;jpd; fy;yilg;G 
G+d;wpaNjhh; gpj;jj;jpd; fy;yilg;G 
Guz;lNjhh; Nrj;Jkj;jpd; fy;yilg;G 
- a+fpitj;jparpe;jhkzp 
Kalladippu 
Definition: 
As per the Siddha text  “Siddha Maruthuvam” (Author: Dr. Kuppusamy), there 
is gradual or sudden obstruction to the flow of urine, pain with burning sensation in the 
urethral tract, low back pain , renal angle pain and sand like crystal deposit in the urine 
are the characteristic features of kalladaippu. 
Pothu kurikunangal: 
According to the text Siddha maruthuvam (pothu) 
 Gradual or sudden obstruction to flow of urine. 
 Unbearable pain (agonizing pain) in the peins. 
 Excruciating pain and swelling is experienced at the tip of penis if the calculus 
attempts to expel. 
 Burning and scanty micturition and haematuria. 
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 Colicky pain radiating from loin to groin, lower abdomen, urethra, and genitalia if 
the calculus is irregular with sharp projection 
Etiology: 
Accoring to Yugi Vaithiya Chinthamani, 
fyq;fpdNjhh; jz;zPh; jhd; Fbj;jNgh;f;Fk; 
fy;nyYk;G kaph;kz;jhd; fye;jd; dj;jpy; 
myq;fpdNjh ud;dq;fs Ue;jyhYk; 
mOfNyhL Kw;wgz;l kUe;jyhYk; 
kyq;fpdNjhh; khg;gz;l kUe;jyhYk; 
ke;jj;jpy; tha;thd gjhh;j;je; jd;id 
Jyq;fpdNjh Urpjd;dpw; Ritj;jyhYk; 
RUf;ffha; fy;yilg;G te;J Njhd;We; jhNd 
- A+fpitj;jparpe;jhkzp. 
 
As per Yugi Vaithiya Chinthamani, Kalladaippu is due to 
 Intake of turbid water 
 Food contaminated with stones, bones, hair and sand 
 Intake of purtrified food stuff and starch substances 
 Eating flatulence producing food while indigestion 
 
njspe;jNjhh; fy;yyilg;Gw; gj;jpNfsha; 
rpwpJehl; Llq;fpNaNkfe; jd;dhy; 
jspe;jNjhh; ryg;igapYjpue; Njha;e;J 
re;jre;jhfNtgUj;Jf; nfhs;Sk; 
tspe;jNjhh;   thjgpj;jq; Nfhgpj; jf;fhy; 
te;JnghUq;fy;yha; ePh;topailj;J 
espe;jNjhh; ehYtpjf; fy;yilg;G 
ez;ghdtuyhWehl;lf; NfNs 
- A+fpitj;jparpe;jhkzp 
Yugimamunivar has revealed about this disease since 14
th
century. 
Yugimamunivar mentioned the following symptoms, blood clot in the urinary bladder 
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due to urinary tract disease followed by distension of urinary bladder, urinary stone 
formation in urinary tract by deranged humour of Vatham and Pitham. 
 
ehl;lkha; fw;gopj;Jf; flidthq;fp 
eypgz; zpf;nfhlhky; tof;FNgrp 
  $l;lkha; FUTilzflikjd;idf; 
nfhlhkNyif ;nfhz;l nfhLik Nahh;f;Fk; 
thl;lkha; tuk;Gjg;gpjphpe;jNgh;f;Fk; 
khWghlhnaLj;Jg; nghUs; fld;; 
fhl;bNaiff; nfhz;Lf gLgz;Zk; 
fhyhe;jh; fy;yilg;gpw; fyq;FthNu 
      -A+fpitj;jparpe;jhkzp 
 
The above mentioned poem explains immoral behaviours, anger and robbery 
causes derangement of three vital humours resulting in Kaladaippu. 
According to Siddha maruthuvangachurukkam, 
 
‘ePupidj; jLj;jy ; nra;apd; 
ePh;f;fl;Lj; Jthuk; Gz;zhk; 
ghwpLQ; re;J re;jpy; 
gz;GW Neht jhFk; 
Nehpyq; faUq; fhkpak; 
epr;ra Nehjy; nra;Ak; 
ghupdpy ghd thA 
gz;Gwr; NrU kd;Nw” 
- rpj;jkUe;Jthq;fr; RUf;fk; 
Siddha maruthuvanga churukkam explains that urination is one of the 14 
visceral reflexes. When one suppresses this visceral reflex causes the inflammation of 
bladder, anuria, arthralgia, pain in the genital region and derangement of keezhnokkum 
kaal leads to the formation of calculus. 
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‘Rf;fpye; jidalf;fpd; 
RuKldPh;f; fl;lhFk; 
gf;fkhq; iffhy; re;J 
ghuNeha; topap wq;Fk; 
kpf;f khh;NehA z;lhFk; 
kpFe;jpLk; gpuNkfe;jhd; 
jf;fNjhh; NghJkhfpd; 
jhpj;jpLk; thAf; $Nw” 
- rpj;jkUj;Jthq;fr; RUf;fk; 
 
The author also explains that ejaculation of semen is one of the 14 visceral 
reflexes.  When one suppresses this visceral reflex, it causes fever, retention of urine 
which favours urinary calculi, chest pain, arthralgia and white discharge. 
 
According to Noi Vilakkam 
fUePulf;ffy; tpiuapy; mbgly; 
ePhpae;jhf; fy; rpWePulf;fy; 
tspNeha;  kpUf;FKzTk; xOf;fKk; 
filg; gpj;jpLjy; NkfKjw; gy 
gpzpAwy; vOkpit abg;gilahff; 
fy;yilg;G nad;Dq; fLk;gpzp tpisAk; 
tspaJ kPwpNa nahL ky;yhJ 
fUeP nuhLq; fye;J ePufj;Jr; 
rpWePh;f; fopT njhLj;jyhYk; 
md;dit fy;nydj; jpuSnkd;g 
- Neha; tpsf;fk; 
 
 Trauma on testes 
 Controlling of urination 
 Vatham aggravating foods 
 Syphilis(Mega Noi) 
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Classification 
Classification of kalladaippu In Yugi Vaithiya Chinthamani: 
Njhd;wpdNjhh; ehypdplehkq; Nfsha; 
RWf;fhd thjj;jpd; fy;y ilg;G 
G+d;wpaNjhh; gpj;jj;jpd; fy;y ilg;G 
Guz;lNjhh; Nrj;Jkj;jpd; fy;y ilg;G 
Njhd;wpaNjhh; njhe;jkhq; fy;yilg;G 
Njfj;jpw; gw;wpNarp wpJ fhyk; 
jhd;wpNa ryg;igapy; te;jp ope;J 
rUtpNa ypq;fj;jpw;w upf;Fe; jhNd 
- A+fpitj;jparpe;jhkzp ( gh.vz; : 728 ) 
There are four types of Kalladaippu according to Yugi Vaithiya Chinthamani 
1. ValiKalladaippu 
2. Azhalkalladaippu 
3. IyyaKalladaippu 
4. ThonthaKalladaippu 
 
thjfy;yilg;G 
jhpj;J ehgpf;Fq;fPo; RUf;fha; Fw;wpr; 
rykye;jhd; tPohkw; wk;gkhfp 
thpj;JNk ypq;fj;jpy; typAkhfp 
kUtpaNjhu; nghj;jpnayhQ; Rue;Jfl;b 
jpupj;jpNa fpilnfhlhg; gpul;l yhfpj; 
Njk;gpNa  %r;Rkha; tapW Kg;Gk; 
chpj;jNjhh; rijNghy cth;g;G khFk; 
Xq;fpa Njhh; thjf;fy; ilg;G jhNd 
- A+fpitj;jparpe;jhkzp (gh.vz; : 729 ) 
In valikalladaippu, pain is felt just below the umbilical region and penis. It is 
characterized by severe colic pain, dyspnoea, abdominal distension, oliguria and 
constipation. 
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gpj;jfy;yilg;G 
milg;ghfpr; rye;jhD kUt yhfp 
maq;fhr;rpr; nrhUfpdhw; NghNy fhZk; 
Gilg;ghfg; nghw;wpnaq; Fk;G Of;fkhfpg; 
G+l;LNghy; gpFthfpg; gpul;lyhFk; 
kilg;ghfp cjpuepw kha;f;fy; yhfp 
te;jpope;J ypq;fj;jpy;  khl;bf; nfhs;Sk; 
Filg;ghfp Fw;wyha;f; $r;ryhfpf; 
Fjl;LNk gpj;jf;fy; yilg;G jhNd 
-A+fpitj;jparpe;jhkzp ( ghly; vz; : 730 ) 
 
Azhalkalladaippu is characterized by, reduced urine output with characteristic 
burning sensation similar to introducing a red-hot needle into the urethra, blood stained  
stones which blocks the ureter causing pricking pain and tenderness. 
 
Nrj;Jkfy;yilg;G 
 
Jhdhd njhg;GspNy tpy;Y Nghyr; 
rypahkw; Rue;JNk rw;Nw Fw;Wk; 
VdhdfhNyhL iffs; re;J 
,Lg;Gjhd; Filr;ryhaprpT fhZk; 
Ntdhd ypq;fj;jpd; ntz;ik jd;dpy; 
tpWtpnwd; NwfLg;ghfp tpah;it ahfk; 
Njdhd ntSg;Gf;fy; rpWfy; yhfr; 
rpf;fyha; te;jpwq;Fr; Nrl;ge; jhNd 
-A+fpitj;jparpe;jhkzp ( gh.vz; : 731 ) 
Iyyakalladaippu is characterized by excruciating pain in the umbilical region, pain 
in  the joints of  upper and lower extremities, Low-backache, spasmodic pain, Sweating 
and gradual passing out of  white coloured stone crystals in the urine. 
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njhe;jfy;yilg;G 
te;jpwq;Fk; ePh;j;jhiu abapw; whDk; 
khtUj;j Kz;lhfp typA khfp 
nehe;jpwq;fp ePh;jhD kUtp ghAk; 
neha;jhd rpWkzy; Nghy; nehWq;fpf; fy;yhd; 
re;jpwq;fp ePh;topapy; te;J tPOk; 
jhf;fhd rpwq;iff;fy; jpdnkhd; Wf;F 
Je;jpwq;fpj; jpde;jpdK kpoe;J nfhy;Yk; 
njhe;jkhq; fy;yilg;Gr; R+l;blhNa. 
- A+fpitj;jparpe;jhkzp (gh.vz; : 732) 
In thonthakalladaippu, severe pain is felt just below the urethral region with 
excess urination.It is characterized by disintegration of stones in to small, sand like 
granules in the urine. 
Classification according to NoiVilakkam 
 
“tspKjy; %d;wpDe; Njhd;wyhYk; 
fUePh; Njhd;wyhYk; 
fy;yilehy; tifg; gLnkd nkhopNa” 
     -Neha; tpsf;fk; 
There are four types of  kalladaippu 
1. Vali kalladaippu 
2. Azhal kalladaippu 
3. Iyya kalladaippu 
4. Karuneer kalladaippu 
tsp fy;yilg;G (Vali kalladaippu) 
 
“ glh;kpfg;  gLj;jy; gw;fs; gpirjy 
eLq;fy; ce;jpAk; FwpAk; gpirjy; 
frLfPo; rspnahLfoyy;  mOjy; 
rpWePh; Jspj;jy; vd;gTk; gpwTk; 
tspapd; fy;yilf; Fwpnadnkhopa ; 
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fWj;JQ; rpte;Jk;  Kidfs; gue;Jk; 
tspapd; fy;yJtbTDnkd;g” 
 
 Tongue biting, palpitation and shivering 
 Lower abdominal colic and pain in the external genitalia 
 Dribbling of urine, the stones are blackish red in colour  
 
moy; fy;yilg;G(Azhal kalladaippu) 
“Rl;nldePhpak; kpfntJk;gpLjYk 
NehjYk; mitf; fy;yilf;FwpNa 
rpte;Jq; fWj;J kQ;rshfpAk; 
Nrq;FU tbtpy; fy;yJ Njhd;Wk;” 
- Neha; tpsf;fk; 
 Burning  micturition, dysuria 
 Passing reddish black or yellow coloured stones 
[afy;yilg;G(Iyya kalladaippu) 
 
“ePupaq; Fj;jy; jpzpj;jy; Fsph;j;jy; 
vDkpit Iaf; fy;yilf; FwpNa 
ntSj;Jk; Njdpwkhfpa nkhsph;e;Jk; 
ngU tbTilaj;jhk; Ia fy;yilg;G” 
        -Neha; tpsf;fk; 
 Pricking pain with severe intensity when  passing urine 
 Fever with rigors 
 White or honey coloured shining or iuminant large size stone expelled. 
fUePh; fy;yilg;G (Karuneer kalladaippu) 
 
“fU ePh;f;fy;ypd; tsp rpde;njOe;J 
tpiufsp dLtpy; mJjidj; jLj;jypd; 
fUePh;f; fy;yil kUtpL nkd;g 
ePupak; Nehjy; rpWePh; jilgly; 
tpiu tPq;fpapUj;jy; vDkpit gpwTk; 
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fUePu;f;  fy;yilf; Fwpnad nkhopa 
fUePu;f;  fy;ypid tspaJ KLfpr; 
rpwpaTk; nghpaTe; Jz;Lfshf nehWf;fpLk; 
mit rpWePh;  top ntspg;glthFk; 
mit rpWePupidj; jLj;jy; epw;Fk; 
rhw;wpa ePhpidj; jLj;J epw;gpd; 
Mw;wy; Fiwjy; tapW Nehjy; 
Ritnfly; ntspW kWg;G ePh;Ntl;if 
nty;tsp naDkpit tpise;jpL nke;g... 
- Neha; tpsf;fk; 
 Sudden or gradual obstruction  to flow of urine 
 Excessive Valikutram breaks the stones into small and large size crystals and 
expels along with urine, sudden stoppage of urine stream 
 Retention of urine, abdominal pain, loss of taste, excessive thirst 
In Dhanvanthirivathiyam, Kalladaippu is classified into four types, they are 
1. Kallerippan 
2. Pithaachamari 
3. Silethumaachmari 
4. Sukilaachmari 
In SiddharAruvaiMaruthuvam, Klladaippu is classified into four types, they are 
1. Valikalladaippu 
2. Azhalkalldaippu 
3. Iyyakalladaippu 
4. Venneerkalladaippu 
Classification inJeevaratchamirthamand Anubhavavaithiyadevaragasiyam: 
Types of Kalladaippu: 
1. Vathaachmari 
2. Pithaachmari 
3. Kabhaachmari 
4. Shukilaachmari 
5. Swagaraachmari 
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Differential Diagnosis of Kalladaippu 
cf;fhu #iy 
‘Fj;J Kf;fhu #iy apd;F ze;jhd; 
Nfhh;itaha; tpyhtjdpy; KJfpy; neQ;rpy; 
mj;jp apdpy; ehgpapy ghdkhq;F jj;jpy; 
mjpf Jd;khq;fpre;jhd; tiu Nktpg; 
gj;Jkzw; gLf;ifg; Nghw; ryj;J thug; 
gjpneUf;fp %j;jpukhq; fphpr;rp Az;lha;j;  
jj;Jrlq; fLg;ngLj;J kjpf yq;fpj;  
jsh;r;rp nahL kaf;ffkha;j; js;Se; jhNd” 
     -A+fp itj;jpa rpe;jhkzp ( gh. vz; 233) 
Excessive growth of muscles in chest region, back of trunk, umbilicus, anal and 
urethral orifice followed by structure of urethral orifice like a sand like crystals blocked 
in urethra, dysuria, body pain, tiredness and giddiness occurs. 
Mukkutra verupaduakal (Siddha pathology) 
The imbalance in one‟s food and fluid intake increases the Azhalkutram. This 
raised kutram dries up the body fluid and urine resulting in concentration of salts, this 
further affects the Keezh nokku kaal. One of the functions of the keezh nokku kaal is to 
excrete urine so when this Keezh nokku kaal is affected, the urine will be obstructed 
within urinary tract. This favours the deposition of urinary salts to develop into calculi 
anywhere in the kidney or urinary salts to develop calculi anywhere in the kidney or 
urinary tract. 
Diagnostic methodology: 
The Diagnostic methodology in siddha system is unique as it is made purely on 
the basis of clinical acumen of the physician. The diagnosis is arrived from, 
 Poriyal arithal (Inspection)  
 Pulanal arithal (Palpation) 
 Vinaathal (Interrogation) 
 Envagaithervu (eight fold examination) 
Pulanal arithal 
The physician should examine the patient‟s pulangal by his Porigal & Pulangal 
 Hearing-Ear  
 Vision-Eye 
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 Taste-Tongue 
 Sensation-Skin 
 Smell-Nose 
Poriyal aridhal: 
The Physician should examine the patient‟s porigal by his porigal 
 Mei- To feel all types of sensation 
 Vaai-For knowing taste 
 Kan- for Vision 
 Mooku- For knowing the smell 
 Sevi- For hearing 
Vinaadhal (Interrogation) 
 The physician should interrogate the patient‟s name, age, occupation, native place, 
Socio economic status, dietary habits, present complaints, history of present illness, 
aggravating factors, history of previous illness etc. 
Envagai thervugal: 
“ehb guprk; ehepwk; nkhoptpop 
kyk; %j;jpukpit kUe;JtuhAjk;” 
     -Njiuah; 
‘mfe;JW Nehia fuj;jhk yfk;Nghy; 
gFj;jwptPu;ehbg; guprk; -njhFj;j epwk; 
fl;Ltifr; nrhy; nkhop fz;l ky %j;jpuk; eh 
vl;Ltif ahY kwptPu;” 
  mfj;jpah; itj;jpa rpe;jhkzp ntz;gh 4000 
` ‘nka;Fwp epwe;njhdp tpopehtpUkyk; iff;Fwp” 
      -Njiuah; 
According to Agatiyar Vaithiya Sinthaamani Venba - 4000, and saint 
Therayar the envagaithervu(Eight types of diagnostic tools) includes Nadi (Pulse), 
Naa (Tongue), Niram (Colour), Mozhi(Voice), Vizhi(Eyes), Malam (Faeces), 
Neer(Urine) and Sparisam(Touch & Palpation). 
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Naadi: (Pulse) 
The „Pluse diagnosis‟ is a unique method in Siddha medicine. The pulse 
should ne examined in the right hand for male and the left hand for female. The 
pulse can be recorded at the radial artery. By keenly observing the pulsation, the 
diagnosis of diseases well as its prognosis can be assessed clearly. 
 ‘ Nfsg;gh GUlUf;F tyJ ifiaf; 
fpUigAld; jhd;gpbj;J nel;il thq;fp> 
R+sg;gh ngUtpuNyh uq;Fyj;Jf; fg;ghw; 
Rfkhf %tpuyh yOj;jpg; ghu;f;f” 
      -ghpg+uz ehb 
‘ ghu;f;fNt ngz;LfSf; fplJ gf;fk;” 
- gupg+uz ehb 
Naadi is nothing but the manifestation of the vital energy that sustains the life 
within ourbody. Naddi plays a most important role in Envagai thervu and it has been 
considered as foremost thing in assessing the prognosis and diagnosis of various diseases. 
Any variation that occurs in the three humours is reflected in the Naadi. These three 
humours organize, regularize and integrate basic functions of the human body. So, Naadi 
serves as a good indicator of all ailments. Aggravation of valinaadi and azhal naadi 
produces symptoms of Kalladaippu. This is emphasized in Agathiyar naadi, Sathaga 
naadi, and Rathina churukka naadi 
 
‘miwe;Njhk; thjNuhfpAly; 
mbfz; KfKk; gykyKk; 
epiwe;j tpopapy;  ePh;tbAk; 
ePz;l ehT fWj;jplTk; 
epiwe;j Ks;sha; jhdpUf;FQ; 
rpWePh; nghUkp fUj;J tUk; 
ciwe;j ePUq;fU fUj;J 
Kiwaha; NuhfK Kz;lha;” 
 -mfj;jpau; ehb 
thj nkDk; ehbaJ Njhd;wpy; 
rPjke;jnkhL tapW nghUky; jpul;rpthA 
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rPjKUq; fpuhzp kNfhjuk; ePuhik 
jpus;thA R+iy typf;fLg;Gj;jPiu 
ePjKUq; fpUkpFd;kk; mz;lthjk; 
epiyaq;ePh;f; fhpr;ruq;fs; je;J Nkfk;” 
- rjf ehb 
‘ Vtyha; Foyha; gpj;j nra;Fzk; tpsk;gf; Nfsha 
Nfhy;Nty; tpoprpte;J Fwph;e;jpUf;F ky;ykhy; 
rPyNt ePh;fLj;J nehe;J RUf;nfd te;JtPOk; 
QhyNk fpWfpnwd;w ehTyh;e;jpUf; Fe;jhNd”  
 - ,uj;jpdr; RUf;f ehb 
As per Sathaga naadi Derangement of Valiazhal naadi also produces symptoms of 
Kalladaippu. 
nghUshd thjj;jpy; gpj;jQ; Nrh;e;J 
nghUe;J Fzq;fsh K\;zthA rj;jp 
nrhpahik Gspj;Njg;gk; nghUky; ePhpw; 
rptg;Gkyk; gpbj;jYUe; jhJ el;lk;” 
- rjf ehb 
Sparisam (Touch): 
By sparisam, the temperature of the skin (thatpam-cold or veppam-hot), 
smoothness, roughness, sweating, dryness, hard parches, swelling, abnormal 
growth of organs and tenderness can be felt.  In Kalladaippu patient feels 
tenderness over the lower abdomen renal angle and lumber region. Swelling can be 
felt in the case of hydronephrosis. 
Naa (Tongue) 
By the examination of the tongue its colour, size coating, moisture, 
movement, ulcer, fissure, crust can be examined in kalladaippu 
‘fUePh;fy;ypd; tsp rpde;njOe;J 
Ritnfly;  ntspW kWg;G ePh;Ntl;if”       
- Neha; tpsf;fk; 
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Niram (colour) 
 Colour of the skin, conjunctiva, tongue, nail bed and hair etc. 
 Vali udal-dark complexion 
 Azhal udal- wheatish yellow complexion 
 Iyya udal - Fair complexion 
Mozhi (Speech): 
By examining mozhi (speech), the various characters are to be noted such 
as hoarseness, slurring etc., and various disorders of speech such as dysarthria can 
also be noted in kalladaippu. There is low pitched voice due to agonizing pain in 
the   lower abdomen and burning sensation in urethra. 
VizhiEye): 
Examine the colour ofconjunctiva whether reddish or yellowsih 
dicolouration and characters like dryness and lacrimation. 
Malam (Stool): 
By examining malam, its nature (consistency), colour, quantity and 
presence of blood can be noted. 
Neerkuri (Urine Examination): 
Urine examination is one of the good diagnostic tool when compared to 
other Envagai thervugal. 
ePh;Fwpr; rpwg;G: 
‘jh;f;frhj; jphpf shNdhh; 
jq;fspw; Nwh;e;J ehb 
th;f;fkhk; ehb jd;dpy; 
tUtJ kaf;f nkd;Nw 
cw;wePh;g; guPi\ aha;e;Nj 
Aiuj;jd hpjw;F Neuha; 
kw;nwhU tpjpE} ypy;iy 
kUj;Jtf; fiytyNyhh;f;Nf” 
- mq;fhjp ghjk; 
 
The exponents have charted out a method called Neerkuri- an incomparable 
method of diagnosis 
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‘ mUe;Jkh ujKk; mtpNuh jkjha; 
m/fy; myh;jy;mfhyT+z; jtph;j;jow; 
Fw;ws tUe;jp cwq;fp itfiw 
Mbf; fyrj; jhtpNa fhJnka; 
njhUK$h;j; jf;fiyf; Fl;gl;L ePhpd; 
epwf;Fwp nea;f;Fwp epUkpj;jy; flNd” 
     -Njiuah; ePh;f;Fwp nea;f;Fwp itj;jpak; 
On the day before the urine test one should have food consist of all the six tastes 
in an harmonious blend at regular time interval based on one‟s digestive fire(appetite) 
after a sound overnight sleep. Urine should be collected in a crystal bowl and the test 
should be done 90 minutes before dawn. 
Characters of urine: 
‘te;j ePh;f;fhp vil kzk; Eiu vQ;rnyd; 
iwe;jpYstit aiwFJ KiwNa” 
- Njiuah; ePh;f;Fwp nea;Fwpitj;jpak; 
1. Niram (Colour) 
2. Edai(Specific gravity) 
3. Nurai (Froth) 
4. Naatram(Smell) 
5. Enjal (Deposits) 
Urine sample should be examined for the above mentioned five parameters 
 
Niram (Colour) 
Nira thogai: 
‘gPjk; nrk;ikigq; fUik ntz;iknad; 
Nwhijq; nfhOikia nahj;JF ePNu” 
     -Njiuah; ePh;f;Fwp nea;f;Fwp itj;jpak; 
1. Yellow 
2. Red 
3. Green 
4. Black 
5. White 
Urine may be of any Colour mentioned above according to the disease condition. 
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fy;yilg;G ePhpd; Fzk; (Colour indicating urinary stones): 
The colour of the urine look like decomposed flesh cleaned water indicates the 
presence of kidney stone 
‘jPg;Gyhy; fOePh;r; nranydph; Fz;bf; 
 fha;j;Jh;g; gyj;jhy; fjpj;j ePuhkj; 
Jh;g;gyf; fgKk; NrhhpAk; nfhjpg;Gwg; 
gw;gfyhfg; igag; gjpe;jNj” 
     -Njiuah; ePu;f;Fwp nea;Fwp itj;jpak; 
‘fhzpjpy; rPOk; fye;jpop kzKwpd; 
fUg;g ehgpfSq; fhk ehsj;JSk; 
tpuzKd;  bd;Nwy; va;Jfy; kwpay 
jpUj;jNy  jpz;z nkdkdj; Jd;nd” 
- Njiuau; ePh;f;Fwp nea;f;Fwp itj;jpak; 
 
Edai(Specific Gravity): 
Urine which is not thick is considered to be healthy one. 
 
‘kpfj; jbg;Gk; kpfj; NjwYk; ,d;nwdpy; 
Rfj;ijj; jUk;  nka;r; Rght ePh; ed;Nw” 
     -Njiuah; ePh;f;Fwp nea;f;Fwp itj;jpak; 
Nurai(Froth): 
“ge;jnka;g; girapsfg;gLk;gUtj; 
je;jhh; g+jkha; mdpy %j;jpuj;jpy; 
rk;ge;jg;gLk; jjpEiug; GdNy” 
    -Njiuah; ePh;f;Fwp nea;f;Fwp itj;jpak;  
Urine may be frothy in nature, reduced froth in the urine indicates derangement of 
Vali, Azhal and Iyyam. 
Naatram (Odour): 
‘xjkzj;Njh ltNjh nkhj;jp wq;Fk; 
rPjsq; fk;kpa NjfpfSf;Nf 
nta;a Jh;f;fe;jk; tPR ePh; Kj;jpug; 
igehskpw;iwg; gw;W Gz;FwpNa 
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mk;nkhopapd;nwdpddpyNk Kjypa  
Kk;kyr; Rjnk %ykd; WzNu” 
     -Njiuah; ePh;f;Fwp nea;f;Fwp itj;jpak; 
 
Enjal (Deposits): 
If the colour of the urine excreted looks like curd water or milk and the presence 
of white colour and sand like deposits in urine indicates stones in the kindney. It is 
mentioned in the following poem, 
 
‘ehu;j;jjp ePh;ghy; Nghy 
eitAw;w fpopT khdhy; 
khuw;g Kw;wh ePhpyb 
yb kz;bf; fple;j jhdhy; 
ghpj;j nkOF khq;fha; 
gw;wpa fy;yp ehNy 
rPUw;w nra;if nad;W 
njhpTwr; nrg;g yhNk” 
-Njiuah; ePh;f;Fwp nea;f;Fwp itj;jpak; 
Neikkuri: 
 The urine was kept in the kidney tray and exposed to sunlight under non wind 
condition. The urine should be examined after dropping a drop of gingelly oil gently in it 
with a glas rod. If the oil spreads like snake, it indicates Valineer, like a ring indicates 
Azhal neer, and float like pearl indicates Iyya neer and if it sinks in urine, it indicates 
mukkutram. 
 
‘epwf;Fwpf; Fiuj;j epUkhz ePupw; 
rpwf;f ntz;nza;Nahh; rpWJsp eLtpLj; 
njd;Wwj; jpwe;njhyp Vfhjikj;jjp 
dpd;wjptiy Nghk; newptpopawpAk; 
nrd;wJ GfYQ; nra;jpia AzNu” 
-Njiuah; ePh;f;Fwp nea;f;Fwp itj;jpak; 
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‘muntd ePz;bd /Nj thjk;” 
‘Mop Nghw; gutpd; m/Nj gpj;jk;” 
‘Kj;njhj;J epw;fpd; nkhoptnjd; fgnk” 
-Njiuah; ePh;f;Fwp nea;f;Fwp itj;jpak; 
 
In kalladaippu patients, either oil spreads like a ring (azhal neer) or like a snake 
(vali neer). 
rhj;jpa mrhj;jpak;: (Prognosis) 
R+l;ba rhj;jpaj;ijr; nrhy;yf; Nfsha; 
RUf;fhFk; thjj;jpd; fy;yilg;G 
G+l;bl;l gpj;jj;jpd; fy;y ilg;Gg; 
Gfohd Nrl;Lkj;jpd; fy;yilg;G 
%l;bl;l ,J%d;W khrj;a khfp 
Kiahd kUe;Jfspw; nrk;ik ahFk; 
Njhl;bl;l njhe;jkhq; fy;y ilg;Gj; 
njhLRwNt nfhy;YkpJ jhNd 
- A+fp itj;jpa rpe;jhkzp 
 
According to Yugi mamunivar, Vali, Azhal and Iyya kalladaippu are curable 
whereas Thontha kalladaippu is incurable. 
 
kUj;Jtk; (Line Of Treatment) 
‘itj;jpar; nray; itj;jpaNk” 
    -jpU%yh; 800 
The main object of treatment is to bring down the deranged mukkutrams to 
equilibrium by giving purgatives, which cure derangement of vatham, one of the cause 
for kalladaippu. 
‘Ngjpahy; thjk; jhOk;”; 
‘the;jpahy; gpj;jk ; jhOk;” 
‘ mQ;rdj;jhy; fgk; jhOk;” 
-tpahr gfthd; ruPu R+j;jpuk; 
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As per the above mentioned poem, the author gave Agasthyar Kuzhambu 130 mg 
with sangankuppi leaves juice as purgative drug to all patients as per their body 
constitution. 
   In Siddha system, treatment is not only for treating the disease but also for 
preventing and improving the body condition 
Diet: 
‘kUe;Nj czT> czNt kUe;J” 
- jpU%yh;. 
‘khWgh by;yh cz;b kWj;Jz;zpd; 
CWgh by;iyA apu;f;F” 
 
- jpUf;Fws;. 
Do’s 
 Drink 3 to 4 litres of water per day. 
 Take more amount of barley rice porridge, tender coconut, stalk of the greens, 
spadix of the plaintain,  kollu kudineer. 
 Fruits: water melon, cucumber, pineapple, lemon, guava 
 Cereals: dal, black gram, green gram, dried pea 
 Vegetables: radish, broad beans, lady‟s finger, bottle guard, white pumpkin. 
 Seeds: cumin seed, cucumber seed. 
Dont’s 
 Tomato, cabbage, cauliflower, coffee, tea chocolate, meat greens, egg, grapes, 
strawberry, caustic soda, tamarind, betle, areca nut, tobacco, liquor. 
 Preserved beverages, foods rich in salts, salty water, milk and milk products spicy 
and fried foods. 
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ANATOMY KIDNEYS 
Kidneys are a pair of excretory organs situated on the posterior abdominal 
wall, behind the peritoneum, one on each side of the lumbar part of the vertebral 
column. The upper pole of the left kidney reaches the 11th rib while the upper pole 
of the right kidney reaches the 11th intercostal space. 
Shape and size 
 Each kidney is bean-shaped and has two poles, upper and lower, two 
borders, medial poles, upper and lower, two borders, medial and lateral and two 
surfaces anterior and posterior. Each Kidney is 7.5 cm in length, 5 cm in breadth 
and 2.5 cm in thickness. Each Kidney weighs about 120 to 150 gm 
 
 
 
Renal fat and fascia 
The kidneys are enclosed in and associated with a unique arrangement of fascia 
and fat. Immediately outside the renal capsule, there is an accumulation of extraperitoneal 
fat the perinephric fat (perirenal fat), which completely surrounds the kidney Enclosing 
the perinephric fat is a membranous condensation of the extraperitoneal fascia (the renal 
fascia). The suprarenal glands are also enclosed in this fascial compartment, usually 
separated from the kidneys by a thin septum. The renal fascia must be incised in any 
surgical approach to this organ. 
25 
At the lateral margins of each kidney, the anterior and posterior layers of the renal 
fascia fuse This fused layer may connect with the transversalis fascia on the lateral 
abdominal wall. 
Above each suprarenal gland, the anterior and posterior layers of the renal fascia 
fuse and blend with the fascia that covers the diaphragm. 
Medially, the anterior layer of the renal fascia continues over the vessels in the 
hilum and fuses with the connective tissue associated with the abdominal aorta and the 
inferior vena cava. In some cases, the anterior layer may cross the midline to the opposite 
side and blend with its companion layer. 
The posterior layer of the renal fascia passes medially between the kidney and the 
fascia covering the quadrates lumborum muscle to fuse with the fascia covering the psoas 
major muscle. 
Inferiorly, the anterior and posterior layers of the renal fascia enclose the ureters. 
In addition to perinephric fat and the renal fascia, a final layer of paranephric fat 
(pararenal fat) completes the fat and fascias associated with the kidney. This fat 
accumulates posterior and posterolateral to each kidney. 
 
Kidney structure 
Each kidney has a smooth anterior and posterior surface covered by a fibrous 
capsule, which is easily removable except during disease. 
On the medial margin of each kidney is the hilum of kidney, which is a deep 
vertical slit through which renal vessels, lymphatics, and nerves enter and leave the 
substance of the kidney Internally, the hilum is continuous with the renal sinus. 
Perinephric fat continues into the hilum and sinus and surrounds all structures. 
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Each kidney consists of an outer renal cortex and an inner renal medulla. 
The bases of the renal pyramids are directed outward, toward the renal cortex, 
while the apex of each renal pyramid projects inward, towards the renal sinus. The apical 
projection (renal papilla) is surrounded by a minor calyx. 
Renal vasculature and lymphatics 
A single large renal artery, a lateral branch of the abdominal aorta, supplies each 
kidney. 
 
 
 As each renal artery approaches the renal hilum, it divides into anterior and 
posterior branches, which supply the renal parenchyma. Accessory renal arteries are 
common. They originate from the lateral aspect of the abdominal aorta, either above or 
below the primary renal arteries, enter the hilum with the primary arteries or pass directly 
into the kidney at some other level, and are commonly called extrahilar arteries. 
Multiple renal veins contribute to the formation of the left and right renal veins, 
both of which are anterior to the renal arteries. 
The lymphatic drainage of each kidney is to the lateral aortic (lumbar) nodes 
around the origin of the renal artery. 
Ureters 
The ureters are muscular tubes that transport urine from the kidneys to the 
bladder.  
Dimensions 
Each ureter is about 25 cm. (10 inc) long of which the upper  half (5 in) lies in the 
abdomen and the lower half (5 in) lies in the pelvis. It measures about 3mm in diameter 
hut it is slightly constituted at three places.  
They are continuous superiorly with the renal pelvis, which is a funnel-shaped 
structure in the renal sinus. The renal pelvis is formed from a condensation of two or 
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three major calices, which in turn are formed by the condensation of several minor 
calices. The minor calices surround a renal papilla. 
Ureteric vasculature and lymphatics 
The ureters receive arterial branches from adjacent vessels as they pass towards the 
bladder. 
 The renal arteries supply the upper end; 
 The middle part may receive branches from the abdominal aorta, the testicular or 
ovarian arteries, and the common iliac arteries; 
 In the pelvic cavity, the ureters are supplied by one or more arteries from branches 
of the internal iliac arteries. 
 In all cases, arteries reaching the ureters divide into ascending and descending 
branches, which form longitudinal anastomoses. 
 Lymphatic drainage of the ureters follows a pattern similar to that of the arterial 
supply. Lymph from: 
 The upper part of each ureter drains to the lateral aortic (lumbar) nodes; 
 The middle part of each ureter drains to lymph nodes associated with the common 
iliac vessels. 
 The inferior part of each ureer drains to lymph nodes associated with the external 
and internal iliac vessels. 
The complications of urinary tract stones include infection, urinary obstruction, 
and renal failure. Stones may also develop within the bladder and produce marked 
irritation, causing pain and discomfort. 
 The diagnosis of urinary tract stones is based upon history and examination. 
Stones are often visible on abdominal radiographs. Special investigations include: 
 Ultrasound scanning, which may demonstrate the dilated renal pelvis and calices 
when the urinary system is obstructed; and 
 An intravenous urogram, which will demonstrate the obstruction, pinpoint the 
exact level, and enable the surgeon to plan a procedure to remove the stone if 
necessary. 
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URINARY BLADDER 
Introduction 
Urinary bladder is the temporary store house of urine which gets emptied through 
the urethra. The urinary bladder is a muscular reservoir of urine, which lies in the 
anterior part of the pelvic cavity. 
Size, Shape and Position 
 The bladder varies in its size, shape and position according to the amount of urine 
it contains. When empty it lies within the pelvin. But as it fills  it extends upwards into 
the  abdominal cavity reaching upto the umbilicus or even higher.   
External Features 
An empty bladder is tetrahedral in shape and has : (a) An apex, directed forwards; 
(b) a base or fundus, directed backwards; (c) a neck, which is the lowest and most fixed 
part of the bladder; (d) three surfaces, superior, and right and left inferolaternal; and (e) 
four borders, two lateral, one anterior and one posterior. 
Ligaments of the Bladder 
True Ligaments 
These are condensations of pelvic fascia around the neck and base of the bladder. 
They are continuous with the fascia on the superior surface of the levator ani. 
1. The lateral true ligament  
2. The lateral puboprostatic ligament 
3. The medial puboprostatic ligament 
4. The median umbilical ligament 
5. The posterior ligament 
False Ligaments 
 These are peritoneal folds, which do not form any support to the bladder. They 
include: (1) The median umbilical fold; (2) The medial umbilical fold; (3) The lateral 
false ligament (4) The posterior false ligament. 
Interior of the Bladder 
It can be examined by cystoscopy, at operation or at autopsy. 
In an empty bladder, the greater part of the mucosa shows irregular folds due to its 
loose attachment to the muscular coat. 
In a small triangular area over the lower part of the base of the bladder, the 
mucosa is smooth due to its firm attachment to the muscular coat. This area is known as 
the trigone of the bladder. The ureters open at the posterolateral angles of the trigone. 
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Their openings are 2.5 cm apart in the empty bladder, and 5 cm apart in a distended 
bladder. 
Capacity of the Bladder 
The mean capacity of the bladder in an adult male is 220 ml, varying from 120 to 
320 ml. Filling beyond 220 ml causes a desire to micturate, and the bladder is usually 
emptied when filled to about 250 to 330 ml. Filling upto 500 ml may be tolerated. 
Arterial Supply 
1. The Superior and inferior vesical arteries, branches of the anterior trunk of the 
internal iliac artery. 
2. Obturator, and inferior gluteal arteries and in females from the uerine and vaginal 
arteries instead of inferior vesical. 
Venous Drainage 
Drain into the internal iliac veins. 
Lymphatic Drainage 
Most of the lymphatics from the urinary bladder terminate in the external iliac 
nodes. A few vessels may pass to the internal iliac nodes or to the lateral aortic nodes. 
Nerve Supply 
The vesical plexus contains both sympathetic and parasympathetic components, 
Each of which contains motor or efferent and sensory or afferent fibres. 
1. Parasympathetic efferent fibres or Nervi erigentes, S2, S3, S4 are motor to the 
detrusor muscle and inhibitory to the sphincter vesicae. If these are destroyed, 
normal micturition is not possible. 
2. Sympathetic efferent fibres (T11 to L2) are said to be inhibitory to the detrusor and 
motor to the sphincter vesicae. Many workers regard them to be chiefly vasomotor. 
3. The somatic, pudendal nerve (S2, S3, S4) supplies the sphincter urethrae which is 
voluntary. 
4. Sensory nerves: Pain sensations, caused by distension or spasm of the bladder wall, 
are carried mainly by parasympathetic nerves and partly by sympathetic nerves. In 
the spinal cord, pain arising in the bladder passes through the lateral spinothalamic 
tract, and awareness of bladder distension is mediated through the posterior 
columns. 
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THE MALE URETHRA 
Definition 
Male urethra is a membranous canal for the external discharge of urine and 
seminal fluid. 
The male urethra is 18 to 20 cm long. 
External and Location 
The urethra extends from the internal urethral orifice at the neck of the urinary 
bladder to the external urethral orifice at the tip of the penis. 
Paris of the Urethra 
 The prostatic part passes through the prostate. 
  The membranous part is surrounded by the sphincter urethrae. 
  The spongy or penile part passes through the bulb and corpus spongiosum of the      
penis. 
 The length of the prostatic part is 3cm; that of the membranous part is 1.5 to 2 cm; and 
that of the spongy part is about 15 cm. 
Sphincters of the Urethra 
1. The internal urethral sphincter or sphincter vesicae is involuntary in nature. It is 
supplied by sympathetic nerves, from lower thoracic and upper lumbar segments of 
spinal cord. 
2. The external urethral sphincter or sphincter urethrae is voluntary in nature. It is 
made up of striated muscle fibres and is supplied by the perineal branch of the  
pudendal nerve (S2 to S4) 
Vessels and Lymphatics 
The urethra is supplied by the vessels of the prostate and of the penis. The 
lymphatics from the prostatic and membranous parts of the urethra pass mostly to the 
internal iliac nodes and partly to the external iliac nodes. Those from the spongy part 
pass mostly to the deep inguinal nodes, but some may end in the superficial inguinal and 
external iliac nodes. 
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THE FEMALE URETHRA 
1. The female urethra is only 4 cm long and 6 mm in diameter. 
2.  It begins at the internal urethral orifice, at the neck of the urinary bladder roughly 
5 cm behind the middle of the pubic symphysis. It runs downwards and forwards 
embedded in the anterior wall of the vagina, traverses the urogenital diaphragm, 
and ends at the external urethral orifice in the vestibule. 
3. The female urethra is easily dilatable, and catheters or cystoscopes can be easily 
passed through it. 
 
PHYSIOLOGY 
Renal Circulation 
Blood is supplied to the kidney by the renal artery, which arises directly from 
abdominal aorta and enters the kidney through the hilus. While passing through renal 
sinus, the renal artery divides into many segmental arteries, which subdivide into 
interlobar arteries.  
Each interlobar artery passes in between the medullary pyramids. At the base of 
the pyramid, it turns and runs parallel to the base of pyramid forming arcuate artery. 
Each arcuate artery gives rise to interlobular arteries. The interlobular arteries run 
through the renal cortex perpendicular to arcuate artery. From each interlobular artery, 
numerous afferent arterioles arise. 
The afferent arteriole enters the Bowman’s capsule and forms glomerular 
capilliary tuft. The afferent arteriole divides into 4 or 5 large capillaries. Each large 
capillary divides into small capillaries, which form the loops. And, the capillary loops 
unite to form the efferent arteriole, which leaves the Bowman’s capsule. 
The efferent arterioles form a second capillary network surrounding the tubular 
portions of the nephrons. These second set of capillaries are called peritubular 
capillaries. Thus the renal circulation forms a portal system by the presence of two sets 
of capillaries  glomerular capillaries and peritubular capillaries. 
The network of peritubular capillaries supplies the tubular portion of cortical 
nephrons are supplied by some specialized capillaries called vasa racta. Vasa recta arise 
directly from the efferent arteriole of the juxtamedullary nephrons and run parallel to the 
renal tubule into the medulla and ascend up towards the cortex. 
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The peritubular capillaries and vasa recta drain into the venous system, which 
includes the peritubular venules, interlobular veins, arcuate veins, interlobar veins, 
segmental veins and finally the renal vein . 
Renal vein leaves the kidney through the hilus and joins inferior vana cava. 
 
URINE FORMATION 
INTRODUCTION 
Kidneys excrete the unwanted substances including metabolic end products 
and those substances, which are present in excess quantities in the body, through 
urine. 
Normally, about 1 to 1.5 liters of urine is formed everyday. The mechanism 
of urine formation includes various processes. 
First, when blood passes through glomerular capillaries, the plasma is 
filtered into the Bowman’s capsule. When this filtrate passes through the tubular 
portion of the nephron, it undergoes various changes both in quality and in 
quantity. Many wanted substances like glucose, amino acids, water and 
electrolytes are reabsorbed from the tubules. This process is called tubular 
reabsorption. 
And, some unwanted substances are secreted into the tubule from 
peritubular blood vessels. This process is called tubular secretion or excretion. 
Thus, the urine formation includes three processes: 
 I. Glomerular filtration 
 II. Tubular reabsorption 
 III. Tubular secretion. 
GLOMERULAR FILTRATION 
When the blood passes through the glomerular capillaries, the plasma is 
filtered into the Bowman’s capsule. All the substances of plasma are filtered 
except the plasma proteins. The filtered fluid is called glomerular filtrate. During 
filtration, the substances pass through a filtering membrance which is formed by 
three layers of structures: 
1. The endothelium of glomerular capillary membrane 
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2. Basement membrane 
3. Epithelium in the visceral layer of Bowman’s capsule. 
 
 
The glomerular filtration is called ultrafiltration because even the minute particles 
are filtered. But, the plasma proteins are not filtered due to their large molecular size. The 
protein molecules are larger than the slit pores present in the endothelium of capillaries. 
Thus, the glomerular filtrate contains all the substances present in plasma except the 
plasma proteins. 
GLOMERULAR FILTRATION RATE (GFR) 
Glomerular filtration rate (GFR) is the total quantity of filtrate formed in all the 
nephrons of both the kidneys in the given unit of time. 
 The normal GFR is 125 ml per minute or about 180 liters per day. 
FILTRATION FRACTION 
The fraction (portion) of the renal plasma which becomes the filtrate is called 
filtration fraction. It is the ratio between renal plasma flow and glomerular filtration rate. 
It is expressed in percentage. 
Thus filtration fraction  = × 100 
     = × 100 
     = 19.2% 
The normal filtration fraction varies from 15 to 20% 
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PRESSURES DETERMINING FILTRATION 
The pressures, which determine the GFR, are: 
1. Glomerular capillary pressue 
2. Colloidal osmotic pressure 
3. Hydrostatic pressure in the Bowman’s capsule. 
These pressures determine the GFR by either favoring or opposing the filtration. 
1. Glomerular Capillary Pressure 
It is the pressure exerted by the blood in glomerular capillaries. It is about 60 
mmHg and, varies between 45 and 70 mmHg. Glomerular capillary pressure is the 
highest capillary pressure in the body. This pressure favors glomerular filtration. 
2. Colloidal Osmotic Pressure 
It is exerted by plasma proteins in the glomeruli. The plasma proteins are not 
filtered through the glomerular capillaries and remain in the glomerular capillaries. 
These proteins develop the colloidal osmotic pressure which is about 25 mmHg. It 
opposes glomerular filtration. 
3. Hydrostatic Pressure in Bowman’s Capsule 
It is the pressure exerted by the filtrate in Bowman’s capsule during filtration. It is 
also called capsular pressure. It is about 15 mmHg. It also opposes glomerular filtration. 
4. Net Filtration Pressure 
Net filtration pressure is the balance between pressure favoring filtration and 
pressures opposing filtration. It is otherwise known as effective filtration pressure or 
essential filtration pressure. It is very essential for the maintenance of GFR. 
The net filtration pressure = 
        Hydrostatic 
Glomerular   Colloidal   pressure in 
Capillary   osmotic +  Bowman’s 
pressure   pressure   capsule 
  
= 60  (25 + 15) = 20 mmHg, and, it varies between 15 and 20 mmHg. 
 The normal net filtration pressure is about 20 mmHg, and, it varies between 15 
and 20 mmHg. 
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FACTORS REGULATING GFR 
1. Tubuloglomerular Feedback 
         The GFR is constantly regulated through a feedback from renal tubule. Macula 
densa of juxtaglomerular apparatus is responsible for this. 
 When the glomerular filtrate passes through the terminal portion of thick 
ascending segment of renal tubule the macula densa acts like a sensor. It detects the 
concentration of sodium chloride and accordingly alters the blood flow and GFR. 
 When the concentration of sodium chloride increases in the filtrate, macula densa 
secretes thromboxane A2. Thromboxane A2 causes contraction of juxtaglomerular cells 
resulting in constriction of afferent arteriole. 
2. Glomerular Capiliary Pressure 
The GFR is directly proportional to glomerular capillary pressure. When 
glomerular capillary pressure increases, the GFR also increases. The capillary pressure, 
in turn depends upon the renal blood flow and arterial blood pressure. 
3. Colloidal Osmotic Pressure 
The GFR is inversely proportional to colloidal osmotic pressure which is exerted 
by plasma proteins in the glomerular capillary blood. 
4. Hydrostatic Pressure in Bowman’s capsule 
GFR is inversely proportional to this also. 
5. Renat Blood Flow 
It is most important factor necessary for glomerular filtration, GFR is directly 
proportional to this. 
6. Constriction of Afferent Arteriole 
The constriction of afferent arteriole reduces the blood flow to the glomerular 
capillaries which in turn reduces GFR. 
7. Constriction of Efferent Arteriole 
If efferent arteriole is constricted, initially the GFR increases. 
8. Systemic Arterial Pressure 
 It is responsible for flow of blood through various organs including kidneys. 
However, increase in mean arterial blood pressure up to 180 mmHg or reduction up to 
60 mmHg does not alter the renal blood flow or GFR. It is due to the autoregulatory 
mechanism . Variation in pressure above 180 mmHg or below 60 mmHg affects the 
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renal blood flow and GFR accordingly because the autoregulatory mechanism fails 
beyond this range. 
9.Sympathetic Stimulation 
Afferent and efferent arterioles are supplied by sympathetic nerves. The mild or 
moderate stimulation of sympathetic nerves does not cause any significant change either 
in renal blood flow or GFR. 
10. Surface Area of Capillary Membrane 
GFR is directly proportional to the surface area of the capillary membrane. 
11. Permeability of Capillary Membrane 
GFR is directly proportional to the permeability of glomerular capillary 
membrane. 
12. Contraction of Glomerular Mesangial Cells 
Contraction of these cells decreases GFR. 
13. Hormonal and Other Factors 
Many hormones and other factors alter GFR by affecting the blood flow through 
glomerulus. 
TUBULAR REABSORPTION 
When the glomerular filtrate flows through the tubular portion of nephron, both 
quantitative and qualitative changes occur. Large quantity of water (more than 99%). 
electrolytes and other substances are reabsorbed by the tubular epithelial cells. The 
rabosorbed substances move into the interstitial fluid of renal medulla. And from here, 
the substances move into the blood in peritubular capillaries. 
Since the substances are taken back into the blood from the glomerular filtrate, the 
entire process is called tubular reabsorption. 
SELECTIVE REABSORPTION 
The tubular cells of kidney selectively reabsorb the substances present in the 
glomerular filtrate, according to the needs of the body. The substances which are 
necessary for the body such as glucose, amino acids and vitamins are completely 
reabsorbed from renat tubule So, the tubular reabsorption is called the selective 
reabsorption 
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MECHANISM OF REABSORPTION 
The basic transport mechanisms involved in tubular reabsorption are of two 
types: 
1. Active reabsorption 
2.  Passive reabsorption 
Active reabsorption is the movement of molecules against the electrochemical (up hill) 
gradient. It needs liberation of energy which is derived from ATP. 
Substances reabsorbed actively 
The substances reabsorbed actively from the renal tubule are sodium, calcium, 
potassium, phosphates, sulfates, bicarbonates, glucose, amino acids, ascorbic acid, uric 
acid and ketone bodies. 
 In this, the molecules move along the electrochemical (down hill) gradient. This 
process does not need energy. 
Substances reabsorbed passively 
The substances reabsorbed by passive transport are chloride, urea and water. 
ROUTES OF REABSORPTION 
There are two routes for the substances to be reabsorbed from tubular lumen into 
the peritubular capillary called trancelluar and paracellular routes. 
Transcellular Route 
It includes: 
1. Transport from tubular lumen into tubular cell through apical (luminal) surface of the 
cell membrane. 
2. Transport from tubular cell into interstitial fluid 
3. Transport from interstitial fluid into capillary. 
Paracelluar Route 
It includes: 
1. Transport from tubular lumen into interstitial fluid present inlateral intercellular 
space through the tight junction between the cells. 
2. Transport from interstitial fluid into capillary. 
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SITE OF REABSORPTION 
The reabsorption of the substances occurs in almost all the segments of tubular 
portion of nephron. 
1. Substances Reabsorbed from 
Proximal Convoluted Tubule  
Glucose, amino acids, sodium, potassium, calcium, bicarbonates, chlorides, phosphates, 
uric acid and water are reabsorbed from proximal convoluted tubule. 
2. Substances Reabsorbed from Loop of Henle 
The substances reabsorbed from loop of Henle are sodium and chloride. 
3. Substances Reabsorbed from 
Distal Convoluted Tubule 
Sodium, bicarbonate and water are reabsorbed from distal convoluted tubule. 
TUBULAR SECRETION 
Some substances are also secreted into the lumen from the peritubular capillaries 
through the tubular epithelial cells. It is known as tubular secretion or tubular excretion. 
SUBSTANCES SECRETED IN DIFFERENT SEGMENTS OF RENAL TUBULES 
1. Potassium is secreted actively by sodium-potassium pump in proximal and distal 
convoluted tubules and collecting ducts. 
2. Ammonia is secreted in the proximal convoluted tubule. 
3. Hydrogen ions are secreted in the proximal and distal convoluted tubules. Maximum 
hydrogen ion secretion occurs in proximal tubule. 
Thus, urine is formed in the nephron by the processes of glomerular filtration, selective 
reabsorption and tubular secretion. 
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RENAL CALCULI 
Renal and Vesical calculi 
Approximately 2% of the populations in the UK have a urinary tract stone at any 
given time a much higher prevalence of stone disease has been recorded elsewhere, 
notably in the Middle East. In the West, most stones occur in the upper urinary tract. The 
incidence of bladder stones has declined in the UK since the eighteenth and nineteenth 
centuries, whereas in some developing countries they are still common. 
Most stones are composed of calcium oxalate and phosphate; these are more 
common in men mixed infective stones, which account for about 15% of all calculi, are 
twice as common in women as in men. The overall male: female ratio of stone disease is 
2:1. 
Stone disease is frequently a recurrent problem. More than 50% of patients with a 
calculus will have formed a further stone or stones within 10 years. The risk of recurrence 
increases if a metabolic or other abnormality predisposing to stone formation is present 
and is not modified by treatment. 
Type and frequency of renal stones in the UK 
 
Type of renal stone 
Approximate 
frequency (%) 
Calcium oxalate usually with calcium phosphate 65 
Calcium phosphate alone 15 
Magnesium ammonium phosophate (struvite) 10-15 
Uric acid 3-5 
Cystine 1-2 
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KIDNEY STONES: PREDISPOSING FACORS: 
 
Environmental and dietary  
 Low urine volumes: high 
ambient temperatures, 
low fluid intake 
 Diet: high protein intake, 
high sodium, low calcium 
 High sodium excretion 
 High oxalate excretion 
 High urate excretion 
 Low citrate excretion 
Other medical conditions 
 Hypercalcaemia of any 
cause 
 Ileal disease or resection 
(leads to increased 
oxalate absorption 
and urinary excretion) 
 Renal tubular acidosis 
type (distal) (e.g. in Sjögren‟s 
syndrome) 
Congential and inherited conditions 
 Familial hypercalciuria 
 Medullary sponge kidney 
 Cystinuria 
 Renal tubular 
acidosis type ( (distal) 
 Primary hyperoxaluria 
 
TYPES OF STONES 
Calcium salts, uric acid, cystine, and struvite, and struvite, (Mg NH4PO4) are the 
basic constituents of most kidney stones in the western hemisphere. Calcium oxalate and 
calcium phosphate stones make up 75 to 85% of the total Calcium stones.Uric acid 
stones, Cystine stones Struvite stones are more common  in men. The average  of onset is 
the third to fourth decade. Approximate 50% of people  who form a single calcium stone 
eventually torn another‟s with in the next x10 years. The  average rate of few stone 
formation in recurrent stone formers is about one stone every 2 or 3 years. Calcium stone 
disease is frequently familial. 
1. Calcium oxalate stones 
Calcium oxalate stones are the most common type of kidney stone.  Kidney stones 
are solid masses that form in the kidney when there are high levels of calcium, 
oxalate, cystine, or phosphate and too little liquid .Calcium oxalate stones are caused 
by too much oxalate in the urine. 
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Oxalate is a natural substance found in many foods.  Your body uses food for 
energy.  After your body uses what it needs, waste products travel through the 
bloodstream to the kidneys and are removed through urine.  Urine has various wastes 
in it.  If there is too much waste in too little liquid, crystals can begin to form.  These 
crystals may stick together and form a solid mass (a kidney stone). Oxalate is one 
type of substance that can form crystals in the urine.  This can happen if there is too 
much oxalate, too little liquid, and the oxalate “sticks” to calcium while urine is 
being made by the kidneys. 
 
Calcium oxalate stone 
 
 
Calcium phosphate stone 
 
Rrisk factors  
Dehydration from not drinking enough fluid 
 A diet too high in: 
 Protein 
 Oxalate 
 Sodium (salt) 
 Sugar (like high fructose corn syrup) 
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 Obesity 
 Medical conditions like: 
 Dent Disease (a rare genetic disorder that affects the kidneys) 
 Hyperparathyroidism (a very high amount of a type of hormone called 
parathyroid hormone in the blood that causes a loss of calcium. Calcium is 
needed to bind with oxalate and leave the body) 
 Digestive Diseases and Surgeries like: 
 Inflammatory Bowel Disease (IBD) such as: 
 Ulcerative Colitis 
 Crohn‟s Disease 
 Gastric bypass surgeries 
It is important to know that kidney stones are more common if you have 
Inflammatory Bowel Disease (IBD). These conditions affect your body‟s ability to absorb 
fats properly.  When fat is not absorbed the right way, the fat binds to calcium and leaves 
oxalate behind. The oxalate is then absorbed and taken to the kidney, where it can form 
stones. Similarly, following gastric bypass surgery, your body absorbs less calcium from 
your digestive system. Because of this, higher levels of oxalate are found in the urinary 
tract.  The build-up of oxalate can form crystals, which can form kidney stones. 
If your calcium oxalate stones keep coming back, your healthcare provider may 
test you for these conditions. Your healthcare provider may also look at your lifestyle to 
help lower your risk factors or help find the cause of your forming calcium oxalate 
stones. 
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2. Uric acid stones: 
Uric acid stones are radiolucent and are also more common in man.  Half of 
patients with uric acid stones have gout, uric and lithiasis is usually familial whether 
or not gout is present. 
 
 
3.  Cystine stones: 
Cystine stones are uncommon. Their radiopaity is due to the sulfur content. 
Cystine crystals appear in the urine as flat hexagonal plates 
. 
 
4. Struvite stones:  
Struvite stones are common and potentially dangerous. These stones  occur 
mainly in women or patients who require chromic bladder  catheterization and result 
from  urinary treat infection with  crease -  producing  bacteria usually protem 
species. The stones can grow to a large size and fill the renal pelvis and calycer to 
produce a „staghorn‟ appearance. They are radio pague. In urine strutivte crystals are 
rectangular prisms.  
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TABLE 3 Major causes of Renal Stones 
Stone type and 
causes 
Percent 
of all 
stones
o
 
Percent 
occurrence 
of specific 
causes
0 
Ratio of 
males to 
females 
Etiology Diagnosis 
 
Calcium stones 
Idiopathic  
 
Hyperuricosuria 
Hyperuricosuria 
 
 
Primary 
Hyperparathyroidism 
75-85 
 
 
50-55 
 
 
20 
 
 
 
 
5 
2:1 to 3:1 
2:1 
 
4:1 
 
 
 
 
3:10 
Hereditary 
(?) 
 
 
Diet 
 
 
 
Neoplasia 
Normocalcemia, 
unexplained 
hypercalciuria
b 
Urine uric and > 750 
mg per 24h 
(women), > 800 mg 
per 24 h (men) 
Unexplained 
hypercalcemia 
 
Distal renal tubular 
acidosis 
 
Dietary hyperoxaluria 
 Rare 
 
 
10-30 
1:1 
 
 
1:1 
Hereditary 
 
 
High oxalate 
diet of low 
calcium diet 
Hyperchloremic 
acidosis, minimum 
urine pH > 5.5 
Urine oxlate >75 mg 
per 24 h 
Enteric hyperoxaluria  ~1-2 1:1 Bowel 
surgery 
Urine oxlate >75 mg 
per 24h 
Hereditary 
Hyperoxaluria 
 Rare 1:1 Hereditary Urine oxlate and 
glycolic or 1-
glyceric acid 
increased 
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Hypocitraturia  15-60 2:1 to 5:1 Hereditary 
(?), diet 
Urine citrate <320 
mg per 24 h 
Idiopathic stone 
disease 
 20 2:1 Unknown None of the above 
present 
Uric acid stones 5-8     
Gout  ~50 3:1 to 4:1 Hereditary Clinical diagnosis 
Idiopathic  ~50 1:1 Hereditary 
(?) 
Uric acid stones, no 
gout 
Dehydration  ? 1:1 Intestinal, 
habit 
History, intestinal 
fluid loss 
Lesch-Nyhan 
syndrome 
 Rare Males 
only 
Hereditary Reduced 
hypoxanthine-
guanine 
phosphoribosyltransf
erase level 
Malignant tumors 
Cystine stones 
1 Rare 1:1 
1:1 
Neoplasia 
Hereditary 
Clinical diagnosis 
Stone type; elevated 
cystine excretion 
Struvite stones 10-15  2:10 Infection Stone type 
 
STAG HORN CALCULI 
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Aetiology of bladder stones 
Bladder stones are endemic in some developing countries. The cause of this is 
unknown but dietary factors are probably important. Stones forming in the bladder do so 
as a result of: 
 Bladder outflow obstruction (e.g. urethral stricture, neuropathic bladder, prostatic 
obstruction) 
 The presence of a foreign body (e.g. catheters, non-absorbable sutures). 
 Significant bacteriuria is usually found in patients with bladder stones. Some 
stones found in the bladder have been passed down from the upper urinary tract. 
INFECTION 
Although urinary tract infection is not a direct consequence of stone disease, it can 
occur after instrumentation and surgery of the urinary tract, which are frequent in the 
treatment of stone disease. Stone disease and urinary tract infection can enhance their 
respective seriousness and interfere with treatment. Obstruction of an infected kidney by 
a stone may lead to sepsis and extensive damage of renal tissue, since it converts the 
urinary tract proximal to the obstruction into a closed, or partially closed, space that can 
become an abscess. Stones may harbor bacteria in the stone matrix, leading to recurrent 
urinary tract infection. On the other hand, infection due to bacteria that possess the 
enzyme urease can cause stones composed of struvite. 
PATHOGENESIS OF STONES 
Urinary stones usually arise because of the breakdown of a delicate balance. The 
kidneys must conserve water, but they must excrete materials that have a low solubility. 
These two opposing requirements must be balanced during adaptation to diet, climate, 
and activity. The problem is mitigated to some extent by the fact that urine contains 
substances that inhibit crystallization of calcium salts and others that bind calcium in 
soluble complexes. These protective mechanisms are less than perfect. When the urine 
becomes supersaturated with insoluble materials, because excretion rates are excessive 
and/or because water conservation is extreme, crystals form and may grow and aggregate 
to form stone. 
SUPERSATURATION 
In a solution in equilibrium with crystals of calcium oxalate, the product of the 
chemical activities of the calcium and oxalate ions in the solution is termed the 
equilibrium solubility product. If crystals are removed, and if either calcium or oxalate 
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ions are added to the solution, the activity product increases, but no new crystals form. 
Such a solution is metastably supersaturated. If new calcium oxalate seed crystals are 
now added, they will grow in size. Ultimately, as calcium or oxalate are added to the 
solution, the activity product reaches a critical value at which a solid phase begins to 
develop spontaneously. This value is called the upper limit of metastability. Stone growth 
in the urinary tract requires a urine that, on average, is above the equilibrium solubility 
product. Excessive supersaturation is common in stone formation. 
 Calcium, oxalate, and phosphate form many stable soluble complexes among 
themselves and with other substances in urine, such as citrate. As a result, their free ion 
activities are below their chemical concentrations and can be measured only by indirect 
techniques. Reduction in ligands such as citrate can increase ion activity, and therefore 
supersaturation, without changing total urinary calcium. Urine sueprsatuation can be 
increased by dehydration or by overexcretion of calcium, oxalate, phosphate, cystine, or 
uric acid. Urine pH is also important; phosphate and uric acid are weak acids that 
dissociate readily over the physiologic range of urine pH. Alkaline urine contains more 
dibasic phosphate, favouring depostis of brushite and apatite. Below a urine pH of 5.5, 
uric acid crystals (pK 5.47) predominate, whereas phosphate crystals are rare. The 
solubility of calcium oxalate, on the other hand, is not influenced by changes in urine pH. 
Measurements of supersaturation in a pooled 24-h urine sample probably underestimate 
the risk of precipitation. Transient dehydration, variation of urine.pH, and postprandial 
bursts of overexcretion may cause values considerably above average. 
NUCLEATION 
 In urine that is supersaturated with respect to calcium oxalate, these two ions 
form clusters. Most small clusters eventually disperse because the internal forces that 
hold them together are too weak to overcome the random tendency of ions to move away. 
Large ion clusters can remain stable because attractive forces balance surface losses. 
Once they are stable, nuclei can grow at levels of supersaturation below that needed for 
their creation. Cell debris, calcifications on the renal papillae, and other urinary crystals 
can serve as templates for crystal formation, a process known as heterogeneous 
nucleation. Heterogeneous nucleation lowers the level of supersaturation required for 
crystal formation and is likely the mechanism by which wtones form in human urine. 
INHIBITORS OF CRYSTAL FORMATION 
Stable nuclei must grow and aggregate to produce a stone of clinical significance. 
Urine contains potent inhibitors of nucleation, growth, and aggregation for calcium 
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oxalate and calcium phosphate but not for uric acid, cystine, or struvite. In-organic 
pyrophosphate is a potent inhibitor that appears to affect calcium phosphate more than 
calcium oxalate crystals. Citrate inhibits crystal growth and nucleation, though most of 
the stone inhibitory activity of citrate is due to lowering urine supersaturation via 
complexation of calcium. Other urine components such as glycoproteins inhibit all three 
processes of calcium oxalate stone formation. As a consequence of the presence of these 
inhibitors, crystal growth in urine is slow compared with growth in simple salt solutions, 
and the upper limit of metastability is higher.  
EVALUATION 
CALCIUM STONES 
 Idiopathic hypercalciuria. This condition appears to be hereditary, and its 
diagnosis is straight forward. In some patients, parimary intestinal hyperabsorption of 
calcium causes transient postprandial hypercalcemia that suppresses secretion of 
parathyroid hormone. The renal tubules are deprived of the normal stimulus to reabsorb 
calcium at the same time that the filtered load of calcium is increased. In other patients, 
reabsorption of calcium by the renal rubules appears to be defective, and secondary 
hyperparathyroidism is evoked by urinary losses of calcium. 
 Renal synthesis of 1,25-dihydroxyvitamin D is increased, enhancing intestinal 
absorption of calcium. In the past, the separation of “absorptive” and “renal” forms of 
hypercalciuria was used to guide treatment. However, these may not be distinct entities 
but the extremes of a contrinum of behavior. Vitamin D overactivity, either through high 
calcitriol levels or excess vitamin D receptor, is a likely explanation for the hypercalciuria 
in many of these patients. Hypercalciuria contributes to stone formation by raising urine 
saturation with respect to calcium oxlate and calcium phosphate. 
TREATMENT 
For many years the standard therapy for hypercalciuria was dietary calcium 
restriction,. However, recent studies have sohwn that low-calcium diets increase the risk 
of incident stone formation. In addition, hypercalciuric stone formers have reduced bone 
mineral density and an increased risk of fracture compared to the non-stone-forming 
population. Low calcium intake likely contributes to the low bone mineral density. A 
recent prospective trial compared the efficacy of a low-calcium diet to a low-protein, low-
sodium, and normal-calcium diet in preventing stone recurrence in male calcium stone 
formers. The group on the low-calcium diet had a significantly greater rate of stone 
relapse. As a whole, low-calcium diets do not appear to be efficacious and carry a long-
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term risk of bone disease in the stone-forming population. Low-sodium and low-protein 
diets are a superior option in stone formers. 
Hyperuricosuria 
About 20% of calcium oxalate stone formers are hyperuricosurics, primarily 
because of an excessive intake of purine from meat, fish, and poultry. The mechanism of 
stone formation is probably due to salting out calcium oxalate by urate. A low-purine diet 
is desirable but difficult for many patients to achieve. 
Primary Hyperparathyrodism. 
The diagnosis of this condition is established by documenting that hypercalcemia 
that cannot be otherwise explained is accompanied by inappropriately elevated serum 
concentrations of parathyroid hormone. Hypercalciuria, usually present, raises the urine 
supersaturation of calcium phosphate and / or calcium oxalate. 
Distal Renal Acidosis 
 The defect in this condition seems to reside in the distal hephron, which cannot 
establish a normal pH gradient between urine and blood, leading to hyperchloremic 
acidosis. The diagnosis is suggested by a minimum urine pH above 5.5 in the presence of 
systemic acidosis. If the diagnosis is in doubt because metabolic abnormalities are mild, 
oral challenge with NH4Cl, 1.9 mmol/kg of body weight, will not lower urine pH below 
5.5 in patients with distal RTA. Hypercalciuria, an alkaline urine, and a low urine citrate 
level cause supersaturation with respect to calcium phosphate. Calcium phosphate stones 
form, nephrocalcinosis is common, and osteomalcia or rickets may occur. Renal damage 
is frequent, and glomerular filtration rate falls gradually. 
Hypocitraturia 
Urine citrate prevents calcium stone formation by creating a soluble complex with 
calcium, effectively reducing free urine calcium. Hypocitraturia is found in 15 to 60% of 
stone formers, either as a single disorder or in combination with other metabolic 
abnormalities. It can be secondary to systemic disorders, such as RTA, chronic diarrheal 
illness, or hypokalemia, or it may be a primary disorder, in which case it is called 
idiopathic hypocitraturia. 
Idopathic Calcium Lithiasis 
 Some patients have no metabolic cause for stones despite a through metabolic 
evaluation. The best treatment appears to be high fluid intake so that the urine specific 
gravity remains at 1.005 or below throughout the day and night. 
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Investigations 
IVU is very accurate and remains the most commonly used investigation world-
wide, but spiral CT gives the most accurate assessment and will identify non-opaque 
stones (e.g. uric acid). 
Patients with a first renal stone should have a minimum set of investigations; the 
yield of more detailed investigation is low, and hence usually reserved for those with 
recurrent or multiple stones, or those with complicated or unexpected presentations e.g. in 
the very young. 
LABORATORY INVESTIGATIONS:  
Microscopic examination of the urine, which may show  
 Red blood cells 
 Bacteria 
 Leukocytes 
 Urinary casts and crystals.  
Urine Culture to identify any infecting organisms present in the urinary tract 
and Sensitivity to determine the susceptibility of these organisms to specific   
antibiotics. 
Complete Blood Count (CBC), looking for neutrophilia(increased neutrophil  
granulocyte count) suggestive of bacterial infection, as seen in the setting of struvite  
stones.  
Renal Function tests to look for abnormally high blood calcium blood 
levels (hypercalcemia).  
24 hour Urine Collection to measure total daily urinary volume, magnesium, 
sodium, uric acid, calcium, citrate, oxalate and phosphate. 
Collection of stones is useful. Chemical analysis of collected stones can 
establish their  composition,  which  in  turn  can  help  future  preventive  and  
therapeutic management.  
IMAGING TECHNIQUES:  
Various imaging techniques are helpful in determining the presence of kidney 
stones. The best approach uses spiral (or helical) computed tomography scans.  
 If these scans are not available, the patient will need o ultrasound or  
 standard  X-rays.  
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  If no stones show up, but the patient has severe pain that suggests 
thepresence of kidney stones, the next step is an intravenous pyelogram.  
X-RAY:  
A standard x-ray of the kidneys, ureters, and bladder may be a good first 
step for identifying stones, since many are visible on x-rays. Calcium stones can be 
identified on x-rays by their white color. Cystine crystals can also show up on x-rays.  
EXCRETION UROGRAPHY:  
It is the most useful investigation to establish thepresence of calculus. It also 
shows where the stone is and gives important information about the function of the 
other kidney.  
ULTRASOUND:  
Ultrasound can detect clear uric acid stones and obstruction in the urinary 
tract. It is not useful for finding very small stones.  
INTRAVENOUS PYELOGRAM:   
In the procedure Intravenous pyelogram (IVP), the patient is injected with dye. 
X rays are taken as the dye travels through the urinary tract. This procedure is done to 
confirm the presence of kidney stones, although some stones may be too small to see.  
RETROGRADE PYLOGRAM  
It is a urologic procedure where the physician injects contrast into the ureter in 
order to visualize the ureter and kidney. The flow of contrast is opposite the usual 
flow of urine, hence the retrograde name.  
SPIRAL (OR HELICAL) COMPUTED TOMOGRAPHY:  
A type of computed tomography (CT) scan called a spiral or helical CT 
scan is currently the best method for diagnosing stones in either the kidneys or the 
ureters. This test is fast, does not require instruments or foreign chemicals to enter 
the body, and provides detailed accurate images of even very small stones. If stones 
are not present, a spiral CT scan can often identify other causes of pain in the kidney 
area. It is better than x-rays, ultrasound, and intravenous pyelogram -- the previous 
standard test for detecting kidney stone 
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PROTOCOL 
Title: 
 
 Clinical evaluation of siddha formulation “SAARA PARPAM” (internal) in 
the treatment of AZHAL KALLADAIPPU NOI. 
 
Study design and conduct of study: 
Study type   : Open clinical trial 
Study place   :  Out patient department  of Ayothidoss 
Pandithar Hospital, 
National Institute of siddha,     
Tambaram sanatorium,  Chennai-47. 
Study period   :    12 months. 
Sample size   :  40 patients both male and female 
 
Treatment: 
Drug                :  SAARA PARPAM 
Dosage    :   2 Kuntri (260mg) (twice/day) after food 
Adjuvant   : Seeraga kudineer (30ml) 
Route of administration :   Oral route 
Duration of the  
drug administration  : 48 days 
Indication        :  Kalladaippu 
Book Ref   : Pathartha guna vilakkam   
Editor name   : C.Kannusami pillai 
Edition   : 4
th
 edition   
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NEARBY GH 
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Subject selection: 
         As and when patients  reporting at out patient department 1 Maruthuvam, 
Ayothidoss Pandithar Hospital, National Institute of Sddha with  symptoms of inclusion 
criteria will be subjected  to screening  test and documentation will be done by using 
screening  proforma.  
 
Selection criteria: 
Inclusion criteria: 
Patients who will being fulfill any of the following criteria will be included in the study   
 
 Age:20-60 years 
 Sex: Both Male, Female 
 Patients who are having the classical symptoms of abdominal pain, distension, 
pain from loin to groin, pain in urethra, agonizing pain, dysuria, oliguria, yellow 
coloured urination, burning micturition, haematuria, nausea, vomiting. 
 Patient with renal calculus detected on USG Abdomen, Stone size:10mm<4mm 
Patient willing to sign the informed consent stating that he/she will 
conscientiously stick to the treatment during 48 days but can opt out of the trial of 
his/her own conscious discretion. 
 Patient who are willing to take Ultrasonography investigation (USG- Abdomen/ 
KUB) and provide blood sample  for lab investigation. 
 
Exclusion criteria: 
A patient who will meet any of the following criteria will be excluded from 
participation in this study: 
 Stone size > 10mm 
 Pregnancy & Lactation 
 Presence of any associated severe systemic illness eg.CA 
 Diabetes mellitus 
 Hypertension 
 Chronic kidney disease 
 Cardiac disease   
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Withdrawal criteria: 
 Intolerance to the drug and development of any serious adverse reactions during 
the trial period. 
 Patient turned unwilling to continue in the course of clinical trial. 
 Increase in severity of symptoms. 
 Patient will not take medication regularly.  
 
Assessments and investigations: 
a. Clinical assessment 
Siddha assessment 
Routine  investigations: 
1. Modern parameters 
2. Siddha parameters 
b. Specific investigations 
USG 
 
Clinical assessment   
 Pain from loin to groin 
 Pain in urethra,  
 Dysuria,  
 Oliguria 
 Abdominal pain distension 
 Yellow coloured urination 
 Burning micturition, 
 Haematuria 
 Nausea 
 Vomiting  
 
Siddha assessment 
Enn vagai thervu ( Eight types of Examination): 
 Naadi 
 Sparisam 
 Naa 
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 Niram    
 Mozhi 
 Vizhi 
 Malam 
 Moothiram                                                                                                 
 
Siddha parameters: 
 Malam         -   Niram: 
                     -   Elakal / Erukal: 
-   Muraigal (Times / day) : 
 Moothiram (urine): 
Neerkkuri (urine signs):                                         Neikkuri: 
i. Niram: 
ii. Edai: 
iii. Manam: 
iv. Nurai: 
v. Enjal 
 
Routine investigations:   
Modern parameters: 
 Haematology 
 Blood sugar level           -  Fasting (mg/dl) 
 Post prandial (mg/dl) 
 Random (mg/dl) 
 Lipid profile 
 Renal function test    -    Blood Urea (mg/dl) 
Serum total creatinine (mg/dl) 
Uric acid (mg/dl) 
 Liver function test    
 Urine test:                     Albumin 
Sugar(fasting and post prandial) 
   Deposits 
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Bile salts 
Bile pigments 
  Urobilinogen 
Motion test:                        ova, 
 Cyst 
 Occult blood  
Special investigations USG Whole Abdomen/KUB 
 
STUDY ENROLLMENT: 
 In this clinical trial, patients reporting at out patient department, Ayothidoss 
Pandithar Hospital,National Institute of Siddha with the clinical symptoms of  
abdominal pain, distension, pain from loin to groin, pain in urethra, agonizing 
pain, dysuria, oliguria, yellow coloured urination, burning micturition, 
haematuria, and vomiting, nausea will be enrolled in the study based on the 
inclusion and exclusion criteria.  
 The patients enrolled in this study  will be informed (Form V) about the objective 
of the study, trial drug, possible outcomes in their own language and terms 
understandable to them. 
 After ascertaining the patient‟s willingness, informed consent will be obtained in 
the consent form (Form VI). 
 All these patients will be given unique registration card which will contains 
information regarding patients‟ Registration number, Address, Phone number and 
Doctors phonenumber etc. so as to report easily if any adverse reaction arises.  
 Complete clinical history, complaints and duration, examination findings will be 
recorded in the prescribed Proforma in the Clinical research form.  
 Patients will be advised to take the trial drug and appropriate dietary advice 
(FormVIII) would be given according to the patients‟ perfect understanding. 
 
CONDUCT OF THE STUDY: 
As per siddha literature, before starting the treatment for azhal kalladaippu, 
purgation will be given with the out patient department medicine Agasthiar Kuzhambu 
130 mg od with 15ml  of nei(ghee) at early morning in empty stomach for one day 
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Next day rest will be  advised to the patients, 3
rd
 day onwards  the trial drug 
“Saara parpam” will be given given  at a dose of 260mg twice a day after food 
continuously for 48 days. At each clinical visit clinical assessment will be done and 
prognosis will be noted.   
Laboratory investigations and USG Abdomen  will be done on  0
th
 day and24
th
 
day of the trial. If any of the trial patient who fails to collect the trial drug on the 
prescribed day but wants to continue in the trial, from the next day or two ,he/ she will be 
allowed, but defaulters of one week and more will not be allowed to continue and be 
withdrawn from the study with fresh case being inducted.   
Follow-up: After the end of the treatment, the patient is advised to visit the out 
patient department for another 2months for follow-up. In this follow-up period patient‟s 
clinical improvement will be recorded.  
 
DATA MANAGEMENT:  
 After enrolling the patient in the study, a separate file for each patient will be 
opened and all forms will be filed in the file. Study No. and Patient No. will be 
entered on the top of file for easy identification.  Whenever  the study patient 
visits out patient department during the study period, the respective patient`s file 
will be taken and necessary recordings will be made at the assessment form or 
other suitable forms. 
 The screening forms will be filed separately. 
 The Data recordings will be monitored for completion by Guide, Statical research 
officer (Statistics) and the adverse event will be monitored by the members of the  
Pharmacovigilance department of National Insitute of Siddha . All forms will be 
further scrutinized in presence of Investigator by Statical Research Officer 
(Statistics) for logical errors and incompleteness of data to avoid any bias. No 
modification in the results is permitted for unbiased reports. 
 
OUT COME OF TREATMENT: 
The  study uutcome is  mainly assessed  by, 
 Primary out come 
Clearance/reduction in the size of renal calculus in USG Abdomen                    
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Secondary out come  
Complete reduction of clinical symptoms and improvement in other lab 
investigations . 
 
ADVERSE EFFECT/SERIOUS EFFECT MANAGEMENT:  
If the trial patient develops any adverse reaction, he/she will be referred to the 
pharmacovigilance department of National Institute of Siddha. The members of this 
department will assess the adverse event and recorded in the prescribed adverse reaction 
form. For any adverse effect the Patient will be given the proper management at National 
Institute of Siddhac with free of cost.  
 
STATISTICAL ANALYSIS: 
All collected data will be entered into the computer and manually cross-checked 
the correctness of the data entry. The number and size of the calculi  will be paired‟t‟ test 
and chi-square test which will be employed to study the efficacy of treatment.  
 
ETHICAL ISSUES: 
1. Informed consent will be obtained from the patient after explaining in the 
understandable    language to the patient. The patient will be informed about the 
clinical trial, diagnosis, treatment and follow-up.  After getting the consent of the 
patient (through consent form) they will be enrolled in the  study. 
2. Patients will be sent to National Accreditation Board for Testing and Calibration 
Laboratories (NABL) certified laboratory to take USG KUB and the charge will 
be borne by the investigator. 
3. Treatment will be provided free of cost. 
4. No other external medicines will be used. There will be no infringement on the 
rights of patient.  
5. To prevent any infection, while collecting blood sample from the patient, only 
disposable syringes, disposable gloves, with proper sterilization of lab equipments 
will be used.  
6. The data collected from the patient will be kept confidentially.  
7. The patients who are excluded [as per the exclusion criteria] will be given proper     
treatment, in the out patient ward,National Institue of siddha . 
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8. All adverse events occurs during the trial period will be recorded by the members 
of Pharmacovigilance department, National Institute ofSiddha. If it is a mild event 
the patient will be treated at out patient department of NIS. If the adverse event is 
severe the patient will be referred to nearby Govt. hospital and taken care of the 
patient until he/she will recover from the symptoms.The treatment will be 
provided at free of cost. 
 
ASSESSMENT FORMS: 
Form - I                      Screening and Selection Proforma 
Form - II            Case record form 
Form - III                   Laboratory investigation form 
 Form – IV                   Drug Compliance form 
 Form - V                     Information sheet 
Form - VI                   Consent form 
Form -VII                  Withdrawal form/ Adverse drug reaction form/                                  
    Pharmacovigilance form 
Form -VIII                 Dietary advice forms  
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STANDARD OPERATING PROCEDURE FOR SAARA PARPAM 
 REQUIRED RAW DRUGS: 
 Vedi uppu(Potassium nitrate) 
 Navasaaram(Ammonium sulphate)  
 Adhathoda[Justicia vasica Linn] 
Source of raw drugs: 
The above said raw drugs will be purchased from a well reputed                  
country shop at Chennai .The herbal raw drugs will be authenticated by Botanist National 
Institute of Siddha and the mineral raw drugs will be authenticated by Siddha council 
research institute Arumbakkam,Chennai. The raw drugs will be purified and the medicine 
will be prepared as per SOP as in the Gunapadam Laboratory of National Institute of 
Siddha, Chennai.  
Purification of ingredients of the trial drug: 
 Purification of Navacharam: 
Take 70gm navacharam dissolve it in cow‟s urine, filter and boil ,till it condenses 
and dry it. 
Purification of Vediuppu: 
Take 70gm Vediuppu one part dissolve it in two parts of sea water ,filter and boil 
it in an iron vessel transfer it  into a copper vessel and keep in cool place and dry. Repeat 
the above process for 5 to 7 times. 
Purification of Adathodai: 
        Take adequate amount Adathodai leaves and wipe with dry clean cloth and remove 
the putrefied parts and mid vein. 
Method of preparation: 
Purified ingredients: 
1. Purified Navasaram (Ammoniam sulphate) - 2 Palam (70gm) 
2. Purified Vediuppu(Potassium nitrate)  - 2 Palam (70gm) 
3. Adathodai charu     - Adequate amount 
Method of preparation 
Step-1 
Purified Navasaram and Vediuppu are taken and ground well with Adathodai leaf 
juice for 12 hours (4 Samam) and made into a villai. 
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Step-2   
The obtained tablets are placed in a mud container. A mud Container with a ring 
finger sized hole is placed appropriately in upside down position over the mud container 
containing villai and fixed by seelai. 
Step-3 
The container is heated in low flame. The hole above the mud container is covered 
by a round container and fixed by cowdung. 
Step-4  
        When the smoke raises speedly over the hole the container placed above is taken 
slightly and closed to minimise speed of the smoke. 
Step-5  
      After the above procedure the obtained medicine is ground well in a mortar and stored 
in a container. 
 
Dose of drug  - 2 kuntri (260 mg) [twice/day] after food 
Adjuvent  - Seeraga kudineer  
Duration  - 48 days 
Indication         -    kalladaippu    
Reference   - Pathartha Kuna vilakkam kannusamy pillai, pg.no.140-141 
 
Drug storage: 
 The prepared drug will be stored in a clean and dry wide mouthed glass bottle. 
Dispensing:  
The prepared drug will be dispensed in sachets(260mg each) once in 8days for 
48days. At each visit the patients will be advised to return the unconsumed drug if any. 
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DRUG REVIEW 
Navachaaram 
1. Chemical name 
Ammonium chloride or ammoni chloridum. 
2. Other names 
Istigai, Salligai, Sooli 
3. Vernacular names 
Sans    -  Navasara; Navasagara 
Eng    -  Sal Ammoniac 
Arab    -  Armina 
Punj 
Perr   -  Noshandar 
Kash   -  Nausaden 
Hind   -  Navasadara 
Ben   -  Navasagara 
Duk, 
Guj, 
Mah, 
Kon   -  Navasagar 
Tam& 
Sintr   -  Navacharam, Navacharum 
Burm   -   Lovas; Zarasa. 
Mal & Tel                  -           Navasaram 
Colour: 
White or grey colors 
Taste 
Bitter , Sour, Urine smell  
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4. Character: 
 Navachaaram is a clourless in odorous and translucent fibrous mass known as 
Salammoniac- Ammonii Chloridum, Murias Ammonia. It is a thick heavy substance, it so 
hard that it cannot be easily powdered and is of a bitter acrid taste. It is soluble in water 
and rectified spirit.  
Synthetic Preparation of Ammonium Chloride: 
 The Sand available at the places where animals and human beings defecate is 
collected and placed in a pot. To one part of the sand four parts of the urine is added; the 
clear liquid obtained is taken out Camphor, alum and potassium nitrate (3500 gm each) 
are powdered and burnt and added to  1300 litre of the liquid. The mixture is poured is 
another pot and the pot is covered and subjected to sublimation. Ammonium Chloride 
settles as a sublimate.  
5. Actions: 
1. Tonic   -  in small doses given for a long period, improves the  
bodystrength. 
2. Stimulant   -  If given in high doses. 
3. Expectorant  -  
4. Diaphoretic  -  It acts on the lymphatic channel and glands.  
5. Diuretic  
6. Rubi facient  
7. Pitha neutralizer  
6. GENERAL PROPERTIES: 
  ‘Fd;kk; Flw;#iy nfhy;Yk; kNfhjuj;ij 
  td;ikAW fy;yilg;ig khw;Wq;fhz; - rd;kf; 
  ftpr;RKj; Njhlq; fdthj ePf;fk; 
  ethr;rhu khNj etpy;” 
Abdominal pain, distended abdomen, urinary calculus, bad odour in the 
skin, sinusitis, amenorrhoea, whooping cough, intermittent fever three humours, 
indigestion, hepatomegaly, hepatitis, splenomegaly, rhinitis, tuberculosis, 
haematemesis, facial paralysis. 
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7. Saththuru and Miththuru 
ethr;rhuj;jpd; rj;JU: 
fy;Yg;G   Rf;fhd; 
,e;Jg;G   fhhPak; 
gbfk;    fly; Eiu 
tisaYg;G   mg;gpufk; 
,Uk;G   rTL 
fhe;jk;   fpspQ;ry; 
 
ethr;rhuj;jpd; kpj;JU 
jhsfk;  rpiy   fy;ehh; nrk;G 
ntbAg;G  tPuk;   epkpis 
,ypq;fk;  ntq;fhuk;  ehfk;  
 
8. Uses: 
 It relieves hepatiac congestion and modifies hepatic secretions.  
 Useful incases of hepatic abscess, chronic hepatic congestion, and is dropsy 
connected with the liver and ovarian diseases.   
 In cirrhosis and in jaundice from catarrh of the bile ducts. 
 For  hepatitis sal - ammoniac 8-15 grains mixed with 105 grains of  absinthium 
(Worm wood) rubbed well in a mortar with a little water and given in a single 
dose will give relief.  
 It is valuable combined with liquid extract of glycyrrhiza or syrup of country 
liquorice and with a few grains of powdered cinnamon in case of whooping 
cough. 
 In amenorrhea, dysmenorrhea, gleet, leucorrhoea, chronic dysentery and other 
similar chronic dischargers from lungs, stomach and other internal organs. „ 
 In hysteria, nervousness, jaundice and other liver complaints and gastric  catarrh 
doses of 10-20 grains three times daily are beneficial.  
 It is often prescribed as a stimulating expectorant in chronic bronchitis and in 
pneumonia in the stage of resolution.   
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 In various forms of neuralgia, in chronic liver disease, organic or functional in 
rheumatic affections of the face.  
 Externally its solution combined with nitre is a nice cooling andstimulant. 
 Mixed with sulphide of arsenic, it is used as an application to scorpion bites.  
 Ammonium chloride is recommended for local application in cases of cataract.  
 The salt dissolved in the decoction of Hygrophila auriculata may act as a diuretic 
and may be effective in the treatment of jaundice, liver enlargement, and 
splenomegaly. 
 Ammonium chloride and potassium nitrate solution may be used for pain in the 
eye and excessive lacrimation.  
 The salt dissolved in camphorated water and administered twice daily for the 
diseases like flatulency, pain and swelling in the uterus bilious vomiting and 
headache.  
VEDIUPPU 
 
1. Chemical name    
Pottasium nitrate 
2. Other names: 
Pottiluppu, Inangan, Padairasan, Boomikoormai, Navachara Mithru 
3. Vernacular Names - 
San   -  Yovakshara, Saindhava 
Hind, Ben 
Punj & Dut  -  Shora, Sora, Shorakhar 
Eng   -  Saltpetre, Nitre, Nitrate of Potash:   
    Purified Nitre.  
Ariah    -  Abkar, Ubkir 
Pers    -  Shoraba 
Hid & 
Guj   -           Shora 
Mah   -  Shora- mitha 
Guj    -  Shorakhar 
Tel   -           Patluppoo 
Tamil   -  Pottil - uppu 
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Mal    -  Veti Uppu 
Can    -  Patluppu, sen - dur lavana 
Kan    -  Sindur lavana 
Sinh    -  Potlunu 
Malay    -  Sundawa. 
 
4. Rit  -  ifg;G 
tPhpak;  - ntg;gk; 
gphpT  -  ifg;G 
nra;if -  rpWePh; ngUf;fp> Fsph;r;rpAz;lhf;fp> 
tpah;itAz;lhf;fp> tpah;it ngUf;fp  
5. General properties: 
 ‘ky;yhU kl;lFd;k khjUj uf;fl;b 
 fy;yh kijg;G ePH;fl;lUf - nyy;yhNk 
 fk;gp fk;gp nad;Wq; fUTz;lh kq;fp epd;w 
 fk;gp fk;gp nad;Wiuf;Fq;fhy; 
 
 ‘#jf thANthL Nrhzpjj;jpd; thjKk; Nghk; 
 thjtyp Fd;kkpit khWq;fhz; - kPjhq; 
 nfhba tapwpopAq; Nfhiofg NkFk; 
 ntbAg;G jd;id tpsk;G” 
 
 gQ;rG+j  cg;gpy; NjAtpd; $whfpa fk;gp cg;gpdhy;  vz;tpj Fdkk;> 
fUg;ghraf;fl;b> %j;jpuf; fphpr;ruk;> ePh;r;RUf;F> #jpfhthjkk;> 
thjNrhzpjk;> rkhdpa thj> gpj;j fg Fd;kq;fs;> ngUtapW><is> 
fgNjhlk;> ,it xopAk;.  Nghpsk; ngz; gUtq;fle;j khjh;fl;Fk;> fh;g;gk; 
cz;lhFk;. ,jdhy; Ruk;> tPf;fk; fPy;thjk; ,uj;j gpj;jk;> gpuNkfk;> 
fz;Nzha;> njhz;il uzk;> Rthr fhrk; KjypatdTk; ePq;Fk;.  
 It is a salt which is prepared after five process from fuller‟s earth - G+ePhpy; 
fha;r;Rk; Ie;jhk; fha;r;rYg;G. 
 It is a salt prepared from the human skull  
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 It consists of white crystalline masses possessing a saline taste, it exists in a 
natural  state in many parts of India.  
 Those sold in the bazaars are sometimes  are not  sufficiently pure for internal use 
and it may be readily cleansed by dissolving it is hot water straining and setting 
the solutions aside to crystallise needle shaped crystals will be formed and they 
are pure.  
 Salt petre stimulates the skin and the kidney increases perspiration and flow of 
urine  and so cooling the body. It  is very  useful in fevers in inflammatory  
affections, common cold, rheumatism, gout,  bronchitis etc.  
6. Other Uses: 
 Pottasium nitrate in solution is a refrigerant efficient,  diuretic and  disphoretic. It 
acts on the vascular system and thus reduces the frequency of the pulse.   
 It is useful also in the early stages of dropsy in cases of small pox measles 
influenza, catarrh, gonorrhoea, acute rheumatism, bleeding from the lungs, 
stomach, uterus or other internal organs attended by fever.   
 A mixture of nitre 2 parts and leaf juice of the Radish 1 part is given in doses of 
80 grains to relieve scalding and retention of urine also suppression or scantiness 
of urine.  
 In obstinate cases of leucorrhoea a combination of nitre 10 grains and alum 5 
grains is recommended to be taken thrice daily. 
 It maybe advantageously given with infusion of Moringa root.   
ADHATODAI –MlhNjhil 
1. BOTANICAL NAMES :  Adhatoda zeylania  
2. FAMILY   :  Acanthaceae 
3. OTHER NAMES  : Vasai 
4.VERNACULAR NAMES:  
San  -  Sinhaparni, Vasaka, Arusak, Vansa 
Eng  -  Malabhar nut 
Hind   -  Adosa, Arusha 
Ben  -  Adulsa, Bakash 
Pers  -  Bansa 
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Duk  -  Adarsa 
Tel  -   Addasaram, Adampuka 
Tami  -  Adhatodai 
Mat  - Ataloetakam 
Guj  -  Aduraspee 
Punj  -  Bhekkar 
5. HABITANT: 
This plant grows in most parts of India especially in the lower Himalayan 
ranges. 
6. PARTS USED 
Leaves, roots, flowers and bark. 
7. CHEMICAL CONSTITUENTS  
 Alkaloid vasicine is reported from all parts, 2-Hyropsy -4 gluosylozychalcone, 
vasicinine from flowers stem and root, arachidic, behenic, cerotic, lignoceric, linoleic and 
oleic acids from seeds. Ether alkaloids, vasicol, vasicinone,vasicinol, vasicinolone, 
adhatodine  are the  components reported from various parts. 
Vasicine 
 The chief alkaloid vasicine is reported in all parts of the plant highest being in 
inflorescence.  
 The alkaloids vasicine and vasicinone are reported to have smooth muscle 
relaxant action.  
 The alkaloid produces a slight full of blood pressure followed by rise to the 
original level. 
8. Properties:  
 White needle shaped crystals. 
 Melting point  190o-191o 
 Souble in alcohol. 
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9. Rit - ifg;G 
 jd;ik - ntg;gk; 
 gphpT -fhh;g;G 
 
10. MlhNjh ilif;fpuj;j gpj;jkWq; fhr 
khde;j thATld; Nkypisg;G Nkfk; 
#lhFk; jhg Ruk;> gpj;jfg thj 
RuNuhfQ; re;epgh jQ;#iy Fl;lk; 
XlhNth the;jptpf;fy; %y Nuhfk; 
xspNjhlk; cl;fdYk; XopAe; jhNd 
thlhJ kdf;fpsh;r;rp ahFkpjd; ngUik 
tFj;Jiuj;jhh;; Kd;Ndhh;fs; tho;e;jplah tUNk 
11. Actions: 
 Expectorant 
 Diuretic 
 Anti spasmodic 
 Alternative 
12. Pharmcological actvities: 
*Anti spasmodic   * Antibacterial 
*Hypotensive    * Antiviral 
*Bronchodilator   * Hypoglycaemic 
*Respiratory Stimulent  * Uterine stimulant 
* Juvenile Hormone Mimicking  * Ahortifacient activities.  
13.  Other uses. 
 The leave and the root of this plant are considered a very efficacious remedy for 
all sorts of coughs being administered along with ginger.  
 The root is diuretic is useful in bronchitis asthma, bilious vomiting, sore eyes, 
fevers gonorrhea.  
 The leaves are also used for rheumatism. 
 The flowers and the  fruit are bitter aromatic and antispasmodic.  
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 The flowers, leaves and root are supposed  to possess antispasmodic properties.  
 Dried leaves in powdered form are given in doses of 30 grains in malaerial fevers.  
 Fresh flowers are bound over the eyes in ophthalmia. 
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rPufk; 
1. BOTANICAL NAME - Cuminum cyminum L 
2. FAMILY   - Apiaceae (Umbelliferce) 
3.OTHER NAMES 
Asai, Seeri, Upkumbapeesam,  Narcherri, Thuththasambalam, Praththiviaka, Pitha 
nasini, Posanakudari, Meththiyam.  
4. VERNACULR NAMES - 
Sans   -  Ajali, Jeeraka, Ajmoda, Kunchika, Jira 
Eng   -  Cumin seed, Caraway Seed 
Hind & Ben  -  Safed Jeera, Zira, Shiajira, Jira 
Tel   -  Jeelakara 
Tamil   -  Shimai Shombu, Cheerakum, Jeerakam. 
Arb   -  Kamum., Kammon 
Guj   - Safed Jiraun 
Sind   -  Zero 
Pers   -  Zeera, Zira 
Guj   -  Safed Jiraun,  
Sind   - zero. 
Mal   -  Cheerakan, Jeerakan 
Can   -  Jeerigay 
Arab   -  Kamun 
5. HABITANT 
A small slender annual herb, cultivated in almost all the states in India except 
Bengal and Assam.  
6. PARTS USED 
Fruit, Seed 
7. CHEMICAL CONSTITUENTS: 
(i) Lipids:  
Cumin seeds contain upto 14.5 percent lipids. The lipids contain: Neutral 
lipids, glycolipids, and phospholipids, 84.8, 10.1 and 5.1% respectively. 
(ii)  Flavonoid  Glycosides: 
 The seed are reported to contain fourteen flavonoid glycosides of which 
seven belong to apigenin five to luteolin and two to chrysoeriol groups.   
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(iii) Essential oil:  
A valuable essential oil thymene rich in carvone obtained from the seeds.  
8. Rit  -  fhh;g;G> ,dpg;G 
jd;ik  -  jl;gk; 
gphpT -  ,dpg;G 
9. Fzk;: 
  the;jp aUrp Fd;kk;  tha;Neha;gP ypfkpiug; 
  Ngw;wpUky; fy;ypilg;gp yhQ;rdKk;  - Nrh;e;j fk;ky; 
  MdF lhhpnaDk; me;j fpufzpAk; 
  NghrdF lhhpAz;zg; Nghk;  
10. Actions : 
 Carminative 
 Aromatic 
 Stomachic 
 Stimulant 
 Astrigent 
11. Pharmacological and biological  studes  
 Anti Tumour 
 Hypoglycaemic 
 Hypercholesterolaemic / Hypocholesterolaemic 
 Hepatoprotective 
 Cholinergic 
 Antioxidant 
 Gatactagogue 
 Nutritional  
 Anti Bacterial 
 Anti fungal 
 Anti viral 
 Insecticidal  
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12.  OTHER USES: 
 Seeds are cooling in effect and used for gonorrhoeae, chronic diarrhoea, and 
dyspepsia. 
 A quality of the seeds slightly smeared with ghee put into a pipe and smoked 
relieves hiccup.  
 Cumin oil can be readily converted artificially into thymol; thymol is used as an 
anthelmintic against hookworm infestaions and also as an antiseptic.  
 Cumin fruits are very useful in digestive disorders like biliousness, morning 
sickness, indigestion atomic dyspepsia, diarrhoea, flatulent colic. 
 Cumin fruits are also very useful in constipation. 
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 DRUG PHOTOS 
NAVACHARAM 
(Before purification)    (After purification) 
   
VEDIUPPU 
(Before purification)    (After purification) 
  
 
ADATHODAI    SEERAKAM  
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SAARA PARPAM 
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OBSERVATION AND RESULTS 
Distribution of cases by Gender 
Table:1 
Gender No. of Cases Percentage 
Male 20 50 
Female 20 50 
Total 40 100 
 
 
Fig-1 
Inference:  
Among 40 cases male and female were affected equal in number. 
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Distribution of Cases by Kaalam (According to Age) 
Table: 2 
Sl. No Kaalam (Age) No of Cases Percentage 
1 Vadha Kaalam (1-33 years) 20 50 
2 Pitha Kaalam (34-66 years) 20 50 
3 Kapa Kaalam (67-100 years) 0 0 
 
 
Fig:2 
 
Inference: 
Out of 40 cases, 20 cases (50%) were found to be in vatha kaalam i.e 1-33 
years and 20cases (50%) were found to be in pitha kaalam i.e 34-66 years.  
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Distribution of Cases by Occupational Status 
Table: 3  
Sl. No Nature of work No of Cases Percentage 
1 Home maker 17 42.5 
2 Field worker 6 15 
3 Desk worker 13 32.5 
4 Welding worker 4 10 
 Total 40 100 
 
 
Fig-3 
 
Inference:  
The majority of patients in this study were home makers (42.5%) 
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Distribution of Cases by Dietary Habit 
Table: 4  
Sl. No Dietary Habit No of Cases Percentage 
1 Vegetarian 1 2.5 
2 Non Vegetarian 39 97.5 
 Total 40 100 
 
 
`  
Fig-4 
Inference:  
Among 40 cases, 39 cases (97.5%) were non vegetarian and one case 
(2.5%) was vegetarian.  
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Distribution of cases based on the types of drinking water 
Table: 5  
 
Sl. No Drinking Water No of Cases Percentage 
1 Well Water 1 2.5 
2 Corporation Water 2 5 
3 Bore Water 2 5 
4 Mineral Water 35 87.5 
 Total 40 100 
 
 
      Fig-5 
Inference: 
Among 40 cases one case(2.5%) was a well water drinker.In corporation and 
bore water drinkers category each 2 cases were reported, 35 cases were reported under 
mineral water drinkers. 
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4. Distribution of Cases by Habits 
Table: 6 
Sl. No Habits No of Cases Percentage 
1 Alcohol Consumer 2 5 
2 Smoker 1 2.5 
3 Betal nut chewer 0 0 
 
 
     Fig-6  
Inference: 
Among 40 cases, 2 cases (5%) were alcohol consumers; one case (2.5%) was a 
smoker. 
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Distribution of Cases by Treatment history(Other than siddha medicine) 
Table : 7 
 
Treatment History No of Cases Percentage 
Yes 2 5 
No 38 95 
Total 40 100 
 
   
  
 
Fig-7 
Inference: 
Among 40 cases, 2 cases (5%) had taken allopathic treatment in the past 
and had discontinued the same. The rest of the 38 cases (95%) had not taken any other 
drugs prior to enrolling for the study.  
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Distribution of Cases by Family history 
Table: 8 
Family History No of Cases Percentage 
Yes 6 15 
No 34 85 
Total 40 100 
 
 
 
 
 
 
 
 
 
 
 
 
      Fig-8 
 
Inference: 
Among 40 cases, 6 cases (15%) had positive family history.  
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Distribution of Cases by Paruva Kaalam (Season) 
Table-9 
Sl. No Paruva Kaalam No of Cases Percentage 
1 Kaar Kaalam (Aug 17-Oct 17) 0 0 
2 Koothir Kaalam (Oct 17-Dec 16) 0 0 
3 Manpani Kaalam (Dec 16-Feb 12) 20 50 
4 Pinpani Kaalam (Feb 13-Apr 13) 20 50 
5 Elavenil Kaalam (Apr 14-Jun 16) 0 0 
6 Muthuvenil Kaalam (Jun 17-Aug 16) 0 0 
 Total 40 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig-9 
Inference:  
Among 40 cases, 20 cases (50%) were admitted in Munpani kalam (Dec16-
Feb12) and 20 cases (50%) were admitted in Pinpani kalam(Feb13-Apr13). 
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5. Distribution of Cases by Thinai (Land) 
Table-10 
Thinai (Land) No of Cases Percentage 
Kurinji (Hill) 0 0 
Mullai (Forest) 0 0 
Marutham (Fertile) 13 32.5 
Neithal (Coastal) 27 67.5 
Paalai (Desert) 0 0 
Total 40 100 
Thinai 
 
 
Fig-10  
Inference:  
Among 40 cases, 27 cases (67.5%) were from Neithal(coastal) thinai and 13 cases 
(32.5%) were from Marutham (fertile) thinai.  
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Distribution of Cases by Yakkai 
Table-11 
Yakkai No of Cases Percentage 
Vadham 16 40 
Pitham 14 35 
Kapham 4 10 
Thontham 6 15 
 
 
 
 YAKKAI 
 
Inference:  
Among 40 cases 16 cases (40%) were Vatha thegi, 14 cases (35%) were Piththa 
thegi, 4cases (10%) were Kaphathegi and 6 cases (15%) were Tontha thegi. 
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Distribution of Cases by Gunam ( Character) 
Table-12 
Gunam No of Cases Percentage 
Saththuva gunam 1 2.5 
Rajo gunam 34 85 
Thamo gunam 5 12.5 
Total 40 100 
 
 
 
 
 
 
 
 
 
Fig-12 
Inference: 
Out of 40 cases, 34 cases (85%) were found to posses Rajo gunam, 5 cases 
(12.5%) were found to posses Thamo gunam and one case was (2.5%) found to posses 
Saththuva gunam.  
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Distribution of Cases by Envagai Thervugal 
Table-13 
Sl. No En Vagai Thervugal No of Cases Percentage 
1 Naa 11 27.5 
2 Niram 5 12.5 
3 Mozhi 0 0 
4 Vizhi 12 30 
5 Sparisam 8 20 
6 Malam 9 22.5 
7 Moothiram 40 100 
8 Naadi 
a. Vatham 
b. Pitham 
c. Vatha Pitham 
d. Vatha Kapam 
e. Pitha vatham 
f. Pitha kapam 
g. Kapa pitham 
 
1 
1 
3 
5 
19 
9 
2 
 
2.5 
2.5 
7.5 
12.5 
47.5 
22.5 
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  Fig-13 
Inference:  
In En vagaithervukal, Naadi was affected in all the 40 cases (100%), Sparisam 
was affected (numbness) in 8 cases (20%). Naa was affected (taste sensation) in 11 
cases (27.5%).  Niram was affected (pale/hypopigmentation) in 5 cases (12.5%). Vizhi 
was affected (vision) in 12 cases (30%). 
Moothiram was found to be affected (burning micturition/oliguria/) in all the 40 
cases (100%).    
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Distribution of Cases by Udal Kattugal 
Table-14 
Sl. No Udal Kattugal No of Cases Percentage 
1 Saaram 20 50 
2 Sennar 8 20 
3 Oon 7 17.5 
4 Kozhuppu 10 25 
5 Enbu 10 25 
6 Moolai - - 
7 Sukkilam / Suronitham 3 7.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig-14 
Inference:  
Among40  patients,  Saaram  was  affected(indigestion, general tiredness)  in  
20  cases(50%). Senneer was affected (reduction in Hb level) in 8 cases (20%).Oon 
was affected (increase muscle mass) in 7 cases (17.5%). Kozhuppu was affected 
(lower back ache) in 10 cases (25%). Enbu was affected (lower back ache, knee joint 
pain) in 10 cases (25%).Suronitham was affected (irregular menstruation) in 3 cases 
(7.5%). 
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Distribution of Cases by Kosangal 
Table-15 
 
Kosam No of Cases Percentage 
Annamaya Kosam 25 62.5 
Pranamaya Kosam 9 22.5 
Manomaya Kosam 0 0 
Vignamaya Kosam 0 0 
Anandamaya Kosam 3 7.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inference: 
Among 40 cases, Annamaya  kosam was affected(abdominal pain/ anorexia) in  
25 cases (62.5%),  Pranamaya  kosam  was  affected(cold, cough ) in 19  cases 
(47.5)Anandamaya kosam was affected(sleep disturbance) in  3 cases (27.5%). 
Manomaya kosam, Vignamaya kosam were normal in almost all cases. 
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Distribution of Cases by Uyir Thathukkal 
Vatham 
Table-16 
Sl. No Classification of Vatham No of Cases Percentage 
  BT AT BT AT 
1 Pranan 9 4 22.5 10 
2 Abanan 19 9 47.5 22.5 
3 Udhanan 9 7 22.5 17.5 
4 Samanan 40 31 100 77.5 
5 Viyanan 40 24 100 60.5 
6 Naagan 6 5 15 12.5 
7 Koorman 6 6 15 15 
8 Kirukaran 15 10 37.5 25 
9 Devathathan 39 39 97.5 97.5 
10 Dhananjayan 0 0 0 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Fig-16 
Inference:  
Among  40   cases,   Abaanan was affected(burning micturition) in 19 cases 
(47.5%), Pranan(anorexia) was affected in 9 
cases(22.5%),Udhanan(nausea,vomiting) was affected in 9 
cases(22.5%),Samanan(derangement of other vayukkal) ,Viyanan  were  
affected(pain from loin to groin)  in  all  the  40  cases   (100%). Naagan was 
affected (dull vision) in 6 cases (15%), Koorman was affected (dull vision) in6 cases 
(15%) Kirukaran was affected (loss of appetite) in 15 cases (37.5%), Dhevathathan was 
affected (general tiredness) in49 cases (97.5%). 
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Pitham 
Table-17 
Sl. No Classification of Pitham No of Cases Percentage 
  BT AT BT AT 
1 Anarpitham 15 8 37.5 20 
2 Ranjagam 5 5 12.5 12.5 
3 Saathagam 0 0 0 0 
4 Alosakam 5 5 12.5 12.5 
5 Prasakam 5 4 12.5 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig-18 
Inference:  
Among 40 cases, .Anar pitham was affected(loss of appetite/abdominal pain )  
in 15 cases (37.5%), Ranjaga pitham was affected(Hb level was reduced)  ( in 5 cases 
(12.5%) , Alosaka pitham was affected(dull vision) in 5% cases (12.5%), Prasaka 
pitham was affected(paleness) in 5 cases (12.5%). 
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Kapam: Table-18 
Sl. No Classification of Kapam  No of Cases 
 
Percentage 
  BT AT BT AT  
1 Avalambagam 33 16 82.5% 40% 
2 Kelethagam 13 4 32.5% 10% 
3 Pothagam 2 1 5% 2% 
4 Tharpagam 21 4 52.5% 10% 
5 Santhigam 9 8 22.5% 20% 
 
 
 
 
 
 
 
 
 
Fig-18 
 
Inference:  
  Avalambagam  was affected(derangement of other kapam) in 33 cases 
(82.5%),Kilethagam was affected(loss of appetite) in13 cases (32.5%),    Pothagam was 
affected(tastelessness) in2 cases  (5%), Tharpagam was affected(burning sensation of 
the eyes) in 21 cases (52.5%), Santhikam(lower back ache) was affected in 9 cases 
(22.5%). 
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Distribution of Cases by Neerkuri 
Table-19 
Sl. No Neerin Niram No of Cases Percentage 
  BT AT BT AT 
1 Pale Yellow 23 24 57.5 60 
2 Yellow 7 9 17.5 22.5 
3 Dark yellow 0 1 0 2.5 
4 Straw colour 2 1 5 2.5 
5 Colourless 8 5 20 12.5 
 
 
 
 
 
 
 
 
 
 
 Fig-19 
Inference:  
Colour 
In before treatment, pale yellow coloured   urine was observed in 23 cases 
(57.5%) c (5%), yellow coloured urine was observed in 7 cases (17.5%),and colourless 
urine was observed in 8 cases (20%) 
In after treatment, pale yellow coloured   urine was observed in 24 cases 
(60%) , yellow coloured   urine was observed in 9 cases (22.5%),dark yellow 
coloured urine was observed in one case(2.5%),  straw coloured urine was observed 
in one case (2.5%), colourless urine was observed in 5 cases (12.5%). 
     Volume - The volume of urine was reduced in amount in 15 cases (37.5%), rest of 
cases had normal urine volume.  
    Manam-foul smell was observed only in 2 cases (5%) 
    Nurai-froth was observed only in one case (2.5%) 
    Edai, - Normal in all cases 
    Enjal- Enjal present in 2 cases (plenty of pus cells), 
inother cases it was normal. 
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Distribution of Cases By Neikuri 
Table-20 
Sl. No Types No of Cases Percentage 
  BT AT BT AT 
1 Serpentine 0 0 0 0 
2 Ring 1 1 2.5 2.5 
3 Pearl 15 30 37.5 75 
4 Round 10 6 25 15 
5 Sieve 12 1 30 2.5 
6 Others 2 2 5 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig-20 
Inference:  
Among  40 cases the neikuri  in  15 cases (37.5%) the neikuri was observed as 
pearl shape (Kapha neer).In one case (2.5%)the neikuri was observed as ring shape 
(Azhal neer).In 10 cases (25%) the neikuri  was observed as round shape.In 12 cases 
(30%) the neikuri was observed as sieve shape . In 2 cases (5%) the neikuri was 
observed as irregular shape.  
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Distribution of Cases by Chronicity of Illness 
Sl. No Duration of Illness No of Cases Percentage 
1 0-3 months 12 30 
2 4-6 months 9 22.5 
3 7-9 months 5 12.5 
4 Above 9 months 14 35 
 
 
Fig-21 
Inference:  
Among 40 cases 0 to 3 months chronicity of illness was found in 12cases (30%), 4 
to 6 months chronicity of illness was found  in 9 cases (22.5%) ,7 to 9 months 
chronicity of illness was found in 5 cases (12.5%) , above 9 months chronicity of 
illness was found in14 case (35%) .  
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Distribution of Cases by Clinical features 
Table-21 
 
Sl. No Clinical features No of Cases Percentage 
1 Pain from loin to groin 29 72.5 
2 Abdominal pain 22 55 
3 Agonizing pain  4 10 
4 Burning micturition 9 22.5 
5 Oliguria 6 15 
6 Nausea 1 2.5 
7 Vomiting 1 2.5 
8 Dysuria 6 15 
9 Pain in Urethra 2 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig-21 
Inference:  
In  clinical  features,   all  the  29 cases  (72.5%)  had  pain  from  loin  to  
groin region,9 cases(22.5%) had burning micturition , 22 cases (55%) had abdominal 
pain,one case (2.5%) had nausea,4 cases (10%) had agonizing pain,one case 
(2.5%) had vomiting, 6 cases (15%) had oliguria,6 cases (15%) had dysuria, and2 
cases (5%) had pain in urethra. 
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Improvement of Clinical Features after treatment 
Table-22 
Sl. No Improvement No of Cases Percentage 
1 Good 22 55% 
2 Moderate 13 32.5% 
3 Poor 5 12.5% 
4 Total 40 100% 
Clinical Features After Treatment 
 
Fig-22 
 
Improvement:   
Among 40 cases 22cases (55%) had clinically good improvement (symptoms 
completely relieved) after treatment with study drug,13 cases (32.5%) had moderate 
improvement (symptoms reduced), 5 cases(12.5%) had no improvement. 
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Improvement in USG Abdomen 
Table-22 
Sl. No Improvement No of Cases Percentage 
1 Good 15 37.5% 
2 Moderate 16 40% 
3 Poor 9 22.5% 
USG Abdomen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig-23 
Inference:  
Among 40 cases stone 15 cases had good improvement (stone completely 
dissolved), 16 cases (40%) cases had moderate improvement (number of stone and 
stone size-4 to10mm was reduced), 9cases (22.5%) showed poor response (no 
changes in number and size of the stone). 
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STATISTICAL ANALYSIS  
All collected data were entered into MS Excel software using different columns as  
variables and rows as patients. SPSS software was used to perform statistical analysis. Basic  
descriptive statistics include frequency distributions and cross-tabulations were 
performed.  
The quantity variables were expressed as Mean ± Standard Deviation and qualitative 
data as percentage. A probability value of <0.05 was considered to indicate as statistical 
significance.  
 
Distribution of number of calculi before treatment 
Table 1: 
Number of calculi Number of cases Number of cases in 
percentage 
1 12 30% 
2 10 25% 
3 6 15% 
4 5 12.5% 
5 3 7.5% 
8 2 5% 
9 1 2.5% 
 
Distribution of number of calculi after treatment 
Table2: 
 
Number of calculi Number of cases Number of cases in percentage 
0 14 40% 
1 11 28% 
2 6 15% 
3 2 5% 
4 1 2.5% 
5 1 2.5% 
6 2 5% 
7 1 2.5% 
8 1 2.5% 
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Distribution of number of cases before and treatment  
Table:3 
 
Number of 
calculi 
                 Before and after  treatment Total 
number of 
cases 0 1 2 >2 
1 5 6 1 0 12 
2 5 3 2 0 10 
3 4 1 1 0 6 
>3 0 1 2 9 12 
 
Out of 40 cases 12 cases are having one number of calculi. In 12 cases 5cases  has 
got cleaned  the calculusfrom the kidney,6 cases has got one calculi , one cases has 
got 2 calculi .  
      Out of 40 cases 10 cases are having 2 calculi .In 10 cases 5cases are cleared the 
calculi  from the kidney,3 cases has got one calculus , 2 cases has got 2 calculi . 
      Out of 40 cases 6 cases are having three (3) calculi. In 6 cases 4 cases are cleared 
the calculi from the kidney, one cases has got onecalculus ,one cases has got 2 
calculi.  In the remaining 12 cases either one or two calculi has not been cleared from 
the kidney. 
 
Treatment effect on number of calculi 
Table:4 
 
Group Mean±Std t value P value 
Before 2.82±2.05 5.77 0.0001% 
After 1.66±2.11 
 
There is a significant reduction in number of calculi exists in the patients .The 
results reveals 42% reduction in number of calculi  which is statistically siginificant 
(<0.0001) 
Total size of renal calculi is measured by adding the length of the calculi 
obtained from theUSG abdomen. The result shows that 
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The size varies from 4 to 45 mm 
 
 
 
 
 
 
 
 
 
 
 
 
 
The size varies  from 3.4 to 41.2mm 
 
0 14 
1 10 
2 2 
3 4 
4 1 
5 1 
8 3 
9 3 
 
Treatment effect on size of calculi 
Table:4 
 
Group Mean±Std t value P value 
Before 12.61±9.12 5.42 0.0001% 
After 7.34±9.26 
 
There is a significant reduction in size of calculi exists in the patients .The 
results reveals 42% reduction in number of calculi  which is statistically siginificant 
(<0.0001) 
1 4-6 10 
2 6-8 6 
3 8-10 7 
4 10-12 0 
5 12-14 3 
6 14-16 3 
7 16-18 1 
8 18-20 3 
9 >20 7 
 BLOOD INVESTIGATION BEFORE AND AFTER TREATMENT 
SL.NO OPD NO AGE/SEX 
Hb gm % T.RBC mill/µl 
BT AT BT AT 
1 I24184 30/19 15.7 16.7 5.3 5.5 
2 R39175 54/F 13.2 12.7 5.0 4.8 
3 H98065 26/F 13.1 13 4.5 4.5 
4 T13626 41/F 11.5 12 3.7 3.8 
5 J27576 38/F 12.1 11.7 4.6 4.6 
6 H30190 25/M 14.8 14.8 4.9 4.8 
7 I17346 37/M 16 16.1 5.2 5.3 
8 H68985 32/M 16.8 14.6 5.9 4.9 
9 I47697 52/M 14.5 15.1 4.7 4.9 
10 I32545 56/F 13.1 13.7 5.0 5.2 
11 I41220 28/M 15.4 15.1 5.3 5.2 
12 I76332 48/F 11.4 10.6 4.8 5.0 
13 E015989 58/M 14.8 15.1 5.3 5.3 
14 H73783 26/F 9.1 9.7 3.9 4.2 
15 I50768 33/M 14.1 14.9 4.5 4.5 
16 I56310 29/M 13.8 13.9 4.6 4.6 
17 I26784 39/M 15.3 15.1 5.4 5.3 
18 I01756 60/M 13.6 13.5 4.4 4.4 
19 I55334 26/M 16.2 15.6 5.6 5.3 
20 I55616 44/M 15.5 16.00 5.4 5.5 
21 I61203 34/M 15.7 15.0 5.5 5.3 
22 I61285 45/M 15.9 15.1 5.8 5.5 
23 I14652 29/M 15.7 14.7 5.4 5.6 
24 I59235 27/F 12.8 12.9 4.8 5.0 
25 I25479 20/F 11.6 11.5 4.6 4.5 
26 I45578 30/M 16.6 16.2 5.5 5.4 
27 I62094 27/M 15.0 15.0 5.0 5.1 
28 H44868 42/F 11.4 10.6 4.1 4.0 
29 I64463 36/F 13.6 13.1 4.5 4.2 
30 H79813 36/F 8.7 9.6 4.1 4.6 
31 H70471 26/F 12.7 13.1 4.4 4.5 
32 I39495 32/F 14.2 13.6 5.0 5.0 
33 I66809 29/F 12.2 11.5 4.4 4.1 
34 I63770 34/F 12.3 12.5 4.5 4.5 
35 H9394 28/M 15.4 14.5 5.2 4.9 
36 I44707 37/F 12.4 12.5 4.8 4.9 
37 I70641 40/F 13.8 13.4 5.0 4.8 
38 H74488 26/M 15.3 6.1 5.4 5.7 
39 I73515 43/F 10.6 10.5 5.2 5.6 
40 i69309 30/F 12.3 11.7 4.5 4.3 
 BLOOD INVESTIGATION BEFORE AND AFTER TREATMENT 
S.NO OPD NO AGE/SEX 
TC cells/µl TC cells/µl 
BT AT 
1 I24184 30/M 8400 8400 
2 I39175 54/F 6400 7300 
3 H98065 26/F 8000 8100 
4 I3626 41/F 5700 6700 
5 I27576 38/F 8500 9400 
6 H30190 25/M 6000 8100 
7 I17346 37/M 10,700 8900 
8 H68985 32/M 7900 7900 
9 I47697 52/M 7100 7500 
10 I32545 56/F 7800 7900 
11 I41220 28/M 2200 8200 
12 I76332 48/F 7600 7900 
13 E015989 58/M 7900 8800 
14 H73783 26/F 5800 7500 
15 I50768 33/M 11,400 12500 
16 D56310 29/M 5500 6200 
17 I26784 39/M 68000 5400 
18 I01756 60/M 6300 7300 
19 I55334 26/M 6000 8200 
20 I55616 44/M 6400 7000 
21 I61203 34/M 5900 7200 
22 I61285 45/M 7500 8300 
23 I14652 29/M 6100 6200 
24 I59235 27/F 7700 7900 
25 I25479 20/F 8200 9000 
26 I45578 30/M 5900 6000 
27 I62094 27/M 7200 7000 
28 H44868 42/F 8000 5600 
29 I64463 36/F 8600 8000 
30 H79813 36/F 10,700 9100 
31 H70471 20/F 9500 8000 
32 I38495 32/F 13900 9100 
33 I66809 29/F 7300 7100 
34 I63770 34/F 7100 6200 
35 H9394 25/M 8900 7100 
36 I44707 37/M 8000 7700 
37 I70641 40/F 11,400 10,100 
38 H74488 26/M 5700 6100 
39 H73575 43/F 8000 6500 
40 I69309 30/F 8400 7600 
 
 
 
 
BLOOD INVESTIGATION BEFORE TREATMENT 
SL.
NO 
OPD NO AGE/SEX 
DC% ESR mm/hr BLOOD 
P L M E B ½ hr 1hr 
Sugar 
mg/dl 
Urea 
mg/dl 
S.creatnine 
mg/dl 
S. Uric 
Acid 
mg/dl F PP 
1 I24184 30/M 66 29 01 04 --- 2 4 80 135 18 1.0 7.9 
2 I39175 54/F 54 40 02 04 --- 8 16 71 74 15 0.8 4.0 
3 H98065 26/F 58 36 02 04 --- 6 12 65 120 10 0.7 2.4 
4 I13626 41/F 64 30 02 06 --- 2 4 73 74 19 0.8 3.5 
5 I27576 38/F 75 22 -- 03 --- 4 8 84 128 17 0.8 4.0 
6 H30190 25/M 63 30 02 05 --- 6 12 76 83 25 0.9 4.3 
7 I17346 37/M 60 34 02 04 --- 6 12 68 125 16 1.0 6.6 
8 H68985 32/M 40 43 01 16 --- 2 4 76 110 17 1.1 6.9 
9 I47697 52/M 65 30 01 04 --- 6 12 76 97 25 1.0 7.4 
10 I32545 56/F 54 42 01 03 --- 14 30 87 110 16 0.9 4.9 
11 I41220 28/M 50 46 00 04 --- 8 16 75 151 18 0.9 5.8 
12 I76332 48/F 56 39 02 02 --- 8 14 76 110 20 0.8 4.5 
13 F015989 58/M 65 27 00 08 --- 10 22 80 114 23 1.2 6.7 
14 H73783 26/F 49 46 01 04 --- 12 26 71 72 10 0.8 4.6 
15 I50768 33/M 65 27 02 05 --- 8 16 73 101 11 1.0 5.4 
16 I56310 29/M 65 30 02 03 --- 10 20 100 95 11 0.9 4.8 
17 I26784 39/M 56 39 01 04 --- 40 8 69 72 14 1.0 4.7 
18 I01756 60/M 60 34 02 04 --- 12 24 89 98 17 1.0 4.8 
19 I55334 26/M 55 40 00 05 --- 2 4 102 114 15 1.0 7.2 
20 I55616 44/M 50 44 02 04 --- 8 16 90 103 17 1.0 5.2 
 
 
 
 
 
BLOOD INVESTIGATION BEFORE TREATMENT 
SL.
NO 
OPD NO AGE/SEX 
DC% ESR mm/hr BLOOD 
P L M E B ½ hr 1hr 
B.Sugar 
 mg/dl 
 
S.Urea 
mg/dl 
 
S.creatinine 
mg/dl 
S. Uric 
Acid 
mg/dl F PP 
21 I61203 34/M 62 32 02 04 --- 2 4 97 136 20 1.1 4.3 
22 I61285 45/M 60 33 02 05 --- 4 8 107 135 20 1.2 3.8 
23 I14652 29/M 60 34 02 04 --- 30 42 111 133 16 1.0 4.8 
24 I59235 27/F 54 43 01 02 --- 40 82 96 114 11 0.9 5.7 
25 I25479 20/F 65 30 00 05 --- 10 22 105 123 09 0.8 3.4 
26 I45578 30/M 48 46 02 04 --- 6 12 109 118 24 1.0 3.8 
27 I62094 27/M 59 34 02 05 --- 6 12 98 130 18 1.0 4.6 
28 H44868 42/F 70 24 01 05 --- 30 62 97 121 15 0.8 3.3 
29 I64463 36/F 60 34 01 05 --- 4 8 100 120 16 1.1 3.6 
30 H79813 36/F 70 26 01 04 --- 16 32 87 130 9 0.7 3.8 
31 H70471 26/F 58 38 01 03 --- 18 26 87 120 14 0.8 4.2 
32 I38495 32/F 65 28 02 05 --- 8 18 99 140 18 0.8 3.9 
33 I66809 29/F 60 37 03 00 --- 12 26 92 124 13 0.8 4.5 
34 I63770 34/F 60 33 02 05 --- 16 32 98.1 92 17.6 0.89 4.6 
35 H9394 20/M 62 29 02 07 --- 04 08 108 101 13 1.0 5.4 
36 I44707 37/F 55 40 01 04 --- 16 32 99 124 13 0.9 4.7 
37 I70641 40/F 68 29 01 02 --- 12 24 106 131 12 1.0 5.1 
38 H74488 26/M 51 44 03 02 --- 4 10 110 130 16 0.9 6.9 
39 I7357 43/F 62 33 01 04 --- 4 8 105 123 12 0.8 4.4 
40 I69309 30/F 75 20 01 04 --- 6 120 105 132 0.6 0.7 4.5 
 
 
BLOOD INVESTIGATION AFTER TREATMENT 
SL.
NO 
OPD NO AGE/SEX 
DC% 
ESR  
mm/hr 
BLOOD 
P L M E B ½ hr 1hr 
Sug 
mg/dl 
Urea 
mg/dl 
S.Crea 
mg/dl 
S.Uric 
Acid 
mg/dl F 
 
PP 
1 I24184 30/M 66 28 02 04 --- 2 4 94 144 14 1.2 6.4 
2 I39175 54/F 60 36 00 04 00 14 28 97 123 16 0.8 3.5 
3 H98065 26/F 55 39 02 04 --- 10 22 93 97 10 0.8 2.6 
4 I13626 41/F 55 40 -- 05 --- 4 8 97 110 19 0.9 3.3 
5 I27576 38/F 70 26 -- 04 --- 16 32 118 130 09 0.9 4.5 
6 H30190 25/M 66 29 02 03 --- 4 8 97 131 23 1.0 5.6 
7 I17346 37/M 55 42 01 02 --- 10 20 103 130 19 1.0 7.5 
8 H68985 32/M 45 40 01 14 --- 2 4 97 100 15 1.1 8.3 
9 I47697 52/M 65 30 -- 05 --- 8 16 105 164 15 1.0 5.9 
10 I32545 56/F 60 38 -- 02 --- 14 30 108 107 23 0.9 4.1 
11 I41220 28/M 56 41 01 02 --- 14 28 116 170 19 1.0 6.3 
12 I76332 48/F 61 36 01 02 --- 6 12 110 100 14 1.0 4.5 
13 F015989 58/M 60 32 00 08 --- 6 12 87 142 20 1.4 6.6 
14 H73783 26/F 55 40 02 03 --- 10 22 88 102 15 0.8 4.1 
15 I50768 33/M 65 27 02 05 --- 4 8 92 130 12 1.2 5.1 
16 I56310 29/M 68 25 02 05 --- 6 12 97 120 15 1.0 7.4 
17 I26784 39/M 60 34 02 04 --- 6 12 89 117 17 1.2 5.8 
18 I01756 60/M 60 33 03 04 --- 4 8 86 113 15 1.1 5.7 
19 I55334 26/M 62 32 02 04 --- 4 8 97 130 20 1.1 7.5 
20 I55616 44/M 66 29 02 03 --- 10 22 96 100 12 0.8 7.1 
 
 
 
BLOOD INVESTIGATION AFTER TREATMENT 
S.N
o 
OPD NO AGE/SEX 
DC% ESR mm/hr BLOOD 
P L M E B ½ hr 1hr 
Sug 
mg/dl 
Urea 
mg/dl 
S.Crea 
mg/dl 
S.Uric 
Acid  
mg/dl F 
 
PP 
21 I61203 34/M 64 31 02 03 --- 2 4 111 132 08 1.0 5.2 
22 I61285 45/M 72 23 02 03 -- 2 4 101 130 20 1.2 4.7 
23 I14652 29/M 64 31 01 04 --- 2 4 111 132 08 1.0 5.2 
24 I59235 27/F 59 38 -- 03 --- 20 40 91 112 12 0.9 5.7 
25 I25479 20/F 68 29 01 02 --- 30 62 100 120 22 1.0 4.1 
26 I45578 30/M 50 44 02 04 --- 4 8 96 131 17 1.1 3.7 
27 I62094 27/M 65 30 01 04 --- 6 10 110 130 18 1.1 4.1 
28 H44868 42/F 64 32 02 02 --- 8 16 95 111 18 0.9 2.5 
29 I64463 36/F 65 30 02 03 --- 10 20 109 98 13 0.9 5.1 
30 H79813 36/F 69 26 01 04 --- 20 42 85 96 09 0.7 4.0 
31 H70471 26/F 65 32 01 02 --- 18 36 111 96 16 0.7 5.0 
32 I38495 32/F 61 31 02 06 --- 2 6 92 111 13 0.9 2.7 
33 I66809 29/F 56 40 -- 04 --- 16 32 84 120 14 0.9 4.6 
34 I63770 34/F 62 34 01 03 --- 42 86 95 88 18 0.9 4.8 
35 H9394 20/M 59 31 04 06 --- 2 4 92 89 24 1.1 5.4 
36 I44707 37/F 63 35 00 02 --- 10 22 88 91 09 1.0 5.3 
37 I70641 40/F 66 31 00 03 --- 12 26 91 110 14 1.1 4.7 
38 H74488 26/M 45 45 02 08 --- 2 6 101 -- 15 1.0 6.0 
39 I73575 43/F 62 32 02 04 --- 4 8 86 120 10.5 0.9 2.9 
40 I69309 30/F 69 27 01 03 --- 3 6 100 133 060.9 0.7 3.5 
 
 
 
BLOOD INVESTIGATION BEFORE AND AFTER TREATMENT 
SL.
NO 
OPD NO AGE/SEX 
BEFORE TREATMENT AFTER TREATMENT 
PCV
% 
MCV 
%ft 
MCH 
pg 
MCHC 
gm/dl 
PLA 
lkh/µl 
PCV% 
MCV 
%ft 
MCH 
pg 
 
MCHC 
gm/dl 
PLATE 
lkh/µl 
1 I24184 30/M 46.6 86.5 29.1 33.7 3.1 49.4 88.5 29.9 33.8 3.5 
2 I39175 54/F 40.7 81.2 26.3 32.4 3.0 39.4 81.7 26.3 32.2 3.0 
3 H98065 26/F 38.5 84.4 28.7 34 2.2 39 86.5 28.8 33.3 2.7 
4 I13626 41/F 34.5 92.5 30.8 33.3 2.3 35.9 93.2 31.2 33.4 2.1 
5 I27576 38/F 37.2 79.7 25.9 32.5 4.5 36 77.4 25.2 32.5 5 
6 H30190 25/M 43 87.6 30.1 34.4 3.3 43.7 90.3 30.6 33.9 3.4 
7 I17346 37/M 44.2 85 30.8 36.2 3.1 45 84.9 30.4 35.8 3.2 
8 H68985 32/M 48.5 81.5 28.2 34.6 3.1 42 85.5 29.7 34.8 3.0 
9 I47697 52/M 44.7 89.8 30.83 33.8 2.7 42.2 89.0 30.6 34.4 2.6 
10 I32545 56/F 40.1 79.9 26.7 33.4 2.2 42 80.2 26.1 32.6 1.9 
11 I41220 28/M 44.7 83.1 28.6 34.5 2.5 44.6 84.8 28.7 33.9 2.3 
12 I76332 48/F 37.2 85.0 28.2 33.3 2.2 35.2 84.2 28.6 33.7 2.0 
13 F015989 58/M 43.9 82.4 27.8 33.7 2.8 43.8 81.4 28.1 34.5 2.6 
14 H73783 26/F 29 74.2 23.3 31.4 3.3 31.1 73.5 22.9 31.2 3.7 
15 I50768 33/M 41.9 91.5 31.2 34.1 3.5 44 95.9 32.5 33.9 4.0 
16 I56310 29/M 39.8 85.4 29.6 34.7 2.4 40.6 87.7 29.6 33.7 2.5 
17 I26784 39/M 46.7 86.0 28.2 32.8 1.9 46 85.8 28.2 32.8 2.0 
18 I01756 60/M 38.5 86.5 30.6 35.3 2.00 38.3 86.5 30.2 35.2 2.8 
19 I55334 26/M 46.7 83.2 28.9 34.9 2.2 45.3 84.0 28.9 34.4 2.1 
20 I55616 44/M 44.9 82.8 28.6 34.5 3 45 84 30 35.4 3.1 
 
 
 
BLOOD INVESTIGATION BEFORE AND AFTER TREATMENT 
SL.
NO 
OPD NO AGE/SEX 
BEFORE TREATMENT AFTER TREATMENT 
PCV
% 
MCV 
%ft 
MCH 
pg 
MCHC 
gm/dl 
PLA 
lkh/µl 
PCV% 
MCV 
%ft 
MCH 
pg 
 
MCHC 
gm/dl 
PLA  
lkh/µl 
21 I61203 34/M 47.8 86.8 28.5 32.8 3.4      
22 I61285 45/M 46.4 79.3 27.2 34.3 1.6 43.6 79.3 27.5 34.6 1.6 
23 I14652 29/M 46.2 84.2 28.6 34.0 2.2 44.0 87.0 29.1 33.4 2.2 
24 I59235 27/F 39.5 81.4 26.4 32.4 4.8 40.5 80.8 25.7 31.9 4.0 
25 I25479 20/F 37.3 80.7 25.1 31.1 3.7 36.9 81.1 25.3 31.2 3.2 
26 I45578 30/M 49.7 88.9 29.7 33.4 2.8 47.6 88.1 30.0 34 28 
27 I62094 27/M 44.3 87.9 29.8 33.9 2.4 44.0 27.0 27.5 31.8 2.5 
28 H44868 42/F 34.0 82.9 27.8 33.5 3.6 33.8 83.5 26.2 31.4 3.2 
29 I64463 36/F 39.6 86.7 29.8 34.3 2.9 44.0 87.0 29 32.7 2.1 
30 H79813 36/F 29.5 71.6 21.1 29.5 4.1 30.7 76.0 23.8 31.3 42 
31 H70471 26/F 38.8 88.2 28.9 32.7 3.7 39.9 87.9 28.9 32.8 3.8 
32 I38495 32/F 43.3 85.2 28 32.8 2.3 41.2 86.2 28.5 33.0 2.5 
33 I66809 29/F 36.0 81.3 27.5 33.9 2.3 33.9 81.9 27.8 33.9 2.6 
34 I63770 34/F 37.9 82.6 26.8 32.5 3.6 38.4 84.2 27.4 32.6 3.6 
35 H9394 20/M 45.5 86.8 29.4 33.8 2.6 42.9 86.5 29.2 33.8 2.6 
36 I44707 37/F 37.8 78.6 25.8 32.8 2.9 38.2 77.8 25.5 32.7 2.8 
37 I70641 40/F 40.8 81.4 27.5 33.8 3.2 40.4 82.6 27.4 33.2 3.1 
38 H74488 26/M 46.1 84.1 27.9 33.2 1.9 47.8 82.7 27.9 33.7 1.8 
39 I73575 43/F 34.0 82 27.5 32.5 2.4 33.7 79.9 24.9 31.2 1.9 
40 I69309 30/F 37.3 81.3 26.8 33.0 3.8 36.5 83.1 26.7 32.1 3.0 
 
 
 
BLOOD INVESTIGATION BEFORE TREATMENT 
SL.
NO 
OPD 
NO 
AGE/
SEX 
T.Bili
rubin 
mg/dl 
D.Bili 
mg/dl 
ID.Bil
irubin 
mg/dl 
SG 
OT 
IU/L 
SG 
PT 
I/UL 
S. 
ALP 
IU/L 
T.Prot
ein 
gm/dl 
S.Alb
umin 
gm/dl 
S.Globi 
gm/dl 
S.Cal
cium
mg/dl 
S.ph
os 
mg/
dl 
T.Ch
omg/
dl 
HD
L 
mg/
dl 
LD
L 
mg/
dl 
VL
DL 
mg/
dl 
TG
L 
mg/
dl 
1 I24184 30/M 0.9 0.3 0.6 29 44 72 7.8 4.8 3.0 9.6 3.0 220 50 129 32 158 
2 I39175 54/F 1.0 0.4 0.6 19 14 69 7.4 4.4 3 9 4.7 234 90 129 14 71 
3 H98065 26/F 0.5 0.2 0.3 15 11 62 7.6 4.5 3.1 9.1 3.2 180 62 105 17 83 
4 I13626 41/F 1.0 0.4 0.6 15 14 41 6.6 4.0 2.6 8.7 3.1 149 55 79 16 78 
5 I27576 38/F 0.2 0.1 0.1 22 17 73 7.5 4.3 3.2 8.7 2.8 158 54 103 29 146 
6 H30190 25/M 0.7 0.3 0.4 19 26 71 7.1 4.5 2.6 8.5 3.5 160 56 87 11 53 
7 I17346 37/M 0.3 0.1 0.2 20 27 56 6.8 4.2 2.6 8.2 3.9 125 35 70 24 119 
8 H68985 32/M 0.8 0.3 0.5 25 33 78 7.9 4.7 3.2 8.9 3.0 180 38 106 23 113 
9 I47697 52/M 0.8 0.3 0.5 16 26 78 7.5 4.3 3.2 9.0 3.1 7.4 49 85 29 144 
10 I32545 56/F 0.8 0.3 0.5 18 19 45 6.9 4.2 2.7 9 3.3 136 38 81 26 130 
11 I41220 28/M 0.6 0.2 0.4 27 34 137 7.8 4.5 3.3 9.2 2.5 148 39 90 24 121 
12 I76332 48/F 0.6 0.2 0.3 21 17 45 7.6 4.5 3.1 9.1 3.7 180 62 105 18 83 
13 F015989 58/M 0.4 0.2 0.2 21 27 84 7.1 4.3 2.8 8.8 2.8 110 52 61 15 76 
14 H73783 26/F 0.5 0.2 0.3 11 10 64 7.0 4.2 2.8 7.7 3.1 136 46 80 17 87 
15 I50768 33/M 0.8 0.3 0.5 22 29 79 7.0 4.6 2.4 8.5 2.5 150 52 76 15 73 
16 I56310 29/M 0.7 0.3 0.4 11 6 55 7.2 4.3 2.9 8.3 3.5 132 42 81 14 72 
17 I26784 39/M 1.1 0.4 0.7 18 22 53 6.8 4.3 2.5 8.3 2.4 160 53 91 15 75 
18 I01756 60/M 0.6 0.3 0.3 15 12 38 6.7 4.5 2.3 9.1 3.7 124 35 71 27 134 
19 I55334 26/M 0.8 0.2 0.6 24 31 126 7.5 4.1 3.4 7.5 2.1 163 45 100 20 99 
20 I55616 44/M 0.8 0.3 0.5 22 25 97 6.8 4.1 2.6 7.9 2.9 148 53 86 19 97 
 
 
 
BLOOD INVESTIGATION BEFORE TREATMENT 
SL.
NO 
OPD 
NO 
AGE/
SEX 
T.Bili
rubin 
mg/dl 
D.Bili 
mg/dl 
ID.Bil
irubin 
mg/dl 
SG 
OT 
IU/L 
SG 
PT 
I/UL 
S. 
ALP 
IU/L 
T.Prot
ein 
gm/dl 
S.Alb
umin 
gm/dl 
S.Globi 
gm/dl 
S.Cal
cium
mg/dl 
S.ph
os 
mg/
dl 
T.Ch
mg/dl 
HD
L 
mg/
dl 
LD
L 
mg/
dl 
VL
DL 
mg/
dl 
TG
L 
mg/
dl 
21 I61203 34/M 0.7 0.2 0.5 18 20 73 7.0 4.0 3.1 7.5 1.3 122 42 65 37 184 
22 I61285 45/M 0.5 0.2 0.3 20 24 67 7.2 4.1 3.1 7.9 1.6 150 46 89 18 92 
23 I14652 29/M 0.7 0.2 0.5 14 15 54 7.6 4.3 3.2 8.5 2.2 202 42 121 37 187 
24 I59235 27/F 0.5 0.2 0.3 14 20 67 7.4 4.2 3.2 7.8 4.0 162 48 97 25 126 
25 I25479 20/F 0.4 0.2 0.2 13 10 70 7.2 4.1 3.1 7.9 2.5 150 46 89 21 107 
26 I45578 30/M 0.6 0.2 0.4 16 31 97 7.4 4.4 3.0 8.1 4.0 165 41 97 39 198 
27 I62094 27/M 1.1 0.4 0.7 34 47 71 7.0 4.3 2.7 8.6 3.3 170 57 100 13 663 
28 H44868 42/F 0.4 0.2 0.2 16 11 75 7.2 4.0 3.2 7.5 3.2 158 47 94 26 130 
29 I64463 36/F 0.6 0.3 0.3 15 10 71 7.1 4.6 2.6 9.0 3.2 174 57 94 18 90 
30 H79813 36/F 0.3 0.1 0.2 12 12 78 7.4 4.2 3.1 7.5 3.6 153 43 91 18 88 
31 H70471 26/F 0.3 0.1 0.2 14 16 56 7.3 4.3 3.0 8.1 3.2 164 56 94 23 115 
32 I38495 32/F 1.2 0.4 0.8 14 12 73 7.1 4.1 3.0 8.7 3.8 204 62 123 30 152 
33 I66809 29/F 0.7 0.3 0.4 16 12 50 7.2 4.3 3.0 8.0 3.2 151 48 84 33 167 
34 I63770 34/F 0.5 0.2 0.3 18 16 59 7.0 4.0 3.0 9.4 3.4 187 49 124 14 71 
35 H9394 20/M 0.3 0.1 0.2 16 13 58 7.4 4.2 3.1 9.1 3.6 106 37 59 11 59 
36 I44707 37/F 0.6 0.2 0.4 15 27 94 7.2 4.5 2.7 9.1 3.4 197 56 120 19 96 
37 I70641 40/F 0.6 0.2 0.3 12 07 84 7.0 4.1 3.0 8.4 3.0 166 59 94 20 104 
38 H74488 26/M 0.9 0.4 0.5 16 27 81 7.1 4.3 2.7 8.9 3.3 194 69 100 28 140 
39 I73575 43/F 0.4 0.2 0.2 16 11 75 4.0 3.2 4.0 7.8 3.0 157 46 90 26 130 
40 I69309 30/F 0.8 0.3 0.5 13 18 90 7.0 4.2 2.8 8.8 3.1 177 57 105 10 49 
 
 
 
BLOOD INVESTIGATION AFTER TREATMENT 
SL.
NO 
OPD 
NO 
AGE/
SEX 
T.Bili
rubin 
mg/dl 
D.Bili 
mg/dl 
ID.Bili
rubin 
mg/dl 
SG 
OT 
IU/L 
SG 
PT 
I/UL 
S. 
ALP 
IU/L 
T.Prot
ein 
gm/dl 
S.Alb
umin 
gm/dl 
S.Globi 
gm/dl 
S.Cal
cium
mg/dl 
S.ph
os 
mg/
dl 
T.Ch
omg/
dl 
HD
L 
mg/
dl 
LD
L 
mg/
dl 
VL
DL 
mg/
dl 
TG
L 
mg/
dl 
1 I24184 30/M 0.5 0.2 0.3 17 24 93 7.5 4.5 3.0 8.3 2.2 183 48 114 23 114 
2 I39175 54/F 1.1 0.4 0.7 21 17 61 7.3 4.2 3.1 7.9 3.6 210 79 123 14 68 
3 H98065 26/F 0.5 0.2 0.3 13 10 74 7 4.4 3.3 8.6 2.9 195 62 115 20 99 
4 I13626 41/F 1 0.5 0.5 13 11 40 6.8 4.0 2.8 8.3 3.0 115 56 64 13 67 
5 I27576 38/F 0.2 0.1 0.1 12 15 68 7.3 3.9 3.4 8.7 3.3 158 54 90 35 175 
6 H30190 25/M 0.9 0.4 0.5 24 50 75 7.5 4.7 2.8 9.3 3.4 165 61 98 13 67 
7 I17346 37/M 0.8 0.3 0.5 18 19 45 6.9 4.2 2.7 9 3.3 136 38 81 26 130 
8 H68985 32/M 0.3 0.2 0.1 41 51 102 7.1 4.2 3.0 8.7 4.0 129 29 83 50 251 
9 I47697 52/M 0.6 0.2 0.4 14 18 86 7.0 4.1 2.9 8.5 3.7 124 46 69 28 139 
10 I32545 56/F 0.5 0.2 0.3 8 11 114 7.7 4.5 3.2 11 2.4 170 47 96 32 161 
11 I41220 28/M 0.9 0.4 0.5 22 31 135 7.5 4.5 2.9 9 2.9 154 37 101 15 74 
12 I76332 48/F 0.6 0.2 0.4 13 11 68 7.5 4.7 2.8 8.2 3.3 115 56 64 35 120 
13 F015989 58/M 0.5 0.2 0.3 17 23 84 6.8 4.2 2.6 8.4 2.8 183 47 49 11 56 
14 H73783 26/F 0.7 0.3 0.4 15 13 66 7.5 4.6 2.9 8.9 4.0 164 54 86 20 99 
15 I50768 33/M 0.7 0.3 0.4 11 6 55 7.2 4.3 2.9 8.3 3.5 132 42 81 14 72 
16 I56310 29/M 0.4 0.2 0.2 18 10 51 7.0 4.4 2.6 9.3 3.6 145 50 77 88 38 
17 I26784 39/M 0.9 0.4 0.5 17 17 56 7.1 4.3 2.7 8.5 3.4 156 44 89 19 93 
18 I01756 60/M 0.6 0.3 0.3 15 11 48 6.7 4.4 2.3 9.3 3.0 123 46 65 21 107 
19 I55334 26/M 0.4 0.2 0.2 17 31 147 7.1 4.3 2.8 4.3 2.8 169 47 92 22 110 
20 I55616 44/M 0.7 0.3 0.4 8 17 113 6.8 4.0 2.8 8.4 2.8 120 56 64 13 100 
 
 
 
BLOOD INVESTIGATION AFTER TREATMENT 
SL.
NO 
OPD 
NO 
AGE/
SEX 
T.Bili
rubin 
mg/dl 
D.Bili 
mg/dl 
ID.Bil
irubin 
mg/dl 
SG 
OT 
IU/L 
SG 
PT 
I/UL 
S. 
ALP 
IU/L 
T.Prot
ein 
gm/dl 
S.Alb
umin 
gm/dl 
S.Globi 
gm/dl 
S.Cal
cium
mg/dl 
S.ph
os 
mg/
dl 
T.Ch
mg/dl 
HD
L 
mg/
dl 
LD
L 
mg/
dl 
VL
DL 
mg/
dl 
TG
L 
mg/
dl 
21 I61203 34/M 0.7 0.2 0.5 20 22 64 6.4 3.2 3.2 9.0 2.5 150 45 85 30 120 
22 I61285 45/M 0.6 0.3 0.3 23 27 65 6.7 3.9 3.0 8.5 2.9 142 48 86 31 154 
23 I14652 29/M 0.7 0.2 0.5 14 15 54 7.6 4.3 3.2 8.5 2.2 202 42 121 37 187 
24 I59235 27/F 0.4 0.1 0.2 12 20 69 7.7 4.4 3.3 8.6 2.6 166 47 88 25 129 
25 I25479 20/F 0.3 0.1 0.2 15 9 73 7.5 4.4 3.1 9.3 4.1 156 42 84 15 77 
26 I45578 30/M 0.7 0.4 0.3 16 21 95 7.2 4.3 3.0 8.9 3.7 135 40 82 48 241 
27 I62094 27/M 0.6 0.3 0.3 18 20 52 7.4 4.2 3.1 9.1 2.3 150 41 84 23 120 
28 H44868 42/F 0.4 0.2 0.2 25 17 76 7.3 4.3 2.7 8.8 3.0 176 48 99 19 97 
29 I64463 36/F 0.6 0.3 0.3 15 10 71 7.1 4.6 2.6 9.0 3.2 174 57 94 18 90 
30 H79813 36/F 0.3 0.1 0.2 13 08 79 7.1 4.0 3.1 7.5 3.2 164 43 96 20 101 
31 H70471 26/F 0.3 0.1 0.2 14 16 56 7.3 4.3 3.0 8.1 3.2 164 56 94 23 145 
32 I38495 32/F 1.2 0.5 0.7 16 09 67 7.0 4.2 2.8 8.5 3.4 162 96 50 19 96 
33 I66809 29/F 0.5 0.2 0.3 20 18 57 6.9 4.1 3.0 9.5 3.5 133 44 79 36 183 
34 I63770 34/F 0.5 0.2 0.3 18 16 59 7.0 4.0 3.0 9.4 3.4 187 49 124 14 71 
35 H9394 20/M 0.5 0.2 0.3 25 24 53 8.0 4.1 4.0 8.8 2.9 107 35 54 10 50 
36 I44707 37/F 0.6 0.2 0.4 14 14 91 6.8 4.4 2.5 9.1 3.3 184 47 107 14 72 
37 I70641 40/F 0.5 0.2 0.3 15 11 88 6.8 3.8 3.0 7.9 3.1 166 57 93 19 94 
38 H74488 26/M 1.5 0.7 0.9 14 29 83 7.3 4.4 3.0 9.6 4.1 217 68 134 34 171 
39 I73575 43/F 0.5 0.2 0.3 14 19 65 8.0 3.7 4.0 7.8 3.0 157 46 90 24 123 
40 I69309 30/F 0.6 0.3 0.3 19 14 76 6.5 3.9 3.0 9.7 3.3 162 48 108 15 74 
 
 
 
URINE ANALYSIS BEFORE AND AFTER TREATMENT 
SL.
NO 
OPD NO 
AGE/
SEX 
BEFORE TREATMENT AFTER TREATMENT 
Alb Sug 
Deposit 
BS BP Uro Alb Sug 
Deposit 
BS BP Uro Pus 
Cell 
Epi 
cell 
Pus 
Cell 
Epi 
cell 
1 I24184 30/M Nil Nil 3-5 2-4 Nil Nil N Nil Nil 2-3 1-2 Nil Nil N 
2 I39175 54/F Nil Nil 1-2 1-3 Nil Nil N Nil Nil 1-2 1-2 Nil Nil N 
3 H98065 26/F Nil Nil 2-4 2-4 Nil Nil N Nil Nil 1-2 1-2 Nil Nil N 
4 I13626 41/F Nil Nil 1-2 2-4 Nil Nil N Nil Nil 4-5 2-3 Nil Nil N 
5 I27576 38/F Nil Nil 1-2 1-2 Nil Nil N Nil Nil 1-2 1-2 Nil Nil N 
6 H30190 25/M Nil Nil 2-3 1-2 Nil Nil N Nil Nil plenty 3-5 Nil Nil N 
7 I17346 37/M Nil Nil 1-2 1-2 Nil Nil N Nil Nil 1-2 1-2 Nil Nil N 
8 H68985 32/M Nil Nil 1-2 2-4 Nil Nil N Nil Nil 6-7 2-3 Nil Nil N 
9 I47697 52/M Nil Nil 4-5 10-12 Nil Nil N Nil Nil 4-5 4-5 Nil Nil N 
10 I32545 56/F Nil Nil 1-2 1-3 Nil Nil N Nil Nil 1-2 2-3 Nil Nil N 
11 I41220 28/M Nil Nil 3-5 4-6 Nil Nil N Nil Nil 3-5 1-2 Nil Nil N 
12 I76332 48/F Nil Nil 1-2 1-2 Nil Nil N Nil Nil 2-3 1-2 Nil Nil N 
13 F015989 58/M Nil Nil 3-5 3-5 Nil Nil N Nil Nil 1-2 2-3 Nil Nil N 
14 H73783 26/F Nil Nil 1-2 1-2 Nil Nil N Nil Nil 2-3 2-3 Nil Nil N 
15 I50768 33/M Nil Nil 2-3 3-5 Nil Nil N Nil Nil 2-3 1-2 Nil Nil N 
16 I56310 29/M Nil Nil 2-3 2-3 Nil Nil N Nil Nil 3-5 3-5 Nil Nil N 
17 I26784 39/M Nil Nil 2-4 2-4 Nil Nil N Nil Nil 3-5 1-2 Nil Nil N 
18 I01756 60/M Nil Nil 2-3 2-3 Nil Nil N Nil Nil 2-4 1-2 Nil Nil N 
19 I55334 26/M Nil Nil 1-2 4-5 Nil Nil N Nil Nil 1-2 1-2 Nil Nil N 
20 I55616 44/M Nil Nil 1-2 2-3 Nil Nil N Nil Nil 2-4 1-2 Nil Nil N 
 
 
 
URINE ANALYSIS BEFORE AND AFTER TREATMENT 
SL.
NO 
OPD NO 
AGE/
SEX 
BEFORE TREATMENT AFTER TREATMENT 
Alb Sug 
Deposit 
BS BP Uro Alb Sug 
Deposit 
BS BP Uro Pus 
Cell 
Epi 
cell 
Pus 
Cell 
Epi 
cell 
21 I61203 34/M Nil Nil 1-2 1-2 Nil Nil N Nil Nil 1-2 1-2 Nil Nil N 
22 I61285 45/M Nil Nil 2-4 1-2 Nil Nil N Nil Nil 1-2 1-2 Nil Nil N 
23 I14652 29/M Nil Nil 2-4 2-4 Nil Nil N Nil Nil 2-3 1-2 Nil Nil N 
24 I59235 27/F Nil Nil 6-7 2-3 Nil Nil N Nil Nil 2-3 1-2 Nil Nil N 
25 I25479 20/F Nil Nil 1-2 1-2 Nil Nil N Nil Nil 4-5 2-3 Nil Nil N 
26 I45578 30/M Nil Nil 3-5 3-5 Nil Nil N Nil Nil 2-3 1-2 Nil Nil N 
27 I62094 27/M Nil Nil 2-4 2-4 Nil Nil N Nil Nil 1-2 1-2 Nil Nil N 
28 H44868 42/F Nil Nil 1-2 2-3 Nil Nil N Nil Nil 2-4 1-2 Nil Nil N 
29 I64463 36/F Nil Nil 1-2 2-4 Nil Nil N Nil Nil 2-3 1-2 Nil Nil N 
30 H79813 36/F Nil Nil 1-2 1-2 Nil Nil N Nil Nil 1-2 1-2 Nil Nil N 
31 H70471 26/F Nil Nil 1-2 1-2 Nil Nil N Nil Nil 2-4 2-4 Nil Nil N 
32 I38495 32/F Nil Nil 1-2 1-2 Nil Nil N Nil Nil 6-8 4-6 Nil Nil N 
33 I66809 29/F Nil Nil loaded loaded Nil Nil N Nil Nil 6-7 2-4 Nil Nil N 
34 I63770 34/F Nil Nil 4-5 2-3 Nil Nil N Nil Nil 3-5 2-4 Nil Nil N 
35 H9394 20/M Nil Nil 4-5 2-3 Nil Nil N Nil Nil 1-2 1-2 Nil Nil N 
36 I44707 37/F Nil Nil plenty 4-5 Nil Nil N Nil Nil 1-2 1-2 Nil Nil N 
37 I70641 40/F Nil Nil 2-4 2-4 Nil Nil N Nil Nil 1-2 3-5 Nil Nil N 
38 H74488 26/M Nil Nil 3-5 1-3 Nil Nil N Nil Nil 1-2 4-5 Nil Nil N 
39 I73575 43/F Nil Nil 2-4 1-2 Nil Nil N Nil Nil 2-4 1-2 Nil Nil N N 
40 I69309 30/F Nil Nil 1-2 1-2 Nil Nil N Nil Nil 3-5 2-4 Nil Nil N 
 
 
 
USG ABDOMEN RESULTS BEFORE AND AFTER TREATMENT 
S. 
NO 
OPD 
NO 
AGE/
SEX 
  SIZE OF THE 
KIDNEY 
SITE OF THE CALCULUS NO OF 
CALCULUS 
SIZE OF THE CALCULUS 
1 I24184 30/M 
RT KIDNEY 
BT 9 .1 × 4.4 Interpole 1 10mm 
AT 9 .5 × 4.5 Interpole 1 10mm 
LT KIDNEY 
BT 9 .5 × 4.1 Ureter, Interpole 2 6mm, 9mm 
AT 10 .9 × 4.2 Interpole 1 10mm 
2 I39175 54/F 
RT KIDNEY 
BT 9 .4 × 3.9 Upperpole 1 4.5mm 
AT 10 × 4.2 upperpole 1 3.8mm 
LT KIDNEY 
BT 9 .6 × 4.4 ---- --- --- 
AT 10 .1 × 4.7 lower calyx 1 4.9mm 
3 H98065 26/F 
RT KIDNEY 
BT 10 .1 × 4 upper, mid lower calyx 4 5.7, 3.8, 4.6, 4.5mm 
AT 9 .1 × 4.7 upper, mid, lower calyx 5 4.3, 3.9, 6.1, 4.7, 4.5mm 
LT KIDNEY 
BT 9 .8 × 4.1 ---- ---- ---- 
AT 10 .1 × 4.8 lower calyx 1 6.1mm 
4. 4 I13626 41/F 
RT KIDNEY 
BT 10 .4 × 4.5 upper, mid  calyx 2 5.4mm, 4.4mm 
AT 9  × 3.9 Upper,  lower calyx 2 3.7mm, 3.4mm 
LT KIDNEY 
BT 10 .5 × 4.2 ---- --- --- 
AT 9 .2 × 4.2 ---- --- --- 
5 I27576 38/F 
RT KIDNEY 
BT 10 .2 × 3.8 Upper  calyx 1 4.3mm 
AT 9 .8 × 3.9 --- --- --- 
LT KIDNEY 
BT 10 .2 × 4.3 ---- --- --- 
AT 11 .5 × 4.8 mid calyx 1 5.0mm 
6 H30190 25/M 
RT KIDNEY 
BT 9 .5 × 5.3 lower, mid, upper calyx 3 6.4mm, 8.9mm, 4.9mm 
AT 9 .6 × 5.2 mid calyx 1 6.8mm 
LT KIDNEY 
BT 11  × 6.1 mid, upper calyx 2 7.3mm, 7.6mm 
AT 9 .7 × 5.1 upper calyx 1 
4.9mm 
 
 
 
7 I17346 37/M 
RT KIDNEY 
BT 10.7 × 5.1 --- --- --- 
AT 9.4 × 5.3 --- --- --- 
LT KIDNEY 
BT 11 × 5.8 
mid calyx, 
mid ureter 
2 5.4mm, 7.6mm 
AT 9.9 × 5.1 Lowerpole 1 4.9mm 
8 H68985 32/M 
RT KIDNEY 
BT 9.6 × 4.6 lower calyx 1 5.8mm 
AT 9.1 × 4.1 --- 0 --- 
LT KIDNEY 
BT 10.6 × 5 --- --- --- 
AT 9.8 × 4.7 --- --- --- 
9 I47697 52/M 
RT KIDNEY 
BT 10.8 × 42 Ureter, upper, mid, lower calyx multiple largest-6mm 
AT 109.8 × 51.2 upper, middle lower calyx 3 largest-6.6mm 
LT KIDNEY 
BT 99 × 42 Lower, mid calyx multiple largest 3mm 
AT 108.7 × 53 mid, lower calyx 3 Largest 3.6mm 
10 I32545 56/F 
RT KIDNEY 
BT 10.0 × 49 --- --- --- 
AT 10.0 × 49 --- --- --- 
LT KIDNEY 
BT 9.8 × 4.0 lower calyx 1 4.5mm 
AT 9.8 × 4.0 --- --- --- 
11 I41220 28/M 
RT KIDNEY 
BT 9.4 × 4.5 upper & lower calyx 2 5.3mm 4.5mm 
AT 9.1 × 4.6 mid, lowerpole 2 3.5mm 5.6mm 
LT KIDNEY 
BT 10 × 4.6 lower calyx, ureter 2 4.5mm 4.5mm 
AT 9.7 × 4.5 upperpole 1 3mm 
12 I76332 48/F 
RT KIDNEY 
BT 10.5 × 3.8 --- --- --- 
AT 9.5 × 3.1 --- --- --- 
LT KIDNEY 
BT 9.5 × 4.6 Vesico ureteric junction 1 4.4mm 
AT 8.9 × 4.5 --- --- --- 
13 F015989 58/M 
RT KIDNEY 
BT 10.9 × 4.8 mid & lowerpole 2 4mm, 6mm 
AT 10.7 × 4.7 mid calyx 1 4.9mm 
LT KIDNEY 
BT 10.7 × 5.2 --- --- --- 
AT 10.3 × 5 --- --- 
--- 
 
 
 
14 H73785 26/F 
RT KIDNEY 
BT 9.1 × 3.7cm --- --- --- 
AT 10 × 4.1cms --- --- --- 
LT KIDNEY 
BT 10.2 × 4.3cm upper & mid calyx 2 3.2 mm 4.6mm 
AT 10.5 × 4.6cm --- --- --- 
15 I50768 33/M 
RT KIDNEY 
BT 10.2 × 4.5 lower midpole 3 Largest 5.6mm 
AT 10.1 × 4.3 midpole 1 5mm 
LT KIDNEY 
BT 11.4 × 4.6 midpole 2 3mm, 4mm 
AT 11.3 × 4.2 --- --- --- 
16 I56310 29/M 
RT KIDNEY 
BT 10.2 × 4.2 upper & mid calyx 2 3mm, 5mm 
AT 10 × 3.9 --- 0 --- 
LT KIDNEY 
BT 11.1 × 4.5 mid calyx 1 5mm 
AT 10.8 × 4.2 --- 0 --- 
17 I26784 39/M 
RT KIDNEY 
BT 9.7 × 4.5 lowerpole 1 5.0mm 
AT 10.1 × 5 midpole 1 4.5mm 
LT KIDNEY 
BT 10.6 × 5.3 --- --- --- 
AT 10.2 × 4.7 --- --- --- 
18 I01756 60/M 
RT KIDNEY 
BT 10.2 × 3.2 Interpole 1 2.5mm 
AT 9.8 × 3.9 --- 0 --- 
LT KIDNEY 
BT 10.2 × 4.5 Interpole 1 4.7mm 
AT 10.5 × 4.3 --- 0 --- 
19 I55334 26/M 
RT KIDNEY 
BT 9.9 × 4.5 renal pelvis multiple large-8mm 
AT 9.2 × 4.4 renal pelvis multiple large-7.2mm 
LT KIDNEY 
BT 11.3 × 4.1 mid pole multiple large 6mm 
AT 10.1 × 5.2 mid pole multiple large 6.7mm 
20 I55616 44/M 
RT KIDNEY 
BT 10.6 × 4.3 upper pole 1 6mm 
AT 10.2 × 4 --- --- --- 
LT KIDNEY 
BT 11.1 × 4.5 VUJ, lower pole 2 5mm 4mm 
AT 10.8 × 4.2 --- --- --- 
 
 
 
S. 
NO 
OPD 
NO 
AGE/
SEX 
  SIZE OF THE 
KIDNEY 
SITE OF THE CALCULUS NO OF 
CALCULUS 
SIZE OF THE CALCULUS 
21 I61203 34/M 
RT KIDNEY 
BT 10 .8 × 4.2 upper calyx 1 4mm 
AT 10 .4 × 4 --- --- --- 
LT KIDNEY 
BT 11 .5 × 4.1 upper & inter polar calyx 2 largest 5.5mm 
AT 10 .9 × 3.8 --- --- --- 
22 I61285 45/M 
RT KIDNEY 
BT 10 .9 × 4.7 Lower pole 1 4.2mm 
AT 10.7 × 4.6 --- --- --- 
LT KIDNEY 
BT 10 .7 × 5.2 mid calyx 1 4.8mm 
AT 10 .3 × 5 --- --- --- 
23 I14652 29/M 
RT KIDNEY 
BT 9 .5 × 4.6 mid calyx 2 3.4,  4.6 mm 
AT 11 × 5.3 --- --- --- 
LT KIDNEY 
BT 11 × 5.2 lower calyx 2 5.7 mm 4.8 mm 
AT 10 .9 × 5.8 ureter mid calyx 2 9.3 mm, 3.8 mm 
24 I59235 27/F 
RT KIDNEY 
BT 9 .8 × 4.7 mid calyx 2 4.2 mm, 2.4 mm 
AT 9.8  × 4.7 --- --- --- 
LT KIDNEY 
BT 8.5 × 4.5 ---- --- --- 
AT 8 .5 × 4.4 ---- --- --- 
25 I25479 20/F 
RT KIDNEY 
BT 8.9 × 4.5 ---- 3 5 mm 
AT 8 .9 × 4.5 --- 3 5 mm 
LT KIDNEY 
BT 9 .1 × 5.7 ---- 2 5 mm 
AT 9 .3 × 5.4 --- 2 5mm 
26 I45578 30/M 
RT KIDNEY 
BT 11 .4 × 5.3 mid pole 1 5 mm 
AT 11.3 × 5.0 mid pole 1 4.8mm 
LT KIDNEY 
BT 11.9  × 5.9 --- --- --- 
AT 11.4 × 5.3 --- --- --- 
27 I62094 27/M 
RT KIDNEY 
BT 9.8 × 4.5 --- --- --- 
AT 9.4 × 4.2 --- --- --- 
LT KIDNEY 
BT 10.6 × 5 Inter polar calyx 1 7.1 mm 
AT 10.8 × 4.2 --- --- --- 
 
 
28 H44868 42/F 
RT KIDNEY 
BT 9.6 × 5.6 --- --- --- 
AT --- --- --- --- 
LT KIDNEY 
BT 9.8 × 5.9 upper calyx 1 5 mm 
AT --- upper calyx 1 5 mm 
29 I64463 36/F 
RT KIDNEY 
BT 9.0 × 4.5 mid calyx 2 5 mm, 3.8 mm 
AT 9 × 3.7 --- --- --- 
LT KIDNEY 
BT 9.9 × 5.2 --- --- --- 
AT 9.9 × 5.4 --- --- --- 
30 H79813 36/F 
RT KIDNEY 
BT 9.6 × 4.6 upper pole, inter pole 2 6.8 mm, 5.6 mm 
AT 9.5 × 4.5 lower pole 1 4.5 mm 
LT KIDNEY 
BT 10.6 × 5 lower pole 1 5 mm 
AT 10.5 × 5 --- --- --- 
31 H70471 26/F 
RT KIDNEY 
BT 10.8 × 4.3 mid calyx 1 4.1 mm 
AT 10.3 × 4.4 mid calyx 1 3.4 mm 
LT KIDNEY 
BT 10.6 × 4.7 --- --- --- 
AT 10.3 × 4.5 --- --- --- 
32 I38495 32/F 
RT KIDNEY 
BT 9.5 × 4.5 mid calyx 1 4 mm 
AT 9.2 × 4.2 mid calyx 1 9.4 mm 
LT KIDNEY 
BT 9.9 × 5.2 --- --- --- 
AT 9.8 × 5.4 --- --- --- 
33 I66809 29/F 
RT KIDNEY 
BT 100.4 × 47.2 upper, middle lower calyx 3 4mm, 6mm,5mm 
AT 104.8 × 48.4 mid lower calyx 3 4.5mm,5.3mm, 5.7mm 
LT KIDNEY 
BT 102 × 63.8 upper, middle lower calyx 6 4mm, 4mm, 5mm, 7mm,6mm, 
AT 104.3 × 48.3 upper, middle lower calyx 5 Largest 4.7mm 
34 I63770 34/F 
RT KIDNEY 
BT 9 × 4.7cm lower pole 1 4 mm 
AT 9 × 3.7cms --- --- -- 
LT KIDNEY 
BT 10.3 × 5.4cm lower pole, inter pole 2 10 mm 4mm 
AT 9.9 × 5.2cm --- 0 
 
 
 
 
35 H9394 20/M 
RT KIDNEY 
BT 10.8 × 5.9 --- Few 5.6mm 
AT 8.5 × 4.6 --- --- --- 
LT KIDNEY 
BT 10.6 × 6.2 --- Few 4-6mm 
AT 10.3 × 4.6 --- --- --- 
36 I44707 37/F 
RT KIDNEY 
BT 10.2 × 5.2 mid lower pole 2 6mm, 7mm 
AT 10 × 4.2 mid lower pole 2 7.5 mm, 3.5 mm 
LT KIDNEY 
BT 10.4 × 4.6 upper lower pole 2 3.4 mm 4 mm 
AT 10.3 × 4.4 upper, lower pole 2 4.5 mm, 4 mm 
37 I70641 40/F 
RT KIDNEY 
BT 10.3 × 5.3 --- --- --- 
AT 10 × 5.1 --- --- --- 
LT KIDNEY 
BT 10.5 × 4.8 lower pole 1 8 mm 
AT 10.3 × 4.2 lower pole 1 4mm 
38 H74488 26/M 
RT KIDNEY 
BT 10.3 × 4.6 lower upper pole calyx 2 7.4 mm, 7 mm 
AT 10.8 × 4.6 mid lower calyx 2 5.3 mm, 4.5 mm 
LT KIDNEY 
BT 11.6 × 5.7 --- --- --- 
AT 11.4 × 5 --- --- --- 
39 I7357 43/F 
RT KIDNEY 
BT 10.7 × 5.8 upper calyx 1 5 mm 
AT 9.5 × 4.6 --- --- --- 
LT KIDNEY 
BT 11.5 × 6.2 --- --- --- 
AT 10.2 × 4.5 --- --- --- 
40 I69309 30/F 
RT KIDNEY 
BT 10.47 × 4.21 upper calyx multiple largest 5.3 mm 
AT 10.2 × 4.7 --- --- --- 
LT KIDNEY 
BT 10.49 × 4.83 VUJ, lower pole 1 4.4mm 
AT 10.1 × 4.9 --- --- --- 
 
 BT-Before Treatment, AT- After Treatment, RT- Right Kidney, LT- Left Kidney 
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BIOCHEMICAL ANALYSIS OF SAARA PARPAM 
Preparation of extract: 
 10g of Saara Parpam is measured accurately and placed in a 250 ml of clean 
beaker and added with 50ml of distilled water. Then it is boiled well for about 10 
minutes. Then it is cooled and filtered in a 100ml volumetric flask and made up to 100ml 
with distilled water.  
S.NO                     EXPERIMENT OBSERVATION          INFERENCE 
1. Appearance of the sample Straw color  
I. Test For Acid Radicles   
1.  Test for Sulphate: 
           2 ml of the above prepared 
extract is taken in a test tube to this 
added 2ml of 4% ammonium 
oxalate solution. 
No cloudy appearance. Absence of 
Sulphate. 
2. Test for Chloride: 
            2 ml of the above prepared 
extract is added with dil. Hno3 till 
the effervescence ceases. Then 2 
ml of silver nitrate solution is 
added. 
Cloudy appearance 
present. 
Presence of 
Chloride. 
3. Test for Phosphate: 
          2ml of the extract is treated 
with 2ml of ammonium molybdate 
solution and 2ml of con.Hno3. 
No cloudy yellow 
appearance. 
Absence of 
Phosphate. 
4.  Test for Carbonate: 
           2ml of the extract is treated 
with 2ml magnesium sulphate 
solution. 
Cloudy appearance 
present. 
Presence of 
Carbonate. 
5. Test for Nitrate:  
            1 drop of the substance is 
heated with copper turnics and 
concentrated H2SO4 and viewed 
the test tube vertically down.  
No characteristic 
changes. 
Absence of nitrate. 
6. Test for Sulphide:  
            1 ml of the substance is 
treated with 2 ml of con.HCL. 
No rotten egg smelling 
gas evolved. 
Absence of 
Sulphide. 
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7. Test for Fluride & Oxalate: 
             2 ml of the extract is 
added with 2ml of dil. Acetic acid 
and 2 ml calcium chloride solution 
and heated. 
 
No cloudy appearance. Absence of Fluride 
and Oxalate. 
8. 
 
Test for Nitrite: 
             3 drops of the extract is 
placed on filter paper on that 2 
drops of acetic acid and 2 drops 
Benzidine solution is placed.  
No characteristic 
changes. 
Absence of Nitrite. 
9. Test for Borate:  
            2 pinches of the substance 
is made into paste by using 
sulphuric acid and alcohol (95%) 
and introducer into the blue flame. 
Bluish green color 
flame not appeared. 
Absence of Borate. 
II. Test for Basic Radicles   
1. Test for Lead:  
             2 ml of the extract is 
added with 2 ml of Potassium 
iodide solution. 
No yellow precipitate 
is obtained. 
Absence of Lead. 
2. Test for Copper: 
           One pinch of substance is 
made into paste with con.HCL in a 
watch glass and introduced into 
the non- luminous part of the 
flame. 
No blue color flame. Absence of copper. 
3. Test for Aluminum:  
           To the 2ml of the extract 
sodium hydroxide is added in 
drops to excess. 
No characteristic 
changes. 
Absence of 
Aluminium. 
4. Test for Iron: 
a. To the 2 ml of extract 
add 2 ml of ammonium 
thiocynate solution. 
b. To the 2ml of extract 2 
ml ammonium thiocynate 
solution and 2 ml of 
con.HNO3 is added. 
Mild red color 
appeared. 
 
 
Blood red color 
appeared. 
Presence of Iron. 
 
 
 
Presence of Iron. 
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5. Test for Zinc:  
             To 2ml of the extract 
sodium hydroxide solution is 
added in drops to excess. 
White precipitate is not 
appeared. 
Absence of Zinc 
6. Test for Calcium: 
            2 ml of the extract is added 
with 2ml of 4% ammonium 
oxalate solution. 
 
No Cloudy appearance. Absence of 
Calcium. 
7. Test for Magnesium: 
              To 2ml of extract sodium 
hydroxide solution is added in 
drops to excess.  
White precipitate is not 
appeared. 
Absence of 
Magnesium 
8. Test for Ammonium: 
             To 2 ml of extract few ml 
of Nessler‟s reagent and excess of 
sodium hydroxide solution are 
added. 
Brown color appeared. Presence of 
Ammonium 
9. Test for Potassium: 
              1 ml of substance is 
treated with 2ml of sodium nitrate 
solution and then treated with 2ml 
of cobalt nitrate in 30% glacial 
acetic acid.  
No yellowish 
precipitate is obtained. 
Absence of 
Potassium. 
10. Test for Sodium:  
            2 pinches of the substance 
is made into paste by using HCL 
and introduced into the blue flame 
of Bunsen burner. 
No yellow color flame 
appeared. 
Absence of sodium. 
11. Test for Mercury: 
             2 ml of the extract is 
treated with 2 ml of sodium 
hydroxide solution. 
No yellow precipitate 
is appeared. 
Absence of 
mercury. 
12. Test for Arsenic: 
            2 ml of the extract is 
treated with 2 ml of sodium 
hydroxide solution. 
No brownish red 
precipitate is obtained. 
Absence of Arsenic. 
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III. Miscellanious   
1. Test for Starch: 
           2ml of the extract is treated 
with weak iodine solution. 
No blue color 
developed. 
Absence of starch. 
 
2. Test for Reducing sugar:  
            5 ml of Benedict‟s 
qualitative solution is taken in a 
test tube and allowed to boil for 
two minutes and added 8 to 10 
drops of the extract and again boil 
it for 2 minutes. The color changes 
are noted. 
No brick red color 
developed. 
Absence of 
Reducing sugar. 
3. Test for the Alkaloids: 
            2 ml of extract is treated 
with 2 ml of picric acid. 
Yellow colour 
developed. 
Presence of 
Alkaloid. 
4. Test for Tannic acid:  
           2 ml of extract is treated 
with 2 ml of ferric chloride 
solution. 
Black color precipitate 
is not appeared. 
Absence of Tannic 
acid. 
5. Test for Unsaturated compound: 
          To the 2 ml of extract 2 ml 
of Potassium permanganate 
solution is added. 
Potassium 
permanganate is not 
decolorized. 
Absence of 
Unsaturated 
compound. 
6. Test for Amino acid:  
         2 drops of the extract is 
placed on a filter paper and dried 
well. 
No violet color 
developed. 
Absence of amino 
acid. 
7. Test for Type of Compound: 
          2 ml of the extract is treated 
2 ml of ferric chloride solution.  
No green color 
developed. 
 
No red color 
developed. 
 
 
No violet color 
developed. 
Absence of 
oxyquinole 
epinephrine and 
pyro catechol. 
Anti pyrine, 
Aliphatic amino 
acids and meconic 
acid are absent. 
Apomorphine 
salicylate and 
Resorcinol are 
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No blue color 
developed. 
absent. 
Morphine, Phenol 
cresol and hydro 
quinine are absent. 
 
Result:  
The chemical study of the trial drug reveals Carbonate, Iron, Chloride, 
Ammonium and Alkaloid  
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RESULTS OF BIOCHEMICAL ANALYSIS 
 
 
 
ANALYTICAL TEST INFERENCE 
Sulphate Absence of Sulphate 
Chloride Presence of Chloride 
Phosphate Absence of  Phosphate 
Carbonate Presence of  Carbonate 
Fluoride &Oxalate Absence  of     fluoride and   oxalate 
Nitrate Absence   of   Nitrate 
Sulphide Absence of   Sulphide 
Nitrite Absence  of  Nitrite 
Borate Absence   of   Borate 
Lead Absence  of   Lead 
Copper Absence   of   Copper 
Aluminium Absence   of Aluminium 
Iron Presence of Iron 
Zinc Absence of  Zinc 
Calcium Absence of  Calcium 
Magnesium Absence    of Magnesium 
Ammonium Presence     of Ammonium 
Pottasium Absence of  Potassium 
Sodium Absence  of   Sodium 
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PHYSICOCHEMICAL EVALUATION 
 
Project ID  :  NRS/AS/0027/02/2017  
Institute  :  National Institute of siddha ,Chennai 
Sample Name  : Chara Parpam 
Sample ID   : CP 
 
Percentage Loss on Drying 
10gm of test drug was accurately weighed in evaporating dish .The sample was 
dried at 105
o
C for 5 hours and then weighed. 
Percentage loss in drying = Loss of weight of sample/ Wt of the sample X 100 
 
Determination of Total Ash 
3 g of test drug was accurately weighed in silica dish and incinerated at the 
furnace a temperature 400 ºC until it turns white in color which indicates absence of 
carbon. Percentage of total ash will be calculated with reference to the weight of air-dried 
drug. 
Total Ash = Weight of Ash/Wt of the Crude drug taken X 100 
 
Determination of Acid Insoluble Ash 
The ash obtained by total ash test will be boiled with 25 ml of dilute hydrochloric 
acid for 6mins. Then the insoluble matter is collected in crucible and will be washed with 
hot water and ignited to constant weight. Percentage of acid insoluble ash will be 
calculated with reference to the weight of air-dried ash. 
Acid insoluble Ash = Weight of Ash/Wt of the Crude drug taken X 100 
 
Determination of Water Soluble Ash 
The ash obtained by total ash test will be boiled with 25 ml of water for 5 mins. 
The insoluble matter is collected in crucible and will be washed with hot water, and ignite 
for 15mins at a temperature not exceeding 450ºC. Weight of the insoluble matter will be 
subtracted from the weight of the ash; the difference in weight represents the water 
soluble ash. Calculate the percentage of water-soluble ash with reference to the air-dried 
drug. 
Water Soluble Ash = Weight of Ash/Wt of the Crude drug taken X 100 
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Determination of pH 
About 5 g of test sample will be dispersed in 25ml of distilled water and filtered 
the resultant solution is allowed to stand for 30 mins and the subjected to pH evaluation  
 
 
 
Final Test report 
Parameter Observation 
Color Milky White  
Smell Agreeable  
Touch Powder 
Appearance Fine Powder consistency 
 
S.No Parameter Mean (n=3) SD 
1.  Loss on Drying at 105 °C (%) 10.87 ± 3.36 
2.  Total Ash (%)  9.22 ± 1.34 
3.  Acid insoluble Ash (%) 12.87 ± 4.02 
4.  Water Soluble Ash (%) 0.74 ± 0.10 
      5. PH  7   
 
Reference:  
1. India Pharmacopeia I Volume I, Government of India, Ministry of Health and 
Family welfare, Indian Pharmacopeia commission, 2014. 
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2. Pharmacopoeial Laboratory for Indian Medicine (PLIM) Guideline for 
standardization and evaluation of indian medicine which  include drugs of  
Ayurveda,  Unani and  Siddha systems. Department AYUSH .Ministry of Health 
& Family Welfare, Govt. of India   
 
GCMS- Analysis Report 
GCMS (Clarus 500 Perkin – elmer (Auto system XL)), NIST Ver.2.1 MS data 
library 
Specification : 
Start Time(min)   End Time(min)   Start m/z  End m/z Scan  Speed 
2.50   18.00   50.00   650.00   2000 
 
Sample Inlet Unit : GC 
 GC-MS Plays a key role in the analysis of unknown components of plant origin. 
GC-MS ionizes compound and measures their mass numbers. Ionization method includes 
EI (Electron Ionization). The EI method produces ions by colliding thermal electrons 
emitted from a filament with sample gas molecules. This method provides high stability 
in ionization and obtained mass spectra show good reproducibility. The EI method 
provides good result for quantitative analysis as well. Quantitative analysis with GC-MS, 
in which only ions specific to the compounds are measured, is highly selective method 
without interfering components. Gas chromatography Technique involves the separation 
of volatile components in a test sample using suitable capillary column coated with polar 
or non-polar or intermediate polar chemicals. Elite-1 column (100% Dimethyl 
polysiloxane) is a non-polar column used for analysis of phyto-components. Elite -5 
column (5% phenyl and 95% methyl polysiloxane) is an intermediate column and also 
used for the estimation of Phytochemical. An inert gas such as hydrogen or nitrogen or 
helium is used as a carrier gas .The compounds of test sample is evaporated in the 
injection port of the GC equipment and segregated in the column by absorption and 
adsorption technique with suitable GC programme. 
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GC-MS CHROMATOGRAM OF CP 
 
 
Peak Report of CP 
 
\  
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PEAK 1 
 
 
PEAK 2 
 
 
PEAK 3 
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PEAK 4
 
 
PEAK 5 
 
 
PEAK 6 
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PEAK 7 
 
 
PEAK 8 
 
 
PEAK 9 
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PEAK 10 
 
 
PEAK 11 
 
 
 
PEAK 12 
 
 
PEAK 13 
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PEAK 14 
 
 
PEAK 15 
 
 
Sample Preparation 
Chara Parpam  (CP) was dissolved in DMSO and the extract was subjected to the 
following analysis 
 
Test for Alkaloid- Mayer's reagent 
To the test drug about 2ml of Mayer's reagent was added and was observed for the 
presence of alkaloids. Appearance of dull white precipitate indicates the presence of 
alkaloids. 
Test for flavonoid 
To 0.1ml of the test sample about 5 ml of dilute ammonia solution were been 
added followed by addition of few drops of conc. Sulfuric acid. Appearance of yellow 
color indicates the presence of Flavonoids. 
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Test for Glycosides -Borntrager’s Test 
Test drug is hydrolysed with concentrated hydrochloric acid for 2 hours on a 
water bath, filtered and the hydrolysate is subjected to the following tests. To 2 ml of 
filtered hydrolysate, 3 ml of choloroform is added and shaken, choloroform layer is 
separated and 10% ammomia solution is added to it. Pink colour indicates presence of 
glycosides. 
 
Test for Triterepnoids 
To the test solution 2ml chloroform was added with few drops of conc. Sulphuric 
acid (3ml) at the side of the test tube. An interface with a reddish brown coloration is 
formed if terpenoids constituent is present. 
 
Test for Steroids - Salkowski test 
To the test solution 2ml of chloroform was added with few drops of conc. 
Sulphuric acid (3ml), and shaken well. The upper layer in the test tube was turns into red 
and sulphuric acid layer showed yellow with green fluorescence. It showed the presence 
of steroids. 
 
Test for Carbohydrates - Benedict’s test 
To 0.5 ml of test drug about 0.5 ml of Benedic‟s reagent is added. The mixture is 
heated on a boiling water bath for 2 minutes. A characteristic coloured precipitate 
indicates the presence of sugar. 
 
Test – Phenol- Lead acetate test 
The test sample is dissolved in of distilled water and to this 3 ml of 10% lead 
acetate solution is added. A bulky white precipitate indicates the presence of phenolic 
compounds. 
 
Test for tannins  
About 0.5ml of test sample is boiled in 20 mL of distilled water in a test tube and then 
filtered. The filtration method used here is the normal method, which includes a conical flask and 
filter paper. The 0.1% FeCl3 is added to the filtered samples and observed for brownish green or a 
blue black coloration, which shows the presence of tannins 
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Test for Saponins 
The test drugs were shaken with water vigorously for 10 mins , copious lather 
formation indicates the presence of saponins. 
 
Test for Proteins (Biuret Test) 
Biuret test: Equal volume of 5% solution of sodium hydroxide and 1% copper 
sulphate were added. Appearance of pink or purple colour indicates the presence of 
proteins and free amino acids. 
 
Test of Coumarins 
 1 ml of extract, 1 ml of 10% sodium hydroxide was added. The presence of 
coumarins is indicated by the formation of yellow color. 
 
Test for Quinones 
The test samples were treated separately with Alc. KOH solution. Appearance of 
colors ranging from red to blue indicates the presence of Quinones. 
 
Test for Anthocyanin 
About 0.2 ml of the extract was weighed in separate test tube, 1ml of 2N Sodium 
hydroxide was added, and heated for 5 minutes at 100 ± 2°C. Observed for the formation 
of bluish green color which indicates the presence of anthocyanin. 
 
Test for Betacyanin 
To 2 ml of the test sample, 1 ml of 2N sodium hydroxide was added andheated for 
5 min at 100ᵒC.  Formation of yellow colour indicates the presence of betacyanin. 
 
Reference 
Brain KR, Turner TD. The Practical Evaluation of Phytopharmaceuticals. 
Bristol:Wright- Scientechnica; 1975:36-45 
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RESULTS 
 
Test for Alkaloid- Mayer's reagent   Test for flavonoid 
       
  
Test for Glycosides -Borntrager’s Test   Test for Triterepnoids 
      
Test for Steroids - Salkowski test  Test for Carbohydrates - Benedict’s test 
 .      
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Test – Phenol- Lead acetate test   Test for tannins  
       
  
     Test for Saponins    Test for Proteins (Biuret Test) 
      
 
Test of Coumarins     Test for Quinones 
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Test for Anthocyanin   Test for Betacyanin 
. .     
PHYTOCOMPONENTS CP 
ALKALOIDS + 
FLAVONOIDS - 
GLYCOSIDES - 
STEROIDS - 
SUGAR - 
TRITEREPNOIDS - 
COUMARINS - 
PHENOLS + 
TANNINS - 
SAPONINS - 
PROTEINS + 
ANTHOCYANIN - 
BETACYANIN - 
QUINONES - 
 
+ Indicates positive 
- Indicates Negative 
 
Quantitative estimation of phytoconstituents of Chara Parpam 
Determination of total Phenol content 
 The total phenol content was determined using Folin–Ciocalteu reagents with 
analytical grade Gallic acid as the standard. 1 ml of CP extract sample was added to 
deionized water (10 ml) and Folin–Ciocalteu phenol reagents (1ml). After 5 minutes, 
20% sodium carbonate (2 ml) was added to the mixture. After being kept in total darkness 
for 1 hr, the absorbance was measured at 750 nm using a spectrophotometer. Amounts of 
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total Phenol was calculated using Gallic acid calibration curve. The results were 
expressed as Gallic acid equivalents (GAE) mg/g of dry plant matter. 
Reference 
Ganesh N. Sharma K, Nitin S, Jyotsana S. Phytochemical screening and 
estimation of Total Phenolic Content in Aegle marmelos Seeds. Int J Pharma Clinc 
Res.2011; 3(2): 27-29.  
 
Estimation of Alkaloid 
 About 5 gm of CP was weighed into a 250 ml beaker and 200 ml of 10% acetic 
acid in ethanol was added and covered and allowed to stand for 4 hr. This was filtered 
and the extract was concentrated on a water bath to one-quarter of the original volume. 
Concentrated ammonium hydroxide was added drop wise to the extract until the 
precipitation was complete. The whole solution was allowed to settle and the precipitated 
was collected and washed with dilute ammonium hydroxide and then filtered. The residue 
is the alkaloid, which was dried and weighed. 
Reference 
Ganga rao B, Umamaheswara rao, Sambasiva rao, Mallikarjuna rao T. Studies on 
phyto chemical constituents, quantification of total phenol, alkaloid content and In-vitro 
anti-oxidant activity of Coccinia cordifolia.Int. J. pharm. life sci.2011; 2(10):1177-1182. 
 
Phyto- constituents CP 
Total phenols                         
 (GAE mg/gm) 
0.25 ± 0.03 
Total alkaloids (mg/gm) 1.27 ± 0.45 
 
Mean with 3 replicates ± SD. 
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TLC Analysis Report 
 
Project ID  :  NRS/AS/0028/02/2017  
Institute  :  National Institute of Siddha 
Sample Name  : Chara Parpam 
Sample ID   :  CP  
 
TLC Analysis 
 
Test sample CP was subjected to thin layer chromatography (TLC) as per conventional 
one dimensional ascending method using silica gel 60F254, 7X6 cm (Merck) were cut with 
ordinary household scissors. Plate markings were made with soft pencil. Micro pipette were used 
to spot the sample for TLC applied sample volume 10-micro liter by using pipette at distance of 1 
cm at 5 tracks. In the twin trough chamber with different solvent system Ethyl acetate: Methanol: 
Water (100:13.5:10) After the run plates are dried and was observed using visible lightShort-wave 
UV light 254nm and light long-wave UV light 365 nm 
 
Sample Spotting 
 
Visible    Short UV  Long UV 
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Reference 
Lukasz Komsta, Monika Waksmundzka-Hajnos, Joseph Sherma .Thin Layer 
Chromatography in Drug Analysis .CRC Press, Taylor and Francis. 
 
High Performance Thin Layer Chromatography Analysis 
HPTLC method is a modern sophisticated and automated separation technique 
derived from TLC. Pre-coated HPTLC graded plates and auto sampler was used to 
achieve precision, sensitive, significant separation both qualitatively and quantitatively. 
High performance thin layer chromatography (HPTLC) is a valuable quality assessment 
tool for the evaluation of botanical materials efficiently and cost effectively. HPTLC 
method offers high degree of selectivity, sensitivity and rapidity combined with single-
step sample preparation. In addition it is a reliable method for the quantitation of nano 
grams level of samples. Thus this method can be conveniently adopted for routine quality 
control analysis. It provides chromatographic fingerprint of phytochemicals which is 
suitable for confirming the identity and purity of medicinal plant raw materials.  
 
Chromatogram Development 
It was carried out in CAMAG Twin Trough chambers. Sample elution was carried 
out according to the adsorption capability of the component to be analysed. After elution, 
plates were taken out of the chamber and dried. 
 
Scanning 
Plates were scanned under UV at 366nm. The data obtained from scanning were 
brought into integration through CAMAG software. Chromatographic finger print was 
developed for the detection of phytoconstituents present in each extract and Rf values 
were tabulated.
 
Reference 
1. Wagner H. Plant Drug Analysis. A thin Layer chromatography Atlas.2nd ed. 
Heidelberg: Springer-Verlag Belgium; 2002:305, 227.  
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HPTLC Chromatographic condition  
Sample   :  CP 
Derivatization Solvent : Anisaldehyde 
Stationary phase  :  Silica gel GF254 
Mobile phase  :  Hexane: Diethyl Ether: Methanol :Acetic 
acid(4:4:2:1)  
Scanning wavelength  :  200-400 nm 
Sample concentration  :  10mg/ml  
Applied volume             :  5 µl  
Application mode         :  CAMAG HPTLC 
 
TLC CHROMATOGRAM OF CP 
 
HPTLC CHROMATOGRAM OF CP 
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Peak Table of HPTLC finger printing of CP 
 
 
 
Evaluationof  Anti-urolithiasis activity using Struvite Crystal growth inhibition 
Assay 
Project Id: NRS/AS/0028/02/2017 
Sample ID  :  CP 
Institute  :  National Institute of Siddha, Chennai. 
Purpose  :  Struvite Crystal growth inhibition Assay 
Sample Description :  Siddha Formulation 
 
PROJECT REPORT 
Objective 
The single diffusion gel growth technique was adopted to evaluate anti-urolithiatic 
potential of the study drug Chara Parpam 
 
Test Drug concentration 
 Test drug was prepared at two different concentrations of 0.5 and 1 % dispersed 
in 1.0 M magnesium acetate solution 
 
Methodology 
An aqueous solution of 0.5M Ammonium dihydrogen phosphate was admixed 
with the sodium metasilicate solution of specific gravity 1.05 in appropriate amount using 
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magnetic stirrer so that the pH value 7.0 .pH of the reaction was ensured by using pH 
probe meter. The gel solution of 10 mL was transferred into the test tubes of 140 mm 
length and 25 mm diameter. After the gelation took place, 5 mL of supernatant solutions 
of 0.5 and 1% conc of test drug in 1.0 M magnesium acetate were gently poured on the 
set gels in test tubes to enumerate the growth inhibition of Struvite crystals. About 5 ml of 
1.0 M magnesium acetate without test drug were added as supernatant to control tubes 
which serves as crystal control group. All the procedures was done in the aseptic medium 
in laminar flow hood to avoid microbial contaminations. All test tubes and other 
glassware were autoclaved at 120°C for 15 min. After pouring supernatant solution, the 
test tubes were capped with airtight stopples. The experiment was conducted at the room 
temperature. Study on growth of crystal were carried out for five consecutive days. 
 
 
Growth Pattern of crystal in control and drug added medium 
 
Growth of Struvite crystals in control Gel medium 
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Growth of Struvite crystals in Gel medium with 0.5% of Chara Parpam 
 
 
Growth of Struvite crystals in Gel medium with 1% of Chara Parpam 
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Size variation of  Struvite crystals 
 
A –  
 
 
 
 
 
 
 
 
 
 
 
 
 
Size variation  of  Struvite crystals in Control Gel medium 
B- Size variation  of  Struvite crystals in Gel medium with 0.5 % of Chara Parpam  
C- Size variation  of  Struvite crystals in Gel medium with  1 % of Chara Parpam 
 
 
Microscopic view of Struvite crystals size after fragmentation. 
 
 
Control Gel medium 
A 
B 
C 
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Gel medium with 0.5 % of Chara Parpam 
 
 
Gel medium with 1 % of Chara Parpam 
 
Report on Average Length of the Crystal in different medium 
S.No Medium 
Average Length of 
the Crystals in cm 
1 Control Gel medium   
  Mean 1.05 
  Std. Deviation 0.264 
  Std. Error 0.132 
2 Gel medium + 0.5 % CP   
  Mean 0.67 
  Std. Deviation 0.125 
  Std. Error 0.062 
3 Gel medium +1% CP   
  Mean 0.45 
  Std. Deviation 0.057 
  Std. Error 0.028 
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Observation 
Control Medium  
Average size of the crystal was higher in the control medium with the Avg 
length of 1.05 cm 
Gel medium + 0.5 % CP 
Average size of the crystal was significantly decreased in medium contains 0.5% 
of test drug CP with the Avg length of 0.67 cm 
Gel medium +1% CP 
Average size of the crystal was much reduced in medium contains 1 % of 
test drug CP with the Avg length of 0.45cm 
 
Conclusion 
From the result of the study it was concluded that the test drug CP has Promising 
anti-urolithiasis property in the tested medium. 
 
Reference 
Chauhan, C.K., K.C. Joseph, B.B. Parekh and M.J. Joshi, 2008. Growth and 
characterization of Struvite crystals, Ind. J. Pure Appl. Phys., 46: 507-512 
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DISCUSSION  
 
The main aim of this study is to evaluate the therapeutic efficacy of the 
study drug Saaraparpam (internal) in the disease azhalkalladaippu.The clinical 
features of azhalkalladaippu can be correlated with renal calculus in modern 
science. As per Yugivathiyachinthamani text, azhalkalladaippu is charecterised by 
oliguria,urethral pain which mimics the  pain caused by the insertion of iron rod 
in the urethra,sweating all over the body,anuria,agonizingpain,blood stained 
calculus stagnated in the urethra.  
The study drug was prepared in Gunapadamlaboratory of National Institute 
of Siddha after the authentication of the herbal raw drugs by Botanist National 
Institute of Siddha and the mineral raw drugs by Rearch officer Chemistry, 
Department of Chemistry, Siddha Council Research Institute, Arumbakkam, and 
Chennai. The study drug was prepared by standard operating procedure as 
mentioned in the protocol. 
The biochemical (qualitative) analysis of the study drug was done at the 
biochemistry laboratory of National Institute of Siddha. It revealedthe presence of 
mineral such as Carbonate, Iron, Chloride, and Ammonium. Physico chemical 
(quantitative) analysis and HPTLC weredone at Nobal Research Solution, 
Sathiyabama University, and Chennai.The study drug revealed the presence of 
phytocomponentssuch as alkaloids, phenols, proteins.. 
HPTLC fingerprint at 254 nmUV showed highest peak in 8
th
 peak (0.56Rf, 
31.54% area) which could serve as a marker and and it is responsible for biological 
action. 
In vitro study was done atNobal Research Solution, Sathiyabama University 
, Chennai. In vitro study revealed that, the study drug “Saaraparpam” has 
liththotriptic action; it acted well on Struvite type of stones. 
The clinical study was conducted with a well defined protocol and a proper 
proformaafter getting the approval from the Institutional Ethical Committee (NIS/6-
20/IEC/15-16).After the screening of 80 cases based on the Exclusion and Inclusion 
criteriareporting at the out patient department of department of Maruthuvam, 
40 cases were inducted to the study. Before enrollment to the study the 
informed consent was obtained from the patients.  
The patients were treated for a period of 48 days with 
Saaraparpam(internal) at the dose of 260mg, twice a day after food with the 
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adjuvant of Seergakudineer.  
Clinical assessment was done during each visit in out patient department patients 
once in 8 days and the data were noted in the prescribed proforma.  
Laboratory investigation & USG abdomen were done on 0th day and 48th day of the 
study for all the enrolled patients. All the patients were put under observation for 2 
months follow up period without the study drug treatment.  
 
THE OBSERVATIONS  
Gender Distribution:  
Among 40 cases male and female were equally affected (male-20, female-20) 
Inference:  
Testosterone may cause increased oxalate production in men.  
Obesity, intake of high salt and sugar in the diet, increase the risk for women. 
Women have higher urinary citrate concentration.(30) 
Kaalam distribution:(Age)  
Among 40 cases, 20 cases (50%) were found to be in vatha kaalam (1-33yrs of age ) 
and 20 cases were (50%) in pitha kaalam ( 34-66yrs of age). 
Inference:  
The peak incidence of renal calculi occurred between 20 and 40 years of age {pitha 
kaalam (34-66 years)} 
 
Occupational Reference:  
Home makers accounts for highest number of occurrence i.e 17 cases (42.5%).  
 
Dietary Habit:  
Among 40 cases, 39 cases (97.5%) were non-vegetarian and one case (2.5%) 
wasvegetarian.  
Inference:  
Animal protein contain oxalate,calcium,phosphate,and other elements often 
lead to an excess excretion of them in urine.High intake of animal protein causes 
high urinary oxalate ,low PH ,low urinary citrate and high intake of salt causes 
hypercalciuria.However ,a reduced calcium diet can increase the risk of further stone 
formation.(28) 
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Drinking water: 
Among 40cases, onecase (2.5%) was a well water drinker.In corporation and bore 
water drinkers category each 2 cases were reported, 35 cases were reported under 
mineral water drinkers. 
Inference 
In mineral water calciumand magnesium ratio is very high which can increase 
the risk of stone formation.(27) 
 
Habits:  
Among 40 cases, 2 cases (5%) were alcohol consumer; one case (2.5%) was 
asmoker.  
 Inference: 
Cigarette smoking may induce urolithiasis by decreasing urinary flow and 
increasing serum cadmium and lead level. 
On the other hand, smoking can increase production of reactive oxygen species 
and oxidative stress in the kidney, leading to renal injury. These injuries increase the 
nucleation, aggregation, and retention of crystals in the kidney thereby promoting the 
formation of stones. Stones are more common in men than in women. Since smoking 
tends to be more common in men this may be one of the reasons for higher rate of stones 
in male sufferers. 
Alcohol act as a diuretic .This means that it causes people to pass so much urine 
that they can become dehydrated. Alcohol also interferes with the body‟s ability to 
excrete uric acid. (29) 
 
Treatment History:  
Among 40 cases, 2 cases (5%) had taken allopathic treatment in the past and 
discontinued 6 months before. The rest the 38 cases (95%) had not taken any other 
drugs prior to   this study. 
 
Family History:  
Among 40 cases, 6 cases (15%) had positive family history.  
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Distribution of cases by Paruva kaalam (Seasons):  
In this study, 20 cases (50%) were admittedin Munpani kaalam (Dec 16- Feb12), 20 
cases (50%) were admitted in Pinpani kalam (Feb13-Apr13) 
 
Thinai Distribution:  
In this study, 27 cases (67.5%) were reported from Neithal thinai (coastal 
region), 13cases (32.5 %%) were reported from Marutham thinai (fertile land).  
Inference:  
Mineral content of water in the Neithal land (coastal area) may contribute to the 
formation of kidney stones.  
 
Yakkai Distribution:  
Among 40 cases, 16 cases (40%) were Vathathegi, 14 cases (35%) were 
Pithathegiand 4 cases (10%) were Kaphathegi, and 6cases were Thonthathegi.  
 
Gunam Distribution:  
Among 40 cases 34 cases (85%) possessed Rajogunam.  
 
Distribution Of Cases By EnvagaiThervugal (Eight- Fold Examination)  
In En vagaithervukal, Naadi was affected in all the 40 cases (100%), Sparisam 
was affected (numbness) in 8 cases (20%). Naa was affected (taste sensation) in 11 
cases (27.5%).  Niram was affected (pale/hypopigmentation) in 5 cases (12.5%).Vizhi 
was affected (myopia or presbiopia) in 12 cases (30%). 
Moothiram was found to be affected (burning micturition /oliguria) in all the 40 
cases (100%).    
Malam was affected(constipation/loose stools) in 9 cases (22.5%) 
 
Distribution of Cases By Naadi:  
In this study, Azhal vali naadi was felt in 19 cases (47.5%).Azhaliyyam naadi 
was felt in 9 cases (22.5%).Valiiyyam naadi was felt in 5 cases(12.5%)Valiazhal naadi 
was felt in 3cases (7.5%).Iyyaazhal naadi was felt in 2 cases (5%). Valinaadi was felt in 
onecase (2.5%). Azhalnaadi was felt in one case (2.5%). 
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Distribution of Cases by Udal kattukal:  
Among 40 patients, Saaram was affected (indigestion, general tiredness)  in  20  
cases(50%). Senneer was affected (reduction in Hb level) in 8 cases (20%) .Oon was 
affected (obesity/knee joint pain) in 7 cases (17.5%). Kozhuppu was affected (lower 
back ache) in 10 cases (25%). Enbu was affected(lower back ache, knee joint pain) in 
10 cases (25%).Suronitham was affected (irregular menstruation) in 3 cases (7.5%)  
 
Distribution of Cases by Kosangal:   
Among 40 cases, Annamayakosam was affected (abdominal pain/ anorexia) in 25 
cases (62.5%), Pranamayakosam was affected (cold, cough) in 19 
cases(47.5%)Anandamayakosam was affected (sleep disturbance) in 3 cases 
(27.5%).Manomayakosam, Vignamayakosam were normal in almost all cases. 
   
Derangement of Vatham:   
Among  40   cases,   Abaanan was affected(burning micturition) in 19 cases 
(47.5%),Pranan (anorexia) was affected in 9 cases(22.5%),    
Udhanan(nausea,vomiting) was affected in 9 cases(22.5%) , Samanan(derangement 
of other vayukkal) and Viyanan  were  affected(pain from loin to groin)  in  all  the  
40  cases   (100%). Naagan was affected (dull vision) in 6 cases (15%), Koorman was 
affected (myopia or presbiopia) in6 cases (15%) Kirukaran was affected (loss of 
appetite) in 15 cases (37.5%), Dhevathathan was affected (general tiredness) in all 40 
cases (100%). 
 
Derangement of Pitham 
Among 40 cases, .Anarpitham was affected(loss of appetite/abdominal pain )  in 
15 cases (37.5%), Ranjagapitham was affected(low Hb gm% )  ( in 5 cases (12.5%) , 
Alosakapitham was affected(dull vision) in 5% cases (12.5%), Prasakapitham was 
affected(dryness of skin) in 5 cases (12.5%). 
 
Derangement of Kapam 
Avalambagam  was affected(derangement of other types of kapam) in 33 cases 
(82.5%),Kilethagam was affected(loss of appetite) in13 cases (32.5%),    Pothagam was 
affected(tastelessness) in2 cases  (5%), Tharpagam was affected(burning sensation of 
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the eyes) in 21 cases (52.5%), Santhikam(lower back ache) was affected in 9 cases 
(22.5%). 
Distribution of cases by Neerkuri:  
Colour 
In before treatment, pale yellow coloured   urine was observed in 23 cases 
(57.5%), yellow coloured urine was observed in 7 cases (17.5%) ,colourless urine was 
observed in 8 cases (20%) 
In after treatment, pale yellow coloured   urine was observed in 24 cases (60%) 
,yellow coloured   urine was observed in 9 cases (22.5%),dark yellow coloured urine 
was observed in one case(2.5%),  straw coloured urine was observed in one case 
(2.5%), colourless urine was observed in 5 cases (12.5%). 
Volume  
The volume of urine was reduced in 15 cases (37.5%), rest of cases had normal urine 
volume.  
Manam 
Foul smell was observed only in 2 cases (5%) 
Nurai 
Froth was observed only in one case (2.5%) 
Edai 
Normal in all cases 
Enjal 
Enjal present in 2 cases (plenty of pus cells), in other cases it was normal. 
 
Distribution of Cases By Neikuri:  
Among  40 cases the neikuri  in  15 cases (37.5%) was observed as pearl 
shaped (kaphaneer).In one case (2.5%)the neikuri was observed as ring shaped 
(Azhalneer).In 10 cases (25%) the neikuri  was observed as round shape.In 12 cases 
(30%) the neikuri was observed as sieve pattern . In 2 cases (5%) theneikuri was 
observed as irregular shape.  
 
Distribution of calculus in Urinary System:  
Among 40 cases, 22 cases (55%) had bilateral renal caculi, 11 cases (27.5%)  
hadin right kidney and 6cases (15%) had in left kidney, one cases (2.5%) had left 
ureteric calculi. 
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Distribution of cases by chronicity of illness:  
Among 40 cases, 0 - 3 months chronicity of illness was found in 12cases (30%), 
4 -6 months chronicity of illness was found in 9 cases (22.5%), 7-9 months chronicity 
of illness was found in 5 cases (12.5%), more than 9 months of chronicity of illness 
was found in14 cases (35%). 
 
Clinical features (before treatment):  
In  clinical  features, all  the  29 cases (72.5%)  had  pain  from  loin  to  groin  
region.9 cases(22.5%) had burning micturition and 22 cases (55%) had abdominal pain, 
onecase (2.5%) had nausea,4 cases (10%) had agonizing pain, one case (2.5%) had 
vomiting and 6 cases (15%) had oliguria , 6 cases (15%) had dysuria, 2 cases (5%) had 
pain in  the urethra. 
 
Outcome:  
Primary Outcome Observation:  
Result From USG Abdomen After Treatment:  
Out of 40 cases stone completely dissolved in 15 cases (37.5%), Size 
(>3mm<10mm)  and  number of stone is reduced in 16 cases (40%) , In 9 cases 
(22.5%) there was no changes in number and size of the stone.  
Based on above results, 15% cases (37.5%) showed good improvement and 16 
cases (40%) showed moderate improvement, 9 cases (22.5%) showed poor response. 
 
Good - Stone completelydissolved 
Moderate -  Reduction in number and size of the calculi. 
Poor -  No change in stone size and number. 
 
Secondary outcome observation: 
Improvement in Clinical Feature: 
Symptoms such as Burning micturition,abdominalpain, yellowcoloured urination, 
oliguria, nausea, vomiting and agonizing pain were relieved in almost all the 40 cases 
(100%). Pain from loin to groin region was relieved in 35 cases (87.5%), except in 5 
cases (12.5%) where (the pain from loin to groin region) persisted.  
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Improvement:  
Among 40 cases 22 cases (55%) had clinically good improvement 
(symptoms completely relieved) after treated with study drug, 13cases (32.5%) had 
moderate improvement (symptoms reduced), 5 cases (12.5%) had no improvement 
(symptoms persisted).  
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SUMMARY 
 
 The aim of the study is to evaluate the therapeutic efficacy of the drug 
Saaraparpam (internal) in Azhalkalladaippu.  
 Before initiating the clinical study, approval was got from the Institutional 
Ethical committee (NIS/6-20/IEC/15-16)   for   conducting   the clinical   
study. 
 The herbal raw drugs were authenticated by Botanist NIS and the mineral raw 
drugs were authenticated by Research Officer chemistry,Department of 
Chemistry,Siddha Council Research Institute ,Arumbakkam,Chennai and the 
study drug was prepared by the investigator in the Gunapadam laboratory of 
National Institute of Siddha as per the standard operating procedure mentioned 
in the protocol. 
 The biochemical (qualitative) analyses were done at the bio chemistry lab of 
National Institute of Siddha. 
 Physico chemical (quantitative) analysis, phytochemical analysis of the study 
drug, HPTLC and in vitro lithotripticactivity of Saara parpam were done at 
Nobal Research Solutions, SathiyabamaUniversity, and Chennai.  
 For clinical study 80 cases were screened based on inclusion and exclusion 
criteria at the out patient department of Department of Maruthuvam, National 
Institute of Siddha.Out of 80 cases 40 cases were recruited for the clinical 
study.Clinical diagnosis of Azhalkalladaippu was arrived by both Siddha and 
modern methodologies.  
 Required laboratory investigations were carried out before and after treatment 
and the concerned data were   recorded   in the proforma.Before initiating the 
study, informed consent was obtained from the patients.  
 A day before starting the study drug treatment, purgation was given (Agathiyar 
kulambu 130mg with Sankankuppi juice) early morning in empty stomach to 
the patientscorrect the elevated mukkutram. 
 The patients were treated for a period of 48 days.The study medicine 
selectedwas Saaaraparpam at the dose of 260mg   twice a day   with   
adjuvant   of   seerga kudineer after food. (Ref. Patharthaguna vilakkam 
page no 140-141) 
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 Clinical assessment was done during each visit once in 8 days and the data were 
noted in the prescribed proforma.  During the study period there was no event 
of any adverse reactions owing to the drug wasreported. 
 The biochemical study of the study drug revealed the presence of chloride, Iron, 
ammonium, etc. 
 The study drug revealed the presence of phytocomponents such as alkaloids, 
phenols, proteins.  
 
 In vitro study revealed that, the study drug “Saaraparpam” has liththotriptic 
action; it acted well on Struvite type of stones. 
 Statistical analysis showed significant difference between before and after 
treatment in the kidney stone size(p<0.0001) and symptoms(p<0.0001)  
 Clinically out of 40 cases, 22 cases (55%) had clinically good improvement 
(symptoms completely relived) after treated with study drug, 13cases (32.5%) 
had moderate improvement (symptoms reduced).  5 cases (12.5%) had no 
improvement. 
 All the 40 cases were taken ultra sonography, before and after the completion 
of the trial drug treatment.  
 Based on the USG Abdomen reports out of 40 cases 15 cases (37.5%) showed 
good improvement stone completely dissolved) 16 
cases (40%) showed moderate improvement(reduction in number and size) 
and 9cases (22.5%) cases showedpoor prognosis (no change in size and 
number of stone). 
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CONCLUSION 
 
The aim of the study was to evaluate the therapeutic efficacy of the study drug 
Saara parpam (internal) in Azhal kalladaippu.  
Clinical study revealed the therapeutic efficacy of the study drug was read from 
USG Abdomen reports. 15 cases (37.5%) showed good improvement (symptoms 
completely relieved), 16 cases (40%) showed moderate improvement (symptoms 
reduced) and 9 cases (22.5%) showed poor prognosis (symptoms persisted).  
After treatment ,out of 40 cases 22 cases (55%) showed  goodclinial 
improvement (symptoms completely relieved) ,13 cases( 32.5%) had moderate 
improvement(symptoms reduced), 5 cases (12.5%) showed no improvement There were 
no adverse reaction complaint received during the study.  
There were no recurrences of renal stone during thefollow up period of two 
months. Statistical analysis showed significant difference between before and after 
treatment in the kidney stone size (p<0.0001) and symptoms (p<0.0001) Because of the 
encouraging clinical outcome, the study may be further carried out with the same drug 
in large number of cases in future.  
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
AN OPEN CLINICAL STUDY ON “AZHAL KALLADAIPPU” (RENAL CALCULI) AND THE 
DRUG OF CHOICE IS “SAARA PARPAM” (INTERNAL) 
 
FORM I -  SCREENING AND SELECTION PROFORMA 
 
1. O.P No   ________      2.  I.P No ________    3. S.No: ________    
 
4. Name: ________________ 5. Age (years):            6. Gender: Female/male 
 
7. Contact No:    ------------------------------------------ 
 
8.INCLUSION CRITERIA: 
 
Patients who will fulfill any of the following criteria will be included in the 
study: 
 Age:20-60 yrs 
 Sex: Both sex 
 Patients who are having the classical symptoms of abdominal pain, distension, 
pain from loin to groin, pain in urethra, agonizing pain, dysuria, oliguria, yellow 
coloured urination, burning micturition, haematuria, nausea, vomiting. 
 Patient with renal calculus detected on USG Abdomen, Stone size:≥4mm & 
10mm≤ 
 Patient willing to sign the informed consent stating that he/she will 
conscientiously stick to the treatment during 48 days but can opt out of the trial 
of his/her own conscious discretion. 
Patient who are willing to take Ultrasonography investigation (USG- Abdomen/ KUB) and 
provide blood for lab investigation 
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9.EXCLUSION CRITERIA: 
Stone size > 10mm 
 
Yes No 
Pregnancy and laction   
Presence of any associated severe 
systemic illness eg.CA 
 
  
Diabetes mellitus   
Hypertension   
Chronic kidney disease 
 
  
Cardiac disease 
  
 
10.ADMITTED TO TRAIL:    YES            NO            If Yes Serial No: 
Date: 
                                                                                                             
Station: 
 
Signature of the Investigator:  
 
Signature of the Lecturer:                                                  
 
                                                                                   Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDOSS PANDITHAR HOSPITAL 
DEPARTMENT OF MARUTHUVAM 
AN OPEN CLINICAL STUDY ON “AZHAL KALLADAIPPU” (RENAL 
CALCULI) AND THE DRUG OF CHOICE IS “SAARA PARPAM” (INTERNAL) 
 
FORM II-CASE RECORD FORM 
 
1. Serial No:   _______________         2. OP/IP No:---------- 
 
3. Name: ________________    4. Gender:   Female/male 
 
5. Age (years): _________   DOB    
 Date       Month            Year 
6.Address:----- 
 
------------------------------------------------------------------------------------------ 
 
7. A)Occupation: -----------------------------             B) Nature of work----------------- 
 
8. Educational Status:   A) Illiterate                  B)Literate  
 
9.Height:  --------- cms                10.Weight: ---------- kg 
 
11. Complaints and Duration:   
________________________________________________________________________ 
 
________________________________________________________________________ 
 
________________________________________________________________________ 
 
________________________________________________________________________ 
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12.Habit of 
A) Smoking                 1. Yes; duration ________ years; Number-              2.No 
B)Tobacco chewing     1. Yes; duration ________ years      2.No                                         
C)Betel chewing          1. Yes; duration ________ years      2.No 
D)Alcoholism              1. Yes; duration ________ years;Quantity-      ml    2.No 
 
13. Dietary style: A.Pure vegetarian         B.Non-vegetarian            C. mixed diet 
 
14. Drug History: Had the patient been treated before with allopathic drug?   
A) Yes              2) No 
 
 
15 MARITAL STATUS:1.Married  2.Unmarried  
 
No of children:             male:          female: 
 
16. FAMILY HISTORY: 
Whether this problem runs in family?   1. Yes                               2.No   
 
If yes, mention the relationship of affected person(s) -------------------------------------------- 
 
17. MENSTRUAL HISTORY: 
 
18. BOWEL HABITS & MICTURITION:  Normal 
 
Historyof habitual constipation     1.Yes                      2.No                                                       
History of frequent diarrhea  1.Yes                      2.No                                                         
History of frequent dysuria            1.Yes                      2.No                
(Burning micturition/haematuria) 
 
19. PSYCHOLOGICAL STATE: 
Normal  Anxiety        Depression 
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20.SIDDHA SYSTEM OF EXAMINATION: 
 ENVAGAI THERVU: 
 
I.NAADI:  
 0
th
 day 8
th
 day              16
th
  day                24
th
day         32
nd 
day 40
th
 day 49
th
 day 
Vali        
Azhal        
Iyyam        
ValiAzhal        
Azhalvali        
Iyyavali        
ValiIyyam        
AzhalIyyam        
IyyaAzhal        
 
II.NAA: 
 0
th
 day 8
th
 day              16
th
  day                24
th
 day         32
nd
 day 40
th
 day 49
th
 day 
Colour normal/ Red 
pale/yellow 
normal/ 
Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ 
Red 
pale/yellow 
normal/ 
Red 
pale/yellow 
normal/ 
Red 
pale/yellow 
normal/ 
Red 
pale/yellow 
Taste Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour
/ Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour
/ Pungent/ 
Bitter/None 
Sweet/Sour
/ Pungent/ 
Bitter/None 
Sweet/Sour
/ Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Coating Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Fissure Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Saliva Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Dryness Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Glossitis Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Baldness Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
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III.NIRAM: 
0
th
 day 8th day 16th day 24th day  32
nd
 day 40
th
 day  49
th
 day 
Dark/pale/ 
Yellow 
tinted/ 
wheatish 
brown 
Dark/pale/ 
Yellow 
tinted/ 
wheatish 
brown 
Dark/pale/ 
Yellow 
tinted/ 
wheatish 
brown 
Dark/pale/ 
Yellow 
tinted/ 
wheatish 
brown 
Dark/pale/ 
Yellow 
tinted/ 
wheatish 
brown 
Dark/pale/ 
Yellow 
tinted/ 
wheatish 
brown 
Dark/pale/ 
Yellow tinted/ 
wheatish 
brown 
 
IV.MOZHI: 
0
th
 day 8th day 16th day 24th day 32
nd
 day 40
th
 day 49
th
 day 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
Medium/ 
High/ 
Low pitched 
 
V.VIZHI: 
0
th
 day 8th day 16th day 24th day 32
nd
 day 40
th
 day 49
th
 day 
normal/ Red 
pale/yellow 
normal/Red 
pale/yellow 
normal/Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
normal/ Red 
pale/yellow 
   
VI. MALAM: 
 0
th
 day   8th day 2
nd
wk 24th day 32
nd
 day 40
th
 day 49
th
 day 
Colour Dark/pale/ 
yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Dark/pale/ 
Yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Consistency Solid/ 
Semisolid/
Watery 
Solid/ 
Semisolid/
Watery 
Solid/ 
Semisolid
/Watery 
Solid/ 
Semisolid/
Watery 
Solid/ 
Semisolid/ 
Watery 
Solid/ 
Semisolid/
Watery 
Solid/ 
Semisolid/
Watery 
stool  bulk                          Normal/
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Constipatio
n   
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Diaarhoea Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
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VII.MOOTHIRAM:    
Neerkkuri 0
th
day   8th day  16th day  24
th
 day 32
nd
 day 40
th
 day 49
th
 day 
Niram 
[Colour] 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal 
clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal 
clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal 
clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal 
clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal clear 
Manam[O
dour] 
Present/ 
Absent 
 Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Nurai[Frot
h] 
Nil/ 
Reduced/ 
Increasd 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Edai[Sp.gr
avity] 
Normal/ 
Increasd/ 
Reduced  
Normal/ 
Increased/ 
Reduced  
Normal/ 
Increased/ 
Reduced  
Normal/ 
Increased/ 
Reduced  
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Enjal[Dep
osits] 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Volume   Normal/ 
Increasd/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
 
Neikkuri 0
th
 day 8th day 16th day 24th day 32
nd
 day 40
th
 day 49
th
 day 
Serpentine 
fashion 
at___ mints at___ mints at___ mints at___ mints at___ mints at___ mints at___ mints 
Annular/ 
Ringed 
fashion 
at___ mints at___ mints at___ mints at___ mints at___ mints at___ mints at___ mints 
Pearl 
beaded 
fashion    
at___ mints at___ mints at___ mints at___ mints at___ mints at___ mints at___ mints 
Mixed 
fashion 
at___ mints at___ mints at___ mints at___ mints at___ mints at___ mints at___ mints 
Other 
fashion 
at___ mints at___ mints at___ mints at___ mints at___ mints at___ mints at___ mints 
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VIII. SPARISAM: 
0
th
 day 8th day 16th day 24th day 32
nd
 day 40
th
 day 49
th
 day 
Warmth/ 
Hot/ 
cold/ Sweat 
Warmth/ 
Hot/cold/ 
Sweat 
Warmth/H
ot 
/cold/ 
Sweat 
Warmth/Hot
/ 
cold/ Sweat 
Warmth/Hot 
/cold/ Sweat 
Warmth/Hot 
/cold/ Sweat 
Warmth/Hot 
/cold/ Sweat 
 
THEGI:   
Vatham predominant  Kabam predominant  
Pitham predominant  Thondha thegi  
 
NILAM:  
Kurinji  Mullai  Marutham  Neithal  Paalai 
 
KAALAM: 
Kaarkalam  Pinpanikalam   Koothirkalam    
Ilavenil   Munpanikalam   Muthuvenil 
 
GUNAM: 
Sathuvam                        Rasatham                       Thamasam 
 
IYMPORIGAL: 
 0
th
 day 8th day 16th day 24th day 32
nd
 day 40
th
 day 48
th
 day 
 Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Mei [Skin        
Vaai 
[Buccalcavity]
  
       
Kan [Eyes] 
 
       
Mooku[Nose] 
 
       
Sevi [ear] 
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KANMA INTHIRIYANGAL: 
 0
th
 day 8
th
 day 16
th
 day 24
th
 day 32
nd
 day 40
th
 day 48
th
 day 
 Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Kai 
[upperlimb] 
       
Kal 
[lowerlimb] 
       
 
Vai[Buccal 
cavity] 
       
Eruvai  
[excretory 
organ] 
       
Karuvai 
[Reproductive 
organ] 
       
 
KOSAM: 
 0
th
 day 8th day 16th day 24th day 32
nd
 day 40
th
 day 49
th
 day 
 Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Annamayakosam        
Pranamaya 
Kosam 
       
Manonmayakosam        
Vingyanamayakosam        
Anandhamayakosam        
 
MUKKUTRAM: 
A) VATHAM:    
 0
th
 day 8th day 16
th
 day 24
th
 day 32
nd
tday 40
th
 day 49
th
 day 
 Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Praanan        
Abaanan
  
       
Samaanan        
Udhaanan        
Viyaanan        
Naahan        
Koorman        
Kirukaran        
Devathathan        
Dhananjeyan        
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B) PITHAM: 
 0
th
 day 8th day 16th day 24th day 32
nd
 day 40
th
 day 49
th
 day 
 Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Analapitham        
Prasakam        
Ranjakam        
Aalosakam        
Saathakam        
 
C) KABAM: 
 0
th
 day 8th day 16th day 24th day 32
nd
 day 40
th
 day 49
th
 day 
 Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Avalambagam        
Kilethagam        
Pothagam        
Tharpagam        
Santhigam        
 
SEVEN DHATHUKKAL:  
 0
th
 day 8th day 16th day 24th day 32
nd
 day 40
th
 day 49
th
 day 
 Normal/ 
Affected       
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Normal/ 
Affected       
Saaram[chyme]        
Senneer[Blood]        
Oon[Muscle]        
Kozhuppu[Fat]        
Enbu[Bones]        
Moolai[Bonemarr
ow] 
       
Sukkilam/ 
Suronitham 
[Genital 
discharges] 
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SYSTEMIC EXAMINATION: 
 0
th
 day 8th day 16th day 24th day 32
nd
 day 40
th
 day 49
th
 day 
CardioVascularS
ystem 
       
Respiratory  
System    
       
Gastrointestinal 
System 
       
CentralNervous 
System  
       
Endocrine 
System 
       
 
GENERAL EXAMINATION: 
 0
th
 day 8th day 16th day 24th day 32
nd
 day 40
th
 day 49thday 
Height (cms)        
Weight (kg)        
Temperature(°F)        
Pulse rate (permin)        
Heart rate (per min)        
Respiratory 
rate(per min) 
       
Blood 
pressure(mm/Hg) 
       
Pallor        
Jaundice        
Cyanosis        
Lymphadenopathy        
Pedal edema        
Clubbing        
Jugular vein 
pulsation 
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CLINICAL SYMPTOMS: 
 0
th
 day 8th day 16th day 24th day 32
nd
 day 40
th
 day 49
th
 day 
Abdominal pain        
Pain from loin to 
groin  
       
Agonizing pain        
Pain in urethra        
Yellow coloured 
urination 
       
Burning micturition        
Oliguria        
Dysuria        
Abdominal distension        
Nausea & Vomiting        
Haematuria        
    
USG- Whole Abdomen 
 
Date: 
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                       
 
 
                                                                                             Signature of the HOD 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASARPANDITHARHOSPITAL 
DEPARTMENT OF MARUTHUVAM 
 
AN OPEN CLINICAL STUDY ON“AZHAL KALLADAIPPU” (RENAL CALCULI) AND 
THE DRUG OF CHOICE IS “SAARA   PARPAM” (INTERNAL) 
 
 
FORM III   LABORATORY PARAMETERS-CHART 
 
1. OP/IP No: ________   2.S. No. ________________4. Name: ________________                    
5. Age:   _______ years      6. Gender: M/F 
 
BLOOD INVESTIGATION 
0
th
 DAY 
Date: 
49
th
 day 
Date 
HB( gms%)   
T.RBC(milli/cu.mm)   
ESR (mm) 
½ hr.   
1 hr.   
T.WBC (cu.mm) 
 
DIFFERENTIAL 
COUNT (%) 
   
Polymorphs   
Lymphocytes   
Monocytes   
Eosinophils   
 Basophils   
 
Blood 
glucose 
(mg/dl) 
Fasting   
PP   
Random   
Lipid 
profile 
(mg/dl) 
Serum cholesterol   
HDL   
LDL   
VLDL   
TGL  
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RFT 
(mg/dl) 
Blood urea   
Serum creatinine   
Serum Uric acid   
LFT (mg/dl) 
Total bilirubin   
Direct bilirubin   
Indirect bilirubin   
Serum totalprotein   
Serum Albumin   
Serum globulin   
Fibrinogen(g/dl)   
Serum calcium   
Serum 
phosphorous 
  
SGOT (IU/L)   
SGPT (IU/L)   
Alkaline 
phosphatase (IU/L) 
  
 
URINE INVESTIGATION 
Before TMT 
Date: 
After TMT 
Date: 
Albumin   
Neerkkuri   
Niram   
Manam   
Nurai   
Edai   
Enjal   
Neikkuri   
Fasting sugar   
PP sugar   
Random Sugar   
Deposits   
Bile salts   
Bile pigments   
Urobilinogen   
Culture & sensitivity   
MALAM   
Ova   
Cyst   
Occult blood   
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SCAN: USG ABDOMEN 
 
 
Specific investigation 
 
Size of the 
kidney 
 
Site of the 
calculus 
 
No of calculus 
 
Size of the 
calculus 
 
 
Hydro 
nephrosis 
 
 
Rt 
kidney 
Before 
treatment   
(0
th
 day) 
     
After 
treatment 
(49
th
 day) 
     
 
 
Lt 
kidney 
Before 
treatment   
(0
th
 day) 
     
After 
treatment 
(49
th
 day) 
     
 
Date: 
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                        
 
 
   Signature of theHOD 
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FORM IV  (DRUG COMPLIANCE FORM) 
 
S. NO: ---------   OPD/IPD NO  : ---------------  NAME :-----------------------         
Name Of The Drug :SAARA PARPAM,  2 kuntri (twice/day) Seeragakudineer 
 
Day Date Morning Evening 
Day 1    
Day2    
Day3    
Day4    
Day5    
Day6    
Day7    
Day8    
Day9    
Day10    
Day11    
Day12    
Day13    
Day14    
Day15    
Day16    
Day17    
Day18    
Day19    
Day20    
Day21    
Day22    
Day23    
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Day24    
Day 25    
Day26    
Day27    
Day28    
Day29    
Day30    
Day31    
Day32    
Day33    
Day34    
Day35    
Day36    
Day37    
Day38    
Day39    
Day40    
Day41    
Day42    
Day43    
Day44    
Day45    
Day46    
Day47    
Day48    
 
Station: 
Date:                                        
Signature of the Investigator: 
Signature of the Lecturer:                                                                   Signature of the HOD      
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Kjd;ikMuha;r;rpahsh; ngah;  : Dr. m. m[pjh 
epWtdj;jpd; ngah;   : Njrparpj;jkUj;JtepWdk; 
       jhk;guk;  rhdl;Nlhhpak; 
       nrd;id-47 
 
 Dr. m. m[pjh Mfpa ehd; Njrpa rpj;j kUj;Jtkidapy; gl;l 
Nkw;gbg;G gapd;W tUfpNwd;. moy; fy;yilg;G Neha; vspjpy; Fzg;gLj;j 
$ba NehahFk;. ,e;NehahdJ rpWePuf kw;Wk; rpWePuf ghijapy; cg;G 
tPo;gbjy; Nghd;w fhuz;qfshy; cz;lhfpwJ. ,e;Neha; ePh;Gioapy; 
,Uk;ig fha;r;rp Rl;lJ Nghy; vhpr;ry; cly; KOtJk; mdyhf ,Uj;jy;: 
rpWePUld; FUjp ntspgLjy;: 
ePh; Gioapy;  FiltJ kw;Wk; Fj;JtJNghy; typj;jy; kw;Wk; ePhpopAk; NghJ 
nre;epwfw;fs;> Nghd;w Fwp Fzq;fis Njhw;Wtpf;Fk;. ,e;Neha;f;F Njrpa 
rpj;j kUj;Jtkidapy;  gy rpj;j kUe;Jfs; gad;gLj;jg;gl;L tUfpd;wJ. 
rpj;j kUj;Jtgl;l Nkw;gbg;gpy;> Ma;tpd; xU gFjpahf Gjpa kUj;Jfis 
gad;gLj;Jk;  Nehf;fpy; (rhugw;gk;) vd;Dk; kUe;jpid ,e;Neha;f;F toq;f 
ghpe;Jiu nra;fpNwhk;. ,e;jkUe;jpd; nra;Kiw. msT> mDghdk; kw;Wk; 
kUj;Jt gad;fs; midj;Jk; mq;fPfhpf;fg;gl;l rpj;j kUj;Jt E}ypy; 
$wg;gl;Ls;sJ. ve;j tpj fl;lhaKkpd;wp jhq;fs; ,e;j kUe;jpid 
ngw;Wf;n fhs;syhk;. ,e;j Ma;tpy; kUe;Jcl;nfhs;Sk; fhyk; 48 ehl;fs; 
MFk;.  thuk; xUKiw Njrpa rpj;j kUj;Jtkidf;F Nehpy; te;J 8 
ehl;fSf;fhd kUe;jpid ngw;Wf; nfhs;s Ntz;Lk;. ,e;j Ma;T 
rk;ge;jkhd Ma;tf ghpNrhjidfs; fl;lzkpd;wp nra;ag;gLk;.  ehl;fs; 
kUe;J cl;nfhs;Sk; fhyk; Kbe;j gpwF Neha;f;fhd Fwp Fzq;fs; kw;Wk; 
Ma;tf ghpNrhjidfs; ,tw;wpd; KbTfspd; mbg;gilapy; kUe;jpd; 
ghpfhpg;Gj ;jpwd; fz;lwpag;gLk;. 
,e;j  Ma;T rk;ge;jkhf rpy Nfs;tpfis jq;fsplk; Nfl;f 
,Uf;fpNwd;. jq;fsplkpUe;J ngwg;gLk;  fUj;Jfs;  kw;Wk; Fwpg;Gfs; 
midj;Jk; ek;gpf;ifahf gjpT nra;ag;gLk;. ,e;j Ma;tpy; jq;fis 
cl;gLj;jpf; nfhs;tjpd; %yk; ve;j tifapYk; ghjpg;Gf;Fs;shf khl;Bh;fs; 
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mspf;fpNwd;. vd cWjp mspf;fpNwd;. ve;j tpj tw;GWj;jYkpd;wp> ,e;j 
Ma;tpy; gq;Nfw;fTk;> ,e;j Ma;T rk;ge;jkhf Nfl;fg;gLk; Nfs;tpfSf;F 
gjpy; $wTk; jq;fSf;F KO Rje;jpuk; mspf;fg;gLfpwJ. ,e;j Ma;tpy; 
gq;Nfw;gjw;F ve;j rd;khdKk; toq;fg;glkhl;lJ. Mdhy;> Ma;T 
KOtJk; vdJ Nkw;ghh;itapYk;> jq;fs; cly; eyd; Fwpj;j jdp 
ftdj;jpYk; Ma;T Nkw;nfhs;sg;gLk;. ,e;Neha;f;fhd Gjpa kUe;jpd; 
ghpfhpg;Gj; jpwid r%fj;jpw;F czh;j;Jk;  tifapy; ,e;j Ma;T 
Nkw;nfhs;sg;gLfpwJ. ,e;j Ma;tpidj; njhlujq;fSf;F tpUg;gk; 
,y;iynadpy; vg;nghOJ Ntz;LkhdYk; Ma;tpd; 144 ,ilapy; tpyfpf; 
nfhs;sTk;> ,k;kUj;Jtkidapy; toq;fg;gLk; ,e;Neha;f;fhd tof;fkhd 
kUe;Jfis ngw;Wf; nfhs;sTk; mwpTWj;jg;gLfpwPh;fs;. 
 ,e;j Ma;tpy;  Nrfhpf;fg;gLk; tpguq;fs; midj;Jk; jq;fSf;F Kjd;ik 
Muha;r;rpahsuhd vdf;Fk; ,ilapy; ufrpakhf itf;fg;gLk;. Nfs;tp 
gjpy; tbtj;jpy; jq;fsplk; Nfs;tpfs;  Nfl;fg;gLk;. midj;Jg; 
gbtq;fspYk; jq;fspd;  ngah; jtph;f;fg;gl;L  Ma;thsuy; jq;fSf;nfd 
jdpf; FwpaPL toq;fg;gLk;> me;jf; FwpaPL Ma;thsUf;F kl;LNk 
njhpe;jjhf ,Uf;Fk;. ePq;fs; ,e;j Ma;tpy; gq;Nfw;f tpUg;gg;gl;lhy;> 
jpl;ltiuT gb Njh;T nra;ag;gLtPh;fs;. 
 ePq;fs; ,e;j Ma;tpy; gq;Nfw;Fk; Kd;> ,e;j Ma;tpidg; gw;wpa 
NkYk; tpguq;fs; ngw Ntz;Lnkd tpUg;gg;l;lhy;> - ,e;j Ma;tpd;  
Muha;r;rpahsh; kw;Wk; Njrpa rpj;j kUj;Jtkid >gl;l Nkw;gbg;Gj; 
Jiwkhztp Dr. m. m[pjhMfpa vd;id 9042753209 vd;w vz;zpy; 
njhlh;G nfhs;syhk;. NkYk;> ePq;fs; ,e;j Ma;tpy;> cq;fsJ gq;Nfw;G 
kw;Wk; chpik gw;wp njhpe;J nfhs;s Njrpa rpj;j kUj;Jtkid> jiyth; / 
nraw;FO cWg;gpdh; mth;fisAk; 91-44-22511611 vd;w vz;zpy; 
njhlh;G nfhs;syhk;. 
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FORM VI-INFORM CONSENT FORM 
CERTIFICATE OF CONSENT 
“I have read the foregoing information, or it has been read to me. I have had 
the opportunity to ask questions about it and any questions I have asked have been 
answered to my satisfaction.  
            I   consent voluntarily to participate as a participant in this study and 
understand that I have the   right to withdraw from the study at any time without in any 
way it affecting my further medical care”. 
"I have received a copy of the information sheet/consent form". 
In case of illiterate participant 
“I have witnessed the accurate reading of the consent form to the potential participant, 
and the individual has had the opportunity to ask questions. I confirm that the 
individual has given consent freely.”                                                   
 
 
Date: 
 Signature of a witness  
    
Left thumb Impression of the  
Participant    
 (Selected by the participant bearing no connection with the survey team) 
 
Date:    
Station:                                                                                  
Signature of participant: 
Signature of the Investigator: 
Signature of the Lecturer:     Signature of the HOD 
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                 From VI -xg;Gjy; gbtk; 
 
 ehd; Nkw;$wpa jfty; gbtj;ij my;yJ gbf;f Nfl;L nfhz;Nld;. 
,J njhlh;ghd tpsf;fq;fisAk; Nfl;L njhpe;J nfhz;Nld;. ve;j tpj 
tw;GWj;jypd;wp> vd; nrhe;j tpUg;gj;jpd; Nghpy; vd;id ,e;j Muha;r;rpf;F 
cl;gLj;j vd; KO kdNjhLk;  Ra epidNthLk; rk;kjk; 
njhptpf;fpd;Nwd;. vdf;F tpUg;gkpy;yhj gl;rj;jpy; ,e;j Muha;r;rpapy; 
,Ue;J vd;id vg;NghJ Ntz;LkhdhYk; tpLtpj;J nfhs;Sk; chpikia 
ngw;Ws;Nsd; vd;gijAk; mwpNtd;. 
 
Njjp: 
,lk;: 
 
rhl;rpf;fhuh; ifnahg;gk;: 
 
rhl;rpf;fhuhpd; ngah;: 
 
ifnahg;gk;:         cwTKiw: 
ngah;:         kU. ifnahg;gk;: 
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FORM VII - (WITHDRAWAL FORM/ADVERSE DRUG REACTION 
FORM/PHARMACOVIGILENCE FORM) 
 
1)S. NO: -----------             2) OPD/ IPD NO: --------------- 
 
4)NAME:------------------------------    5) AGE: ---------             6) GENDER: M/F-------- 
 
Date of trial commencement:  
 
Date of withdrawal from trial:  
 
REASONS FOR WITHDRAWAL: 
 Long absence at reporting   :    Yes/ No 
 Irregular treatment   :    Yes/ No 
 Shift of locality     :  Yes/No 
 Increase in severity of symptoms  : Yes/No 
 Complication/Adverse reactions if any :        Yes/No 
 Poor patient compliance   :       Yes/No 
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NATIONAL PHARMACOVIGILANCE PROGRAMME FOR  SIDDHA DRUGS 
 
 
1 Please note:  
i. All consumers / patients and reporters information will remain confidential. 
ii. It is requested to report all suspected reactions to the concerned, even if  it 
does not have complete data, as soon as possible. 
 
Peripheral Center code:     State:  
1. Patient / consumer identification (please complete or tick boxes below as 
appropriate) 
 
Name  Father name 
 
Patient / Record No. 
Ethnicity  Occupation 
Address  
Village / Town 
Post / Via 
District / State    
Date of Birth / Age: 
 
Sex:     Male / Female  
Weight : 
Degam: 
 
2. Description of the suspected Adverse Reactions (please complete boxes below) 
 
Date and time  of 
initial observation 
 Season: 
Description of 
reaction   
 
 Geographical area: 
 
 
 
 
Reporting Form for Suspected Adverse Reactions to Siddha Drugs 
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3. List of all medicines / Formulations including drugs of other systems used by the 
patient during the reporting period: 
 
Medicine Daily 
dose 
Route of 
administration 
& Vehicle – 
Adjuvant 
Date  Diagnosis for 
which medicine 
taken  
Starting Stopped 
Siddha 
 
 
 
 
     
Any other system 
of medicines 
     
 
4. Brief details of the Siddha Medicine which seems to be toxic : 
 
Details Drug – 1 Drug – 2 Drug - 3 
a) Name of the medicine    
b) Manufacturing unit and 
batch No. and date 
   
c) Expiry date    
d) Purchased and obtained 
from 
   
e) Composition of the 
formulation / Part of the drug 
used 
   
 
a) Dietary Restrictions if any 
b) Whether the drug is consumed under Institutionally qualified medical supervision 
or used as self medication.  
c) Any other relevant information. 
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5. Treatment provided for adverse reaction: 
 
6. The result of the adverse reaction / side effect / untoward effects (please complete 
the boxes below) 
 
Recovered:           Not 
recovered: 
 Unknown: Fatal: If Fatal 
Date of death: 
Severe:   Yes   /   No. Reaction abated after drug stopped or dose reduced: 
 
Reaction reappeared after re introduction: 
 
 
Was the patient admitted to hospital? If 
yes, give name and address of hospital 
 
 
7. Any laboratory investigations done to evaluate other possibilities?  If Yes specify:  
 
8. Whether the patient is suffering with any chronic disorders? 
Hepatic    Renal    Cardiac    Diabetes    Malnutrition  
 
Any Others  
 
9. H/O previous allergies / Drug reactions:  
 
10. Other illness (please describe): 
 
11. Identification of the reporter: 
Type (please tick):  Nurse / Doctor / Pharmacist / Health worker / Patient / Attendant / 
Manufacturer /                                                                      
                                Distributor / Supplier / Any others (please specify) 
Name: 
Address: 
Telephone / E – mail if any : 
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Signature of the reporter:       Date: 
Please send the completed form to:  
     The Director 
     National Institute of Siddha, 
(Pharmacovigilance Regional  Centre For Siddha Medicine), 
 Tambaram Sanatorium, Chennai-600 047. 
 (O) 044-22381314  Fax : 044 – 22381314 
Website :www.nischennai.org 
 Email: nischennaisiddha@yahoo.co.in 
 
 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ** * * * * 
 
This filled-in ADR report may be sent within one month of observation /occurrence 
of ADR 
 
 
 
Date:                                                                              
Station:  
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                             
Date :      
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                         
 
    Signature of the HOD 
  
Name & address of the RRC-
ASU / PPC-ASU 
Who Can Report?     
 Any Health care professionals like Siddha Doctors /  Nurses / Siddha Pharmacists / 
Patients etc.  
What to Report?  
 All reactions,  Drug interactions,  
Confidentiality  
 The patient‟s identity will be held in strict confidence and protected to the fullest 
extent.  
 Submission of report will be taken up for remedial measures only not for legal claim  
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FORM VIII 
DIETARY ADVISE FORM 
jtph;f;fNtz;baitfs; 
 
 jf;fhsp 
 Kl;ilNfh]; 
 fhypgpsth; 
 gPd;]; 
 fhgp / B 
 rhf;Nyl; 
 khkprk; 
 Fsph;ghdk; 
 jpuhl;ir 
 ghy;>ghy; nghUl;fs; 
 cUisfpoq;F 
 gPl;&l; 
 fhshd; 
 Gifapiy 
 gjg;gLj;jg;gl;lczTfs; 
 fhunghUl;fs; 
 mjpfcg;Gepiwe;jczTkw;Wk; ePh; 
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Nrh;j;Jf; nfhs;sNtz;baitfs; 
 
 Ks;sq;fp 
 fPiujz;L 
 rpWfPiu 
 griyfPiu 
 ntz;il 
 mtiu 
 fhrpdpfPiu 
 ghh;ypmhprpfQ;rp 
 thioj;jz;L 
 Riuf;fha; 
 Nful; 
 jh;G+rdp 
 md;dhrp 
 gg;ghsp 
 rPufFbePh; 
 nfhs;S 
 jz;zPh; 1 ½ - 3 ypl;lh;  
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174 
 
 
 
 
 
175 
 
 
 
 
 
176 
 
 
 
 
177 
 
 
 
 
 
 
178 
 
 
 
 
 
179 
 
 
180 
 
 
 
 
181 
 
 
 
 
 
182 
 
 
183 
 
 
 
 
 
 
184 
 
 
 
185 
 
 
 
 
 
 
 
 
186 
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